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ABSTRACT 
While the integration of anti-TB and cART therapies is associated with substantial clinical 
improvement in the majority of patients, HIV-Tuberculosis associated Immune 
Reconstitution Inflammatory Syndrome (TB-IRIS) has been shown to occur in a significant 
subset of these patients. TB-IRIS is an inflammatory complication of the combined 
treatments for HIV-1 and tuberculosis, which is being reported increasingly, particularly in 
areas endemic to both diseases. This work aimed to characterise the immunopathogenesis of 
paradoxical HIV-Tuberculosis associated immune reconstitution inflammatory syndrome.  
 
Patients were recruited at health centres in Cape Town. TB-IRIS patients were diagnosed 
according to a validated consensus case definition while controls were similar HIV-TB 
patients who were prescribed the same duration of cART but who did not develop TB-IRIS. 
PBMC were cultured in the presence or absence of heat killed M. tuberculosis (MTB) H37Rv 
for 6 and 24 hours. RNA from cultures was analysed by quantitative RT-PCR and culture 
supernatant and the corresponding serum analysed by multiplex for various immune 
mediators. Stimulation with M. tuberculosis increased the transcript abundance for many of 
the pro- and anti-inflammatory cytokines analysed. IL-1 Beta, IL-5, IL-6, IL-10, IL-13, IL-
17A, IFN-gamma, GM-CSF and TNF transcripts were significantly higher in stimulated TB-
IRIS cultures at either the 6 or 24 hour time points (pcorr. ≤ 0.05). Gene induction for IL-6, IL-
10, IL-12p40, IL-13, IL-17A and IFN-gamma was significantly greater in TB-IRIS patients 
(pcorr. ≤ 0.05). Luminex analysis in the corresponding tissue culture supernatants showed the 
largest and significant fold differences in IL-1Beta, IL-2, IL-6, IL-8, IL-10, IL-12p40, IFN 
gamma, GM-CSF and TNF (pcorr. ≤ 0.04). Serum analysis showed that the levels of TNF, IL-
6 and IFN-gamma were significantly higher in TB-IRIS patients (pcorr. ≤ 0.02). Furthermore, 
the serum levels of IL-6 and TNF decreased significantly in prednisone treated (pcorr. ≤ 0.04) 
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but not in placebo treated TB-IRIS patients. Many pro- and anti-inflammatory cytokine 
transcript and protein levels are elevated in TB-IRIS patients indicating that cytokine release 
contributes to the immunopathology. IL-6 and TNF were elevated under all conditions and 
decreased in serum during corticosteroid therapy. These results suggest that specific blockade 
of IL-6 and TNF may be a novel and rational approach to immunomodulation in TB-IRIS.  
 
The role of tissue degrading enzymes and the effect of corticosteroid treatment was 
investigated by analysing MMP gene expression and protein concentration in vitro and in 
vivo in TB-IRIS patients and relevant controls.  Increased expression of MMP-1, -3, -7, -10 
and MMP-12 genes was observed in TB-IRIS (p ≤ 0.05) compared to controls.  Protein 
secretion in 24 hour stimulated cultures was also higher in TB-IRIS for MMP-1, -3, -7, and -
10 (p≤ 0.008). Circulating MMP-7 concentrations were significantly elevated in the serum of 
TB-IRIS. Furthermore, a 4 week course of corticosteroid therapy suppressed MMP-7 gene 
expression and serum levels in TB-IRIS. This study showed the association of TB-IRIS with 
a distinct pattern of MMP activation with MMP-7 being the most consistently elevated and 
was modulated by prednisone therapy. Modulation of dysregulated MMP activity, 
particularly MMP-7 may represent a promising and novel therapeutic approach to alleviate 
TB-IRIS. 
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1 CHAPTER 1:  INTRODUCTION 
 
1.1 The HIV epidemic  
Since the time of its initial description more than two decades ago, the human 
immunodeficiency virus (HIV-1) continues to be a major health challenge, spreading 
relentlessly all around the globe (Sharma, Mohan et al. 2005). Over 33 million people are 
infected with the virus that causes the acquired immunodeficiency syndrome (AIDS) and 
more than 67% (22.5 million in 2009) of the HIV-infected population worldwide is from the 
African region (WHO 2010).  In 2009, at least 2.6 million people were newly infected with 
HIV-1 globally, translating to over 7000 new infections a day. While more than 1.8 million 
AIDS-related deaths were recorded in the same year, about 1.3 million of these were from 
Sub-Saharan Africa (WHO 2010).  
 
1.2 Epidemiology of Tuberculosis 
Tuberculosis (TB) is a  ancient bacterial disease, which remains a major health problem in 
much of the developing world. The disease is caused by infection with Mycobacterium 
tuberculosis (and occasionally by Mycobacterium bovis and Mycobacterium africanum) 
(Zumla and Grange 2001) and spreads almost exclusively by the respiratory route. 
Tuberculosis infection occurs when a person carries tuberculle bacilli which if kept under 
control by the immune system, are capable of persisting in a dormant or latent state in the 
tissues for many years without causing disease in more than 90% of infected persons 
(Harries, Maher et al. 2004). More than a third of the world’s population is Mycobacterium 
Tuberculosis infected with 95% of the cases and 98% of all TB deaths occurring in 
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developing countries. Worldwide, more than 1.7 million people die from tuberculosis every 
year. In 2009 alone, more than 9.4 million incident cases of TB were recorded globally 
(equivalent to 137 cases per 100 000 population. As shown in Figure 1, southern Africa has 
the highest prevalence of HIV in new TB cases, and thus has the worst burden of HIV/TB 
coinfections as reported in 2009 (WHO 2010). 
 
 
Figure 1 Map showing world distribution of TB/HIV coinfections 
(2010 Global TB Control Report) 
 
 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 3 
1.3 The HIV/TB Association 
HIV infection is the strongest of all known risk factors for the development of tuberculosis. 
The global resurgence of TB has largely been driven by the HIV-1 pandemic. The two 
diseases have a synergistic interaction, each accentuating the progression of the other. Th1 
type immune response characterised by adequate cell-mediated immunity is the crucial host 
defence against M. tuberculosis (Schluger and Rom 1998). HIV infection primarily affects 
those components of the host immune response responsible for cell-mediated immunity, and 
this results in increased activation of latent Mycobacterium tuberculosis (MTB) infection, 
while HIV-infected persons are more susceptible to new tuberculosis infection (Corbett, Watt 
et al. 2003).  
 
In persons infected with MTB only, the lifetime risk of developing TB ranges between 5% 
and 10%, while the annual risk of tuberculosis amongst HIV-1 infected persons in high 
incidence settings can exceed 20% (Corbett, Watt et al. 2003). Globally, 9% of all new TB 
cases (31% in Africa) in adults were attributable to HIV/AIDS, as were 12% of the 1.8 
million deaths from TB in the year 2000 (Sharma, Mohan et al. 2005). About a third of the 
HIV-infected population worldwide is co-infected with Mycobacterium tuberculosis and this 
accounts for about 14 million people world- wide. Thus, the dual epidemic of (HIV) and 
tuberculosis (TB) remains a formidable health challenge, particularly in sub-Saharan Africa 
(Maartens and Wilkinson 2007). The South East Asia region of the World Health 
Organisation (WHO) accounts for nearly 40% of all tuberculosis cases globally and 18% of 
the world’s HIV-infected persons also live in this region. Thus, the social and economic 
implications of the two epidemics on the economies of the developing world cannot be over-
emphasised. Table 1 below is a summary of the statistics of TB/HIV co-infections by WHO 
regions. 
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Table 1 Numbers of Adults (15-49 yr) co-infected with HIV and TB in WHO regions as of year 
2000 
Adapted from Harries et al WHO, 2004 
 
 
 
 
 
1.4 Combination Antiretroviral Therapy (cART) 
1.4.1 HIV and cART 
Since the advent of highly-active anti-retroviral therapy or Combination Antiretroviral 
Therapy (cART) in 1996, a combination of at least three drugs that typically includes either a 
protease inhibitor (PI) or a non-nucleoside-analogue reverse transcriptase inhibitor (NNRTI) 
and two nucleoside analogue reverse-transcriptase inhibitors (NRTIs), the prognosis of HIV-
1-infected patients has substantially improved (Egger, Smith et al. 1997; Hogg, Yip et al. 
1999). In general, the introduction of cART has led to a sustained reduction in the incidence 
of AIDS-related opportunistic infections and a substantial reduction in HIV-associated 
WHO Region Number of people co-
infected with HIV and TB 
(thousands) 
% of Global Total 
Africa 7979 70 
Americas 468 4 
Eastern Mediterranean 163 1 
Europe 133 1 
South-East Asia 2269 20 
Western Pacific 427 4 
Total 11440 100 
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mortality and a reduced risk of tuberculosis in HIV-1 infected persons of 59-80% (Egger, 
Smith et al. 1997; Badri, Wilson et al. 2002; Maartens and Wilkinson 2007).  Integrated 
antitubercular and cART (as opposed to sequential) therapies are associated with a mortality 
reduction of greater than 50% (Abdool Karim, Naidoo et al. 2010).   
In the majority of patients, successful commencing of cART is associated with a drop in 
plasma viral load to below detectable limits (> 90%) within the first few months. This allows 
for the reappearance of immune effector cells, typically CD4 T cells, which are usually 
depleted during HIV infection (Lawn and Wilkinson 2006). The restoration of CD4 cell 
recovery during cART usually occurs in two principal phases. The initial phase is 
characterised by a dramatic rise in CD4+ cells within the first 1-2 weeks of commencing 
cART and is a result of the redistribution of activated CD4+ CD45RO+ memory cells 
previously sequestered in lymphoid tissue (Autran, Carcelain et al. 1997; Evans, Bonnez et 
al. 1998; Carcelain, Debré et al. 2001). Following this phase is a more sustained rise in naïve 
CD4+ T cells, which is thymus-dependent and is associated with the expansion of naïve 
CD45RA+CD62L+ cells. This second phase is more gradual and persists for 1-2 years in 
many patients. The increase in circulating CD4 cell numbers is also associated with an 
improvement in effector function, the extent of which is directly related to the degree of viral 
load suppression and the CD4 cell counts in the longer term (Lederman 2001). These findings 
are supported by a more recent study by Wilkinson et al in M. tuberculosis sensitized HIV-
infected patients documenting the reconstitution of different cell types in cohort of patients 
who were followed up for 48 weeks. In this study, a decrease in viral load and an increase in 
CD4 counts, with a significant expansion of central memory cells by 12 weeks, and 
expansion of naive T cells by 36 weeks was observed (Wilkinson, Seldon et al. 2009). These 
findings support the hypothesis that the initial CD4+ count recovery is memory cell 
mediated, while the subsequent increase in CD 4 count is due to naive T cell expansion. 
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1.4.2 cART and IRIS 
The major clinical benefits of cART result from a gradual restoration of pathogen-specific 
immune responses. However, during the initial months of cART immune reconstitution is 
complicated by adverse clinical phenomena in which either previously subclinical infections 
are “unmasked” or pre-existing partly treated opportunistic infections clinically deteriorate 
(Lawn and Wood 2005; Meintjes, Lawn et al. 2008; Meintjes, Rabie et al. 2009). Clinical 
deterioration has been reported in between 11 and 43% of HIV-infected patients commencing 
cART. These clinical phenomena are thought to result from immunopathological host 
inflammatory responses being “switched on” as the immune system recovers (Lawn and 
Wood 2005). Several terms can be used interchangeably to describe this phenomenon such as 
immune reconstitution syndrome, immune reconstitution inflammatory syndrome, immune 
restoration disease, immunorestitution disease, and immune reconstitution phenomena. In this 
thesis, the term Immune Reconstitution Inflammatory Syndrome (IRIS) will be used when 
referring to this condition. 
 
While IRIS has become more frequent with the advent of cART in HIV-infected individuals, 
it is not a new phenomenon, nor is it specific to HIV-infected individuals receiving cART. 
The potential for IRIS exists whenever patients who have been severely 
immunocompromised have rapid restoration of immune function (Cheng, Yuen et al. 2000). 
However, the frequency of IRIS has dramatically increased since the introduction of triple 
antiretroviral therapy, particularly its introduction to the developing world, where patients 
commence cART when already highly immunosuppressed, and where there is often a high 
pathogen burden, such as tuberculosis and Cryptococcus in Southern Africa (Keiser, Anastos 
et al. 2008). 
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1.5 The Immune Reconstitution Inflammatory Syndrome (IRIS) 
1.5.1 The history of IRIS  
The first indication that the restoration of pathogen specific immunity could lead to 
immunopathological reactions was reported in 1992, when atypical presentations of 
Mycobacterium avium complex (MAC) were seen in patients on zidovudine antiretroviral 
monotherapy (French, Mallal et al. 1992). MAC as an opportunistic infection usually presents 
as disseminated infection, and is associated with anergy towards mycobacterial antigens. 
However, in the case of IRIS, MAC infection presented as localized infection, and was 
associated with the recovery of delayed type hypersensitivity (DTH) reaction to 
mycobacterial antigens (French, Mallal et al. 1992). IRIS typically occurs within the first few 
months of initiating cART and can be associated with various bacterial, invasive fungal and 
chronic viral infections. Among the pathogens commonly associated with IRIS are 
mycobacterial infections such as Mycobacterium Avium complex (MAC), Mycobacterium 
tuberculosis and Mycobacterium leprae as well as viral infections such as, herpes viruses, 
hepatitis B and C virus, and JC virus (Shelburne, Hamill et al. 2002; French, Price et al. 2004; 
Lawn and Wilkinson 2006). IRIS has also been described in other non-HIV related settings in 
which rapid restoration of immune function occurs, such as withdrawal of 
immunosuppressive therapy or after stopping cancer chemotherapy resulting in recovery from 
neutropenia (Cheng, Yuen et al. 2000). 
 
1.5.2 HIV-Tuberculosis associated-IRIS  
Despite the diverse association and presentations of IRIS, HIV-tuberculosis associated IRIS 
(TB-IRIS) remains most commonly occurring form of immune reconstitution inflammatory 
syndrome worldwide and is particularly common in countries with a huge burden of both 
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diseases (Burman, Weis et al. 2007). Manifestations of TB-IRIS range from mild symptoms 
such as fever, to life-threatening conditions such as respiratory failure. In many case, the 
clinical manifestations of TB-IRIS resemble the original disease, such as fever, malaise, 
weight loss, cough etc. Common presenting features include severe fever, cervical and intra-
thoracic lymphadenopathy, and pulmonary infiltrates (Dhasmana, Dheda et al. 2008). 
Tuberculomas, meningitis, cold abscess and ascites are other less common manifestations of 
the syndrome, which have been reported.  
 
1.5.3 Defining HIV-TB associated IRIS 
Due to the diverse presentation of the condition, there have been difficulties in clearly 
defining IRIS. There is no investigation or biological test that confirms the diagnosis of 
paradoxical tuberculosis IRIS. Thus, confirmation of the disease relies heavily upon case 
definitions incorporating clinical and laboratory data (Dhasmana, Dheda et al. 2008). In most 
cases, diagnosis of the condition is mainly based on a diagnosis of exclusion, consistent 
history and the exclusion of alternative diagnoses such as non-compliance with treatment for 
the opportunistic infection (OI), the emergence of a new OI, or drug toxicity (Meintjes, Lawn 
et al. 2008). In areas where drug-resistant tuberculosis is frequent, extra efforts have to be 
made to exclude drug resistance as a cause for deterioration. To some extent, the lack of 
consensus case definitions and clear diagnosis has until recently hindered research on IRIS. 
General case definitions have been previously proposed, but were not validated and so there 
has been no consensus on their validity and applicability, particularly in resource-constrained 
settings with limited laboratory facilities.  
 
To this end, the International Network of HIV-associated IRIS (INSHI) has now modified 
the previously proposed case definitions for IRIS to make them applicable in resource-limited 
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settings. The INSHI definitions have since been independently validated by various 
international research groupings (Manosuthi, Tieu et al. 2009; Eshun-Wilson, Havers et al. 
2010; Haddow, Moosa et al. 2010). This definition has 3 main components which include the 
(i) primary or antecedent requirements, (ii) clinical criteria which include major or minor 
criteria and (iii) exclusion of possible diagnosis as confirmatory criteria in the definition of 
paradoxical TB-IRIS (Meintjes, Lawn et al. 2008). The primary criteria in the diagnosis of 
paradoxical TB-IRIS are the microbiological confirmation of tuberculosis or strong clinical 
evidence of TB before starting cART in addition to evidence of an initial response to anti-
tubercular therapy prior to the initiation of cART. Clinical criterion include that the onset of 
IRIS should be within 3 months of starting cART and one of the major criterion or two of the 
minor criteria. The major criteria include new or worsening lymph nodes or cold abscesses 
and radiological features while minor criteria include worsening of clinical symptoms. The 
exclusion of alternative explanations for clinical deterioration such as treatment failure, drug 
resistance, poor adherence or drug toxicity or other opportunistic infections form the third 
component of the INSHI case definition for paradoxical TB-IRIS (Meintjes, Lawn et al. 
2008). 
 
The major revisions incorporated in the INSHI case definitions which make them applicable 
in resource limited settings are the omission of changes in plasma viral load/CD4 cell counts 
as necessary criteria in confirming IRIS and the inclusion of a time frame for onset of clinical 
manifestations for a diagnosis of tuberculosis-associated IRIS to be made (Meintjes, Lawn et 
al. 2008). 
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1.5.4 Categorising TB-IRIS 
HIV-Tuberculosis-associated-IRIS (TB-IRIS) is recognised to present temporally as one of 
two main forms i.e. either as (i) paradoxical TB-IRIS or (ii) unmasking TB-IRIS. Figure 2 
below is a schematic diagram showing how the two recognised forms of TB-IRIS are 
distinguished from each other.  
 
Figure 2 Schematic diagram showing the two categories of TB-IRIS.  
Adapted from (Meintjes, Lawn et al. 2008) 
1.5.4.1 Paradoxical TB-IRIS 
Paradoxical TB-IRIS usually manifests in patients who are diagnosed with tuberculosis prior 
to initiating cART and are responding well and improving on tuberculosis treatment. Various 
studies show that the average time of paradoxical TB-IRIS onset after cART initiation ranges 
from 1-4 weeks (Narita, Ashkin et al. 1998; Breen, Smith et al. 2004; Michailidis, Pozniak et 
al. 2005). However, incidences of IRIS developing much earlier, in some cases, as early as 3 
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days after cART commencement while late cases of IRIS, (years after initiation of cART), 
have also been described (Olalla, Pulido et al. 2002; Huyst, Lynen et al. 2007). On starting 
cART, these patients develop recurrent, worsening or new symptoms and manifestations of 
tuberculosis (Lawn, Bekker et al. 2005; Lawn, Myer et al. 2007). Common manifestations 
include return of symptoms, fever, enlargement of lymph nodes, worsening chest X-rays and 
pulmonary infiltrates and enlarging effusions (Dhasmana, Dheda et al. 2008). Figure 3 and 4 
below illustrate some of the commonly reported features of paradoxical TB-IRIS. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 Figure 3 Illustrative case of a female patient with paradoxical TB-IRIS 
 
Figure 3 shows an example of Paradoxical Tuberculosis-associated immune reconstitution 
inflammatory syndrome lymphadenitis. This young woman was diagnosed with pulmonary 
TB on the basis of an MTB positive sputum culture that grew Mycobacterium tuberculosis 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 12 
sensitive to rifampicin and isoniazid and had small neck lymph nodes at that time. 
Symptomatic response to anti-TB therapy was reported after 3 weeks. She was started on 
cART at this point at CD4 count of 143 cells/µL. Three weeks latter she developed painful 
right supraclavicular lymhadenitis with overlying erythema and tenderness. 
 
 
 
 
Figure 4a and 4b Worsening chest radiographs in a case of Paradoxical TB-IRIS    
 
Figures 4a and 4b show an example of patient who developed Paradoxical Tuberculosis-
associated immune reconstitution syndrome with chest radiograph deterioration. This HIV-
infected patient was diagnosed with smear positive pulmonary tuberculosis. Pulmonary 
infiltrate was noted at that point. She reported an initial symptomatic response to anti-
tubercular therapy. She commenced cART at a CD4 count of 63 cells/µL, 3 months after 
antitubercular therapy. One week later she developed recurrence of her cough and night 
sweats, consistent with TB-IRIS. Chest radiograph (a) was taken at the onset of TB-IRIS and 
radiography (b) was taken 10 days later. The upper part of (b) shows an extension of the left-
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sided infiltrate with cavitation as well as a new right-sided infiltrate, which was not evident at 
onset in Figure 4a. 
 
1.5.4.2 Unmasking TB-IRIS  
Unlike paradoxical TB-IRIS, the unmasking form of TB-IRIS is less well characterised. 
Unmasking IRIS typically occurs in patients with unrecognised tuberculosis infection who 
are not receiving anti-tubercular treatment and on starting cART they manifest with active 
tuberculosis with unusually accelerated degrees of inflammation (Goldsack, Allen et al. 2003; 
Breen, Smith et al. 2004; Meintjes, Rabie et al. 2009). The term ‘unmasking TB-IRIS’ does 
not refer to all patients who develop tuberculosis while receiving cART. In settings of high 
tuberculosis incidence, reactivation and re-infection tuberculosis, which may not be related to 
cART-mediated immune reconstitution, occurs quite commonly in patients on cART. Many 
cases may also occur because of persistent immunodeficiency. ‘Unmasking TB-IRIS’ may 
therefore be classified as a subset of cART-associated tuberculosis (French 2007). This form 
of IRIS is less well understood and was not the subject of this thesis. 
 
1.6 Risk factors for developing TB-IRIS  
Evidence gathered from several studies has identified certain risk factors that predispose 
patients to developing TB-IRIS, among them are (i) disseminated TB disease or a high 
antigen load (ii) a low baseline CD4+ count (iii) high baseline viral load and subsequent rapid 
fall in response to cART  (iv) a short interval between anti-tubercular therapy and cART and 
(v) to a limited extent, genetic factors. 
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1.6.1 Disseminated TB disease 
Disseminated and extrapulmonary tuberculosis, which can also be interpreted as higher 
antigen load has been identified as one of the major risk factors associated with the 
occurrence of IRIS from various studies (Breton, Duval et al. 2004). In their study of TB-
IRIS in Thailand, Manosuthi et al. reported an eight-fold increase in the chance of developing 
TB-IRIS in patients with extra pulmonary disease (Wendel, Alwood et al. 2001; Manosuthi, 
Tieu et al. 2009) found higher frequencies of IRIS in patients presenting with both 
extrapulmonary and pulmonary TB. Several other researchers have since reproduced the 
findings. This can be explained by the fact that disseminated TB is associated with a higher 
bacterial load of MTB. HIV-infected TB patients present more often with disseminated 
tuberculosis, suggesting that the recovering immunity of patients starting cART with 
underlying TB infection will encounter a higher mycobacterial antigen load. Immune 
reconstitution inflammatory syndrome to MTB can be seen as a reflection of the interaction 
between the number and function of appropriate immune cells and the amount of antigen they 
encounter (Breton, Duval et al. 2004). 
1.6.2 Low-baseline CD4 count 
Advanced immunodeficiency when starting cART has been described as a risk factor for the 
development of IRIS (French, Lenzo et al. 2000; Michailidis, Pozniak et al. 2005). Several 
studies have shown that a CD4 count of below 200 cells/µL prior to starting cART is a risk 
factor for developing IRIS. IRIS has been reported to occur less frequently in patients starting 
cART with a CD 4 count of greater than 350 cells/µL. A higher degree of immune 
suppression means that patients are more prone to opportunistic infections and at the same 
time the homeostatic balance is more advanced in a more damaged immune system (French, 
Lenzo et al. 2000; Manabe, Breen et al. 2009).  
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Michailidis et al. reported a baseline CD4 count of less than 100 cells/mm3 as a risk factor 
for TB-IRIS which was also reported by French et al (Michailidis, Pozniak et al. 2005). In 
other instances the baseline CD4 percentage has been emphasised as a risk factor for TB-
IRIS, rather than absolute count (French, Lenzo et al. 2000; Ratnam, Chiu et al. 2006). This 
may reflect the increased susceptibility of dysregulated immune recovery once HAART is 
commenced. The significance of the rate of immune recovery and risk of IRIS has had 
varying reports. French et al. reported that the rate of immune recovery measured by increase 
in CD4 cell count and percentage over 24 weeks had no effect on the risk of IRIS (French, 
Lenzo et al. 2000), whereas Shelburne et al. and Breton et al. who focussed exclusively on 
mycobacterial IRIS, found that CD4 cell percentage increase and CD4:CD8 ratio were factors 
associated with the development of the syndrome, again raising the issue of an unbalanced 
immune response in the pathogenesis of IRIS (Shelburne, Hamill et al. 2002; Breton, Duval 
et al. 2004).  
 
1.6.3 High baseline viral load and subsequent rapid fall in response to cART   
Being cART naïve and an excellent virologic response (as illustrated by a rapid fall in 
plasma viral load) has been found to be another risk factor for the development of IRIS in 
many patients. Patients with a decrease of greater than 2-logs in HIV-1 RNA plasma viral 
load within 3 months of initiating cART were shown to be more likely to develop IRIS 
(Shelburne, Hamill et al. 2002; Manabe, Breen et al. 2009). In general, patients lacking a 
virologic response are unlikely to develop a meaningful immune recovery, and thus are at 
lower risk of developing IRIS (Boulware, Callens et al. 2008). 
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1.6.4 Timing of cART and TB treatment 
A shorter delay between commencing TB treatment and commencing cART has been 
identified as a significant factor associated with an increased risk of developing IRIS (Breen, 
Smith et al. 2004; Breton, Duval et al. 2004). This may be explained by the presence of a 
higher mycobacterial antigen load that the immune system encounters as it is rapidly restored 
by cART. Various studies have reported that starting cART within 2 months of initiating anti-
tubercular treatment is associated with between zero to tenfold increase in the risk of 
developing IRIS (Shelburne, Hamill et al. 2002; Lawn, Bekker et al. 2005; Lawn, Myer et al. 
2007). However, in clinical settings there is a need to balance the risks of opportunistic 
infections and IRIS when managing patients and considering delaying cART, particularly in 
the light of recent studies that have shown clear benefits for early initiation of cART in HIV-
infected patients (Zolopa, Andersen et al. 2008). 
 
1.6.5 Genetic factors 
There have been indications that patients may have a predisposition to developing IRIS due 
to genetic factors affecting th  Th1-Th2 balance. To this end some work has been done to 
investigate whether certain polymorphisms in cytokine genes exacerbate the 
immunopathological response to various pathogens (Price, Morahan et al. 2002). There were 
two findings relating to mycobacterial IRIS; firstly, carriage of a C allele at IL-6-174 was 
common in patients and controls, but was rare in patients with mycobacteria- associated IRIS 
a (non-carriage of IL-6-174*C). In addition to this, all patients with MAC or MTB 
associated IRIS were also shown to be homozygous for TNFA-308*1. TNFA-308*1 has 
been associated with lower production of tumour necrosis factor-α in monocytes, suggesting 
that it may facilitate IRIS by limiting “TNF-mediated bacteriocidal activity” (Price, Morahan 
et al. 2002).  Genetic polymorphism and racial difference may play a role in IRIS 
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phenomenon. However, it is important to note that irrespective of these intermittent reports, 
there has not been a sufficiently large enough study to investigate the effect of genetic 
predisposition to the development of IRIS and more work still needs to be done on this 
subject.  
 
1.7 Incidences of TB-IRIS  
The reported incidences of TB related IRIS in HIV-infected persons from different 
populations ranges from 2-43 % (Breton, Duval et al. 2004). Table 2 shows a summary of the 
various studies and the reported incidences of TB-IRIS from the different studies across the 
world up to 2010. 
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Table 2 Summary of reported incidences of TB-IRIS worldwide  
(Adapted from Muller et al, 2010)  
 
Study Country Number of Patients with AIDS at enrolment Proportion of Patients developing TB-IRIS Mortality from IRIS 
Narita et al (1998) USA 33(100%) 12 (36%) 
Wendel et al (2001) USA 24 (100%) 3(13'%) 
Navas et al (2002) Spain 24(100%) 6(35%) 
Breton et al (2004) France 17 (100%) 16(43%) 
Kuramasamy et al (2004) France 144(100%) 11 (8%) 
Mi chai Ii di 5 (2005) UK 55 (10Cl''';) 14(25%) 
Bo urgarit et al (2006) France 19 (lOCI''';) 7 (37%) 
Chew et al (2006) Ireland 16 (lOCI''';) 4(25%) 
Manosuthi et al (2006) Thailand 167 (10Cl''';) 21(13%) 1% 
Elli ot et al (2007) Cambodia 27 (10Cl''';) 6(21%) 4% 
Lawn et al (2007) South Africa 160 (10Cl''';) 19(12%) 1% 
Park et al (2007) South Korea 9(2%) 
Serra et al (2007) Brazil 84 (lOCI''';) 10(12%) 
Eshun-Wilson et al (2009) South Africa 337 (lOCI''';) 56(17%) 
Kumarasamy et al (2009) India 1731 (10Cl''';) 95 (5%) 2% 
Manosuthi et al (2009) Thailand 126 (lOCI''';) 21(17%) 
Breen et al (2004) UK 28 (lOCI''';) 8 (25%) 
5helburne et al (2005) USA 86 (10Cl''';) 26 (3C1''';) 
Michailidiset al (2005) UK 28 (lOCI''';) 9 (32%) 
Burman et al (2007) USA 109 (10Cl''';) 19(17%) 
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1.8 Mortality and morbidity due to TB-IRIS 
In general, mortality from tuberculosis-associated IRIS is low and is reported very 
infrequently reported in literature (Table 2). In a systematic review of major IRIS literature, 
Muller et al have estimated the mortality of TB-related IRIS to be about 3.2% on average 
(Müller, Wandel et al. 2010). However, morbidity is high and the need for hospitalisation is 
frequent, resulting in significant draining of resources, particularly in resource-limited 
settings where the burden is highest. Despite the generally low IRIS-related mortality, of 
particular note is neurological tuberculosis-associated IRIS, which is particularly associated 
with poor outcome (Pepper, Rebe et al. 2009). 
 
1.9 Management of TB-IRIS: The use of corticosteroids to treat IRIS 
The management and treatment of IRIS remains a grey area with not much consensus and 
management is often on a case-by-case basis. The use of anti-inflammatory agents such as 
non-steroidal drugs has been suggested in the treatment of IRIS as these may arrest the acute 
inflammatory damage during cART initiation in HIV-infected persons (Cheng, Yuen et al. 
2000). However, there has not been much clinical evidence published to support their use.  
Therapeutic aspiration can also be used to temporarily reduce lymph node bulk in cases of 
massive lympadenitis (Kumarasamy, Chaguturu et al. 2004). 
 
Anecdotal reports on the use of corticosteroids in the treatment of IRIS report evidence of 
symptomatic improvement without compromising clinical care (Cheng, Yuen et al. 2000; 
Safdar, Rubocki et al. 2002). In a more recent and comprehensive randomised clinical trial 
(RCT) Meintjes et al showed that the use of corticosteroid therapy is a potentially useful 
intervention in treatment and management of paradoxical TB-IRIS (Meintjes, Wilkinson et 
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al. 2010). Patients were randomised to recive either a 4-week course of prednisone or placebo 
treatment. Prednisone treatment was shown to reduce (i) days of hospitalisation, (ii) the need 
for therapeutic procedures and (iii) resulted in more rapid improvements in symptoms, 
radiography, markers of inflammation such as creatine reactive protein (CRP) as well as 
performance and quality of life (Meintjes, Wilkinson et al. 2010). However, the use of 
cortecosteroid should be employed with caution in immuno-suppressed HIV-infected 
patients.  
 
It is important that a clear diagnosis of paradoxical TB-IRIS be made and antitubercular drug 
resistance be excluded when considering corticosteroid therapy. The proper screening for 
symptomatic infection and giving appropriate prophylactic treatment and antimicrobial 
treatment remains one of the ways of controlling and limiting the frequency of IRIS cases 
(Cheng, Yuen et al. 2000; Lawn and Wilkinson 2006). It is also important to note that in 
many cases, paradoxical TB-IRIS is self-limiting, and only rarely is withdrawal of cART 
recommended as a means of resolving TB-IRIS. 
 
1.10 Immunopathogenesis of TB-IRIS 
In many of the cases, the immunopathogenesis of IRIS appears to be pathogen dependent as 
different types of IRIS seem to have different pathological mechanisms (Lederman 2001). 
Although data are limited, the inflammatory response associated with IRIS appears to be cell-
mediated and antigen-driven (French 2007). As described previously in section 1.6, the 
development of IRIS generally requires advanced HIV infection and consequently, advanced 
immuno-suppresion, a rapid response to cART, the presence of inciting antigens and the 
apparent loss of normal homeostatic control of immune responses, resulting in exaggerated 
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inflammatory responses (Kestens, Seddiki et al. 2008). It appears that the pathogenesis of 
IRIS implicates those components that normally maintain homeostasis and modulate the 
function of the effector cells of the immune system (Munier and Kelleher 2007). 
Understanding the immunopathogenesis of TB-IRIS will have implications in improved 
diagnosis and treatment of this syndrome. In this section the various reports and hypotheses 
that have been put forward on the immunopathogenesis of IRIS are discussed. 
 
1.10.1 The Role of CD4 T cell expansion in TB-IRIS 
The majority of paradoxical TB-IRIS cases, particularly paradoxical TB-IRIS, occur in the 
first 3 months after cART has been initiated or restarted (Meintjes, Lawn et al. 2008). This 
corresponds to the first phase of immune reconstitution in which there is a rapid increase and 
redistribution in both the number of circulating CD45RO+ memory cells and CD4 cell 
function (Autran, Carcelain et al. 1997; Lawn, Myer et al. 2006). The extent of sequestration 
of activated CD45RO+ memory cells in lymphoid tissue may be directly related to the HIV 
load with the greatest phase 1 rates of CD4+ cell recovery during cART resulting in increased 
risk of IRIS (Lederman 2001). In another study, Wilkinson et al also reported significant 
reductions in viral loads and increases in the numbers of CD4+ T cells as well as expansions 
in naïve T cells and effector memory cells in HIV-infected, MTB-sensitized patients 
(Wilkinson, Seldon et al. 2009). Recirculation of this previously sequestered population may 
provide the opportunity for relevant pathogen specific cells to gain access to sites of infection 
and engage in the host inflammatory response to foreign antigen. In a more recent study, 
Antonelli et al reported that IRIS patients had a higher proportion of activated T cells even 
before ART initiation, including a higher proportion of activated and, so possibly, a 
dysfunctional Treg suggestive of high antigen load (Mohan, Seaton et al. 2002). In this study 
IRIS events were reportedly accompanied by high serum levels of IFN-gammaჼ and IL-7, 
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suggesting a dysregulated effector response to the profound lymphopenia and 
immunosuppression in these patients. Suggestions on the possibility of IL-7 as a potential 
biomarker have been put forward based on this work (Schonbeck, Mach et al. 1998), but 
require further investigation in other patient cohorts to confirm this hypothesis. 
 
1.10.2 Restoration of the delayed-type hypersensitivity reaction 
HIV infection causes gradual CD4 lymphocytopaenia, along with the inhibition of 
interleukin-2 mediated lymphocyte activation and proliferation (Boulware and Bohjanen 
2007). There is an increase in type 2 cytokine secretion, associated with immunoregulatory 
mechanisms, which inhibit cell-mediated immune function. This depression of cell-mediated 
immunity in HIV-infected patients results in non-response to cutaneous PPD, i.e. no skin 
reaction to the TST even if the patient has had prior exposure to TB. The development of 
IRIS has been shown to coincide with the restoration of IFN-γ secretion and cell-mediated 
immune responses to mycobacteria all of which are associated with expansions in the number 
of antigen-specific T cells leading to restoration of DTH skin test responses to mycobacterial 
antigens (French and Price 2008; Price, Murdoch et al. 2009). The first indication that the 
restoration of pathogen specific immunity could lead to immunopathological reactions was 
observed, when atypical presentations of Mycobacterium avium complex (MAC) were seen 
in patients on zidovudine (ARV) monotherapy (French, Mallal et al. 1992). MAC as an 
opportunistic infection usually presents as disseminated infection, and is associated with 
decreased response towards mycobacterial antigens. However, in the case of IRIS, MAC 
infection presented as localized infection, and was associated with the recovery of a delayed 
type hypersensitivity reaction to mycobacterial antigens (French, Mallal et al. 1992). 
Granulomatous inflammation and tissue necrosis are typical of DTH responses (French, Price 
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et al. 2004). Following these discoveries, other case studies have reported the restoration of a 
DTH response at the time of TB-IRIS presentation (Narita, Ashkin et al. 1998). 
1.10.3 Antigen-specific responses and TB-IRIS 
While different studies have suggested that antigen-specific responses may be responsible 
for the development of IRIS, Bourgarit et al were the first group to show evidence of this 
effect (Bourgarit, Carcelain et al. 2006). In a small prospective trial investigating the 
immunopathology related to TB-IRIS, HIV and TB co-infected patients initiating anti-TB and 
cART therapies, enzyme linked immunospot (ELISpot) assays were carried out to quantify 
interferon-γ secreting Th1 cells specific to various TB antigens (ESAT-6, 85B and PPD). TB-
IRIS was shown to be associated with PPD specific TH1 responses with pro-inflammatory 
events in response to cART, but no significant responses to ESAT-6 and 85B. An increase in 
the number of PPD- specific cells producing IFN-γ during IRIS in 7 IRIS patients which was 
not evident in similar control patients who did not develop IRIS was observed (Bourgarit, 
Carcelain et al. 2006). These data suggested that the acute inflammatory response seen in TB-
IRIS patients may be directed against persistent antigens within purified protein derivative. In 
vitro analysis of immunomodulatory cytokines and chemokines in the antigen-stimulated 
PBMC supernatants of these patients showed high levels of Th1 related 
cytokines/chemokines but not Th2 cytokines. A larger cross-sectional study by Meintjes et al 
has since shown that while there is an association between dynamic T-cell expansions and 
TB-IRIS, similar expansions were also observed in non-IRIS patients (Meintjes, Wilkinson et 
al. 2008). This study also showed that TB-IRIS is associated with high levels of CRP and 
confirmed the association with high frequencies of M.tuberculosis antigen-specific IFN-γ 
secreting T cells (Meintjes, Wilkinson et al. 2008). 
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1.10.4 Regulatory T cells in TB-IRIS 
In general, regulatory T cells (Tregs) are the main cells responsible for maintenance of a 
homeostatic state by suppressing other immune cells and preventing host damage from 
inflammatory responses. Tregs suppress the proliferation of effector CD4+ and CD8+ T cells 
and suppress their cytokine production, thus limiting the immune response to microbial 
antigens (Boulware and Bohjanen 2007). Since the balance between allowing clearance of 
infections and preventing immuopathology is delicate, it was suggested that an unbalanced 
immune reconstitution of effector and regulatory T cells in patients receiving cART may 
result in IRIS (Kestens, Seddiki et al. 2008). In a small study comparing a subset of patients 
who developed Mycobacterium avium and intracellulare (MAI) IRIS and non-IRIS controls, 
Seddiki et al showed that IRIS was characterised by the presence of a subset of CD4+ T cells 
specific to MAI antigen which produced high levels of IFN-γ and IL-2. The study also 
confirmed an increased proportion of Treg cells in IRIS patients compared with healthy 
controls, as did another study which observed an increase in Treg at the peak of IRIS 
symptoms (Tan, Yong et al. 2008; Seddiki, Sasson et al. 2009). Thus the lack of suppression 
of Tregs may effectively be contributing to IRIS. The high levels of IL-2 seen in these 
patients may be involved in the survival and maintenance of these Tregs (Fontenot, 
Rasmussen et al. 2005).  
 
1.10.5 The role of cytokines and other immunomodulators in TB-IRIS 
There have been suggestions that immunomodulation of interleukins and cytokines may be a 
possible direction for future treatment of IRIS (Cheng, Yuen et al. 2000), although clinical 
trials are yet to be done to investigate this. Several cytokines have been implicated in the 
immunopathology of IRIS although it remains unclear whether an increase in the levels of 
certain cytokines is a cause or consequence of IRIS. In a study of patients who had a history 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 25 
of IRIS, Stone et al reported a higher constitutive expression of IL-6 and soluble IL-6 
receptor (sIL-6R) in the tissue culture supernatants of patients with a history of IRIS 
compared to those with no history of IRIS or HIV-negative controls (Stone, Price et al. 2002). 
The levels of these two proteins were also observed to be higher in mitogen-stimulated and in 
plasma samples of these patients, although no differences were noted for IFN-γ levels for 
these patients (Stone, Price et al. 2002). The study by Bourgarit supported the findings of 
high IL-6 levels in 3 IRIS patients in addition to TNF, IL-1b, IL-10, RANTES and MCP-1 
(Bourgarit, Carcelain et al. 2006). In a more recent study Oliver et al have suggested that TB-
IRIS is associated with perturbations of the innate immune response to M.tuberculosis by 
showing decreased levels of CCL2 before and after cART and incresead levels of IL-18 and 
CXCL10. CXCL-10 regulates the trafficking of effector T cells and NK cells to sites of 
inflammation (Robertson 2002).  
1.10.6 The role of Matrix Metalloproteinases (MMPs) and their inhibitors in TB-IRIS 
Matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases, which belong to a 
larger group of metzincin superfamily. Collectively, MMPs are implicated in tissue 
remodelling processes, chronic inflammatory conditions and are capable of degrading all 
kinds of extracellular matrix proteins (ECM). More recently they have been found to be 
involved in multiple mechanisms of immunomodulation (Taylor, Hattle et al. 2006; Sheen, 
O’Kane et al. 2009). MMPs are also known to be involved in the cleavage of cell surface 
receptor proteins, processing of bioreactive molecules, chemokine processing, defensin 
activation, wound healing and have a major role in cell behaviours such as cell-trafficking 
and leucocyte recruitment (Elkington, O’Kane et al. 2005; Gueders, Foida et al. 2006).   
 
MMPs can be classified broadly by substrate specificity into stromelysins (MMP-3, MMP-10 
and MMP-11), collagenases (MMP-1, MMP-8, MMP-13 and MMP-18), gelatinases (MMP-2, 
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and MMP-9), elastases (MMP-7, MMP-12) and membrane-type MMPs (MT-MMPs, MMP-
14, MMP-15, MMP-16 and MMP-17) (Parks, Wilson et al. 2004). However, this 
classification is artificial as there tends to be overlap in substrate specificity and redundancy 
of function among many of the MMPs. Table 3 is a summary of the various classes of MMPs 
and Tissue inhibitors of metalloproteinases (TIMPs) analysed in this study as well as their 
biological roles and the alternative names. Table 3 shows a summary of the different MMPs 
and their classifications as well as some common biological functions. 
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(Adapted from Parks et al 2001, Manocone and McGuire 2008, Visse and Nagase 2003, 
Shapiro and Senior 2009) 
 
 
 
 
 
 
Table 3 Summary of the classification of different MMP and TIMP genes and their biological function 
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In healthy lung, MMPs and their physiological inhibitors, TIMPs are produced in the 
respiratory tract by a panel of different structural cells and perform multiple roles in normal 
immune response to infection (Elkington, O’Kane et al. 2005). A strong connection between 
immune responses and MMP activity has recently emerged and MMPs have been shown to 
mediate the expression of immunity to infectious pathogens as well as inflammatory 
processes (Taylor, Hattle et al. 2006). Excessive MMP secretion has been linked with tissue 
damage in rheumatoid arthritis, pulmonary fibrosis and chronic obstructive pulmonary 
disease. Host derived MMPs are necessary for the successful eradication of infection which 
requires the influx of effector cells, killing of pathogen, resolution of inflammation and the 
remodelling of ECM (Elkington, O’Kane et al. 2005). 
 
As with most enzymes with the potential to damage the host, MMPs are tightly regulated. 
There are three main regulation mechanisms of MMP synthesis and function:  
1. Transcriptional activation of MMPs as they are rarely stored, but requires increased 
gene transcription to drive secretion. 
2. Post-transcriptional processing of MMPs secreted as latent pro-enzymes that undergo 
proteolytic cleavage for activation. 
3. Control of MMP activity by secretion of specific endogenous inhibitors (TIMPs) and 
α-macroglobulin which bind in a non-covalent manner to the MMPs (Gueders, Foida et al. 
2006). 
	  
Emerging data suggests a strong association of MMP activity with the various pathological 
states associated with tuberculosis (Sheen, O’Kane et al. 2009; Elkington, D'Armiento et al. 
2011). A number of studies have shown that MMPs, particularly MMP-9 is highly expressed 
during various manifestations of tuberculosis, including active cavitary and tuberculous 
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pleuritis. In order to disseminate, MTB must drive host tissue destruction, thus resulting in 
pulmonary cavitation. MTB disseminates from an initial seeding site to initiate a host 
response that results in an inflammatory lesion within the lung apex, resulting in cavitation. 
Once cavitary disease develops, MTB proliferates exponentially, uncontrolled by the immune 
system and is able to disseminate. The pathogenesis of destructive lung disease caused by 
tuberculosis remains poorly understood. Evidence of tissue destruction seen frequently in 
IRIS cases includes abscess formation, suppurative lymphadenitis. Thus, there is evidence to 
suggest that MMPs may be involved in the immunopathology of TB-IRIS.  
 
 
1.11 Major Aims of the Study 
The main of my study was to characterise the immunopathogenesis of paradoxical HIV-
Tuberculosis Immune Reconstitution Inflammatory Syndrome by analysing various 
biological samples collected from patients who developed paradoxical TB-IRIS and compare 
these to similar patients who did not develop the condition. The major objectives for this 
study were: 
1. To determine levels of mRNA for selected cytokines, MMP genes and other immune 
markers in the PBMC of IRIS and non-IRIS patients i.e. in vitro. 
2. To measure the protein levels of selected cytokines and MMPs secreted in tissue 
culture supernatants of IRIS and non-IRIS control patients using different immunoassays. 
3. To determine the protein levels of the cytokines and MMPs from (1) and (2) above in 
vivo i.e. in serum samples 
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4. To determine the immune-modulatory effect of prednisone treatment in vivo on 
cytokine and MMP protein levels in sequential samples of IRIS and non-IRIS control 
patients. 
5. To determine the level of MMP activity in biological samples from IRIS patients and 
non-IRIS controls 
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2 CHAPTER 2: MATERIALS AND METHODS 
The studies presented in this thesis were aimed at characterising the immunopathogenesis of 
paradoxical HIV-Tuberculosis associated immune reconstitution inflammatory syndrome 
(HIV-TB-IRIS). In this chapter, detailed descriptions of the clinical enrolment of patients, the 
various immunological methodologies and a summary of the statistical methods that were 
employed in these studies are outlined. 
2.1 Study sites, clinical recruitment and treatment of patients 
Patient assessment, recruitment and collection of the clinical samples was conducted by 
Professor G. Meintjes and other clinical colleagues. Patients with suspected TB-IRIS were 
recruited at GF Jooste Hospital a community-based referral hospital, in Cape Town, South 
Africa, that serves communities with a high prevalence of HIV infection and TB. Patients 
were also recruited from the Ubuntu Clinic, site B Khayelitsha, Cape Town, South Africa 
between March 2005 and September 2007 Most patients are commenced on TB treatment 
and ART in community primary care clinics, but are referred to GF Jooste Hospital when 
complications occur for investigations and/or admission. New TB cases were treated with 6 
months of standard first l ne therapy consisting of isoniazid, rifampicin, pyrazinamide and 
ethambutol (HRZE) for 2 months followed by HR for 4 months (2HRZE/4HR) while patients 
with a previous history of TB had streptomycin added to their treatment regimen. All patients 
were prescribed first line cART combination of stavudine (d4T), lamivudine (3TC), and 
either efavirenz (EFZ) or nevirapine (NVP). Participants were monitored fortnightly for a 
period of two months after initiation of cART. Observation during this study was 12 weeks 
(84 days) after starting cART. Patients who developed paradoxical TB-IRIS were recruited at 
onset of symptoms while non-IRIS controls were recruited on day 14 of follow-up after 
commencing 
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cART. This period was shown to be the median time to the development of IRIS in HIV 
positive TB patients on cART.  
2.2 Inclusion/exclusion criteria and case definitions 
Paradoxical-TB-IRIS was defined according to the published and validated International 
Network of HIV-associated IRIS (INSHI) case definition, which is described in detail in 
Section 1.5.3. (Chapter 1). Generally, patients included into the study were: cART naive, 
responded to treatment, had either clinically or microbiologically confirmed tuberculosis in 
addition to other clinical criteria. In the case of TB-IRIS, patients had to have a clear and 
confirmed diagnosis of paradoxical TB-IRIS based on a validated case definition and 
conform to WHO definitions for HIV-associated-tuberculosis. Exclusion criteria included a 
biological age less than 18 years, known rifampicin-resistant tuberculosis or multi-drug 
resistant tuberculosis, previous glucorcorticoid therapy, prior cART exposure, life-
threatening TB-IRIS and pregnancy among other clinical criteria. A diagnosis of exclusion 
was conducted to exclude alternative reasons for clinical deterioration of the TB patients. 
2.3 Ethical Approval 
The University of Cape Town Human Research Ethics Committee approved the studies 
(REC 337/2004 and 173/2005). All participants enrolled into these studies provided written 
informed consent. 
2.4 Study Designs 
Longitudinal and cross-sectional study designs were employed for the analyses presented in 
this thesis. Immunological analyses were performed on different patient subsets and are 
described in  detail in subsequent section 2.5. 
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2.4.1 Cross sectional study  
A cross-sectional study nested within an IRIS cohort was conducted to compare paradoxical 
TB-IRIS cases and control patients. Patients who were diagnosed with paradoxical TB-IRIS 
were matched with similar comparable HIV-TB control patients who were treated similarly 
but did not develop TB-IRIS. The clinical treatment of these patients is outlined in section 
2.1. For the case-control cross-sectional analysis, 22 TB-IRIS patient samples (of 32 
available) were selected randomly and compared with 22 non-IRIS control patients who 
participated in a prospective cohort study of 62 HIV-TB patients commencing cART. 
Selection of the 22 paradoxical TB-IRIS patients and 22 non-IRIS controls was then done in 
order of sample storage in the freezer provided all samples (supernatnants, RNA and serum) 
were available for each patient. Patient inclusion criteria into the study included patients who 
were (1) cART naive, (2) had clinically or microbiologically confirmed tuberculosis or 
conformed to WHO definitions for HIV-associated TB and responded to treatment (3) in the 
case of TB-IRIS had a clear and confirmed diagnosis of paradoxical TB-IRIS based on a 
validated of consensus (INSHI) case definition definition. Patients with confirmed or 
suspected rifampicin resistance o  multi-drug resistant TB were excluded. Cases and controls 
were prospectively enrolled subject to inclusion and exclusion criteria and the availability of 
sufficient sample to perform analyses (Figure 5). Observation during this study was 12 weeks 
(84 days) after starting cART and non-IRIS controls were selected from 28 patients with 
complete follow-up and sufficient sample who did not develop TB-IRIS (Figure 6). Non-IRIS 
controls were not individually matched to TB-IRIS cases: instead the range of nadir CD4, 
days of anti-TB treatment, duration of TB treatment to cART, disease form, age and gender 
of TB-IRIS cases were used to define similar non-IRIS controls. Baseline viral load was not 
available in all cases and was therefore not factored. The median interval between starting 
antiretroviral therapy and the onset of TB-IRIS was 14 days (table 5). The baseline and 
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clinical charecteristics of these patients are summarised in Section 3.2. and in Table 5. Figure 
5 and Figure 6 below show flow diagrams to illustrate the patient recruitment and selection 
for TB-IRIS and non-IRIS control patients described in the studies presented in Chapters 3, 4 
and 5 of this thesis. Results of the cross-sectional analysis are presented in Chapters 3, 4 and 
6 of this thesis. 
 
2.4.2 Randomised Placebo-controlled trial of prednisone for Paradoxical TB-IRIS 
Between 2 June 2005 and 20 December 2008, prior to my involvement in the study, patients 
were enrolled participants into a randomized placebo-controlled clinical trial of prednisone 
for the treatment of paradoxical TB-IRIS at G.F. Jooste Hospital in Cape Town, South Africa. 
Consecutive patients were screened using the standardised INSHI TB-IRIS case definitions. 
Enrolment was limited to the following four TB-IRIS manifestations to reduce clinical 
heterogeneity and allow longitudinal radiographic comparison. Only patients with new or 
recurrent tuberculosis symptoms and at least one of the following TB-IRIS manifestations 
were enrolled: infiltrate on chest radiograph, enlarging lymph nodes, serous effusion, or cold 
abscess. If significant clinical deterioration occurred after 2 weeks of follow up, the study 
protocol allowed participants to be switched to open label prednisone or earlier if life-
threatening deterioration occurred. Follow-up was for 12 weeks. Patients were closely 
monitored during the follow-up period to ensure that cases of TB-IRIS were identified early, 
thus ensuring compliance and adherence to cART and TB therapy. An increase in CD4 count 
was also evidence of immunological response, hence compliance to cART in these patients. 
Additionally, since TB-IRIS is a complication of the two combined therapies, non-adherence 
to cART and anti-TB therapy would prevent the developmnet of TB-IRIS.  
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The primary endpoint of this study was cumulative number of days hospitalized and number 
of outpatient therapeutic procedures performed counted as one additional hospital day. 
Secondary endpoints of efficacy included symptom score, quality of life score, Karnofsky 
performance score, chest radiography and C-reactive protein. Patients with immediately life 
threatening TB-IRIS were excluded. TB diagnosis was made mainly on the basis of culture, 
smear microscopy or clinico-radiological diagnosis.  
 
Patients were randomised either onto the study drug which consisted of 5mg of prednisone 
tablets or matching placebo. Participants received study medication of 1.5mg/kg per day for 
two weeks followed by another 0.75 mg/kg per day for two weeks. Patients were followed up 
at 1, 2, 3, 4, 8 and 12 weeks and blood samples taken at each time point.  Each participant 
underwent full clinical evaluation and chest radiography. Further investigations were 
conducted to exclude alternative reasons for clinical deterioration. Patient selection for the 
subset of RCT patients analysed and presented in this thesis, patient selection was also 
dependent on availability of a complete set of follow-up sample samples for the 
immunological analysis. For the analysis presented in Chapters 3 and 4 of this thesis, 16 
prednisone treated and 12 placebo treated patients who had sufficient samples (RNA, 
supernatant and serum) at the 0, 2 and 4 week time-points of follow-up were selected for 
analysis. 
2.4.3 Longitudinal study 
Consecutive patients with suspected TB-IRIS were evaluated from January 2006 through 
September 2007 at G.F Jooste, a community-based secondary hospital in Cape Town, South 
Africa (Meintjes, Wilkinson et al. 2008). Patients were recruited as per the INSHI clinical 
case definition exclusion using the inclusion criteria described above in section 2.2. 
Longitudinal analysis was of a prospective cohort of 50 adult patients who started cART 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 36 
whilst on TB treatment. Participants were prospectively followed-up during the study period 
and were monitored four times for a period of 12 weeks after initiation of cART. The main 
clinical outcome was paradoxical TB-IRIS. Eleven patients developed TB-IRIS while 39 did 
not develop symptoms of TB-IRIS. The 11 patients who developed TB-IRIS were compared 
to 16 controls who did not develop TB-IRIS under the same conditions for the longitudinal 
analysis (on the basis of adequate follow-up sample availability). Figure 5 and 6 below show 
summary flow diagrams of the general patient recruitment of TB-IRIS and non-IRIS control 
patients for these studies. 
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Figure 5 Flow chart summarizing the patient recruitment and selection of TB-IRIS patients. 
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Figure 6 Flow chart showing the patient recruitment and selection of control non TB-IRIS 
patients. 
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2.5 Tissue culture protocols and sample cryopreservation 
2.5.1  PBMC Isolation  
Dr Katalin Wilkinson, Kerryn Matthews, Keira Skolimowska and other colleagues in the 
Wilkinson lab are acknowledged for the preliminary tissue culture, sample processing and  
sample cryopreservation that was performed prior to my involvement in this study. The tissue 
culture work included isolation of PBMC, cell culture, tissue culture supernatants, processing 
of serum samples and sample cryopreservation. Blood (9mls) was collected by venipuncture 
into sodium-heparin containing plastic tubes and transported at RT for processing in the lab. 
Blood was diluted with an equal volume of PBS and carefully layered onto 10ml of Ficoll-
Paque in a new 50ml Falcon tube (Ficoll-Paque TM Plus GE Healthcare, Uppsala, Sweden). 
The tube was centrifuged for 20 minutes at 700 x g. After this the white layer of cells at the 
PBS/Ficoll inter-phase was carefully aspirated off using a Pasteur pipette and transferred into 
a tube containing 15ml of fresh RPMI. Cells were washed twice by centrifuging in RPMI at 
600 x g for 10 minutes. After the second wash, cells were resuspended into 10 ml of RPMI. A 
10ml aliquot was stained with Trypan blue and cells counted on a haemacytometer to 
determine viability and numbers. The remainder of the PBMC was then used in the tissue 
culture protocols as described below.  
 
2.5.2  Cell Culture Experiments 
PBMC were plated in RPMI/10% FCS as follows:  5x106/2ml/well in 6 well plates (4 wells) 
OR  2.5x106/ml/well in 6 well plates (4 wells) OR 2.5x106/1ml/well in 6 well plates (2 wells 
for the 24 hour time point i.e. RNA& supernatant). For these experiments, we wanted to 
stimulate the PBMC with the most relevant antigen, a whole bacterium. H37Rv is the best 
characterised and most widely used laboratory strain of Mycobacterium tuberculosis and is a 
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whole antigen and hence was used in these assays. We hypothesized that the immune 
response in IRIS would be in response to dead mycobacteria, hence we used heat killed 
H37Rv. Additionally, the heat killing would make H37Rv non-virulent, allowing the assays 
to be conducted in a Biosafety Level 2 (P2) laboratory facility. Cells were rested overnight in 
an incubator and re-stimulated the following morning with Heat Killed H37Rv 
Mycobacterium tuberculosis antigen (kindly supplied by Professor Mark Nicol). Antigen was 
aliquoted at 5 X107 and PBMC infected at a multiplicity of infection (MOI) =1 (Bacteria: 
PBMC).  Table 4 shows a summary of how the tissue culture experiments were performed. 
 
Table 4 Summary of Cell Culture protocols 
 
 
2.5.3 Serum isolation procedure 
Serum was harvested from 5mls of blood collected in a yellow top BD vacutainer tube by 
spinning the blood for 7 minutes and aspirating the serum. Na-azide (10µL of 1% solution) 
PBMC + 
HkH37Rv 
(stimulated) 
PBMC- 
HkH37Rv 
(unstimulated) 
PBMC + 
HkH37Rv 
(stimulated) 
PBMC- 
HkH37Rv 
(unstimulated) 
6 hours 6 hours 24 hours 24 hours 
Supernatant 
Discarded 
PBMC Lysed for 
RNA 
Supernatant 
Discarded 
PBMC Lysed for 
RNA 
Supernatant 
cryopreserved 
PBMC Lysed for 
RNA 
Supernatant 
cryopreserved 
PBMC Lysed for 
RNA 
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was added to the serum to make a final concentration of 0.01% before cryopreserving the 
serum samples at -80°C for further analyses. 
2.5.4 RNA Lysis Procedure 
After 6 and 24 hours of stimulation, cells were lysed in 350µL of RLT-lysing buffer 
(Qiagen, Valencia, CA) with Beta-Mercaptoethanol added. A cell scrapper was used to 
dislodge the cells. Cells were aspirated in lysis buffer and then transferred to QIAshredder 
column (Qiagen, Valencia, CA). The QIAshredder was placed in collecting tubes and the 
tubes centrifuged at 14 000 rpm for 2 minutes. Tubes were labeled and the lysates stored at -
80°C until required for RNA extraction. 
2.6  Quantitative RT-PCR 
2.6.1 RNA Extraction Procedure 
RNA was extracted from cryopreserved PBMC lysates (using the RNeasy Kit Mini (Spin) 
Protocol for Isolation of Total RNA from Animal Cells (Qiagen, Ontario, Canada) as per 
manufacturer’s instructions. About 350µL of 70% ethanol was added to the homogenized 
lysate and mixed by pipetting up and down. Sample (700µL) was then applied to the RNeasy 
mini column placed in a 2ml collection tube which was then centrifuged for 15 seconds at 10 
000 rpm. Flow-through was discarded before addition of and washing of the column with 700 
µL of Buffer RW1. The column was washed twice by spinning with RW1 buffer and the flow 
through being discarded each time. To ensure complete drying and removal of residual 
ethanol from the column, after washing with Buffer RPE buffer, the column was spun at full 
speed to remove excess alcohol. RNA was finally eluted from the column by spinning the 
column for 1 minute at 10 000 rpm with 30-50 µL of RNase-free water. Eluted mRNA 
concentration was measured using the NanoDropTM ND-1000. To attain an RNA working 
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solution of at least 10ng/µL for each sample mRNA samples were diluted appropriately using 
RNase-DNase free water. 
 
2.6.2 Real Time-PCR  
The TaqManR RNA-to-CtTM 1-Step Kit Protocol (P/N 4392668) from Applied Biosystems 
was used for RT-PCR according to the manufacturer’s instructions (Foster City, California, 
USA). The reaction mixture was set-up as outlined below: 10µ L of Predesigned Ready to 
use Assay (PDAR), 1µL of RT-PCR Mix, 0.5µL of TaqManR RT-Enzyme Mix and 8.5µL of 
diluted mRNA to make up a reaction volume of 20µL for each sample. Non-template controls 
were included and the reaction performed in MicroAmpR Optical 96-well reaction plates on 
an Applied Biosystems sequence detection system (ABI 7000). The following universal PCR 
thermal cycling conditions were used: reverse transcription Step at 48°C for 15 minutes 
(hold), enzyme activation step 95°C for 10 minutes (hold), denaturation Step 95°C for 15sec 
(40 cycles), and annealing/primer extension 60°C for 1 minute (40 cycles).  
 
Normalisation of RT-PCR was performed using Beta Actin primers purchased from the 
University of Cape Town Molecular and Synthetic DNA Laboratory, while probes were 
purchased from Applera South Africa (Foster City, California, USA). The Beta Actin assay 
was performed as per manufacturer’s instructions. The sequences of the Beta Actin primers 
and probes used in these assays are described below:  
Beta actin Forward Primer: 5' CCT GGCACCAGCACAAT 3' 
Beta actin Reverse Primer: 5' GCCGATCCACACGGAGTACT 3' 
Beta actin Probe: 5' ATCAAGATCATTGCTCCTCCTGAGCGC 3' + MGB probes 
The reaction was performed by mixing 0.5µL with 0.75 µL of the forward primer and 0.75 
µL of the reverse primer together with 8.5µl of diluted mRNA or water (in the non-template 
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controls) to make up a volume of 20µL for each reaction. The PCR reaction was performed 
under the same conditions as described below. 
 
2.6.3 TaqManR Gene Expression Assays and Assay Details 
Primers and probes were purchased from Applied Biosystems (Applied Biosystems, Foster 
City, California, USA) as Predesigned ready to used (inventoried) assay reagents in a single 
formulation tube. Primers with a shorter amplification length were preferred. The following 
TaqManR gene expression assays were used: Assay ID: IL-1β, Catalogue Number 
Hs00174097_m1; Assay ID: IL-2, Catalogue Number Hs00174114_m1; Assay ID: IL-4, 
Catalogue Number Hs00174122_m1; Assay ID: IL-5, Catalogue Number, Hs00174200_m1; 
Assay ID: IL-6, Catalogue Number Hs00985639_m1; Assay ID: IFN-γ, Hs00174143_m1; 
Assay ID: TNF-α, Catalogue Number Hs00174128_m1; Assay ID: IL-8, Catalogue Number 
Hs01038788_m1; Assay ID: IL-10, Catalogue Number Hs00174086_m1; Assay ID: IL-
12p40, Catalogue Number Hs01011518_m1;  Assay ID: lL-13, Catalogue Number 
Hs00174379_m1; Assay ID: IL-15, Catalogue Number Hs00542562_m1; Assay ID: IL-17A, 
Catalogue Number Hs00174383_m1;  Assay ID: IL-18, Catalogue Number Hs01038788_m1; 
Assay ID: IL-19, Catalogue Number Hs00604657_m1;  Assay ID: IL-20, Catalogue Number 
Hs00218888; Assay ID: IL-21, Catalogue Number Hs00222327_m1; Assay ID: IL-22, 
Catalogue Number Hs00222327_m1; Assay ID: IL-23 , Hs00413259_m1; Assay ID: IL-24, 
Catalogue Number Hs01114274_m1; Assay ID: IL-26, Hs00218189_m1; Assay ID: IL-27, 
Catalogue Number Hs00377366_m1; Assay ID: IL-28, Catalogue Number 
Hs0000820125_m1; Assay ID: IL-29, Catalogue Number Hs00601677_m1; Assay ID: GM-
CSF, Catalogue Number Hs00171266_m1; Assay ID: TGF-β1, Catalogue Number 
Hs00171257_m1;  Assay ID: TNF, Catalogue Number Hs00174128_m1; Assay ID: MMP-1: 
Hs00899658_m1;  Assay ID: MMP-2: Hs00234422_m1;  Assay ID: MMP-3: 
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Hs00968308_m1; Assay ID: MMP-7: Hs01042795_m1; Assay ID: MMP-
8:Hs01029057_m1; Assay ID: MMP-9: Hs00957555_m1; Assay ID: MMP-10: 
Hs00233987_m1; Assay ID MMP-11: Hs00968295_m1; Assay ID: MMP-12: 
Hs00159178_m1, Assay ID:  MMP-13: Hs00233992_m1; Assay ID: TIMP-1: 
Hs99999139_m1; Assay ID  TIMP-2: Hs00234278_m1. 
 
2.7 Cytokine Protein Quantification 
Luminex  XMAPTM technology is a fluorescent bead-based technology based on a 
combination of existing flow cytometry technology, microspheres (or beads), lasers, digital 
signal processing and traditional chemistry. Microspheres are dyed internally with red and 
infrared fluorophores in different ratios.  At least 100 different ratios are used to make 100 
different bead sets, which allows for the simultaneous detection of multiple analytes in a 
single sample. Each bead is unique with a spectral signature determined by the red and 
infrared dye ratio and can be uniquely identified by a classification laser. The immune-
complex microsphere is then excited by the classification laser. Luminex is able to identify 
the specific bead and quantify the specific emission. Luminex kits from different 
manufactures are commercially available. Detailed descriptions of the kits used in this work 
are outlined in the following section. 
 
2.7.1 Luminex Analysis of Cytokines 
Customized commercial MilliplexTM XMAP kits were purchased from Millipore (Human 
Cytokine/Chemokine, Catalog Number: MPXHCYTO-60K, MPXHCYTO-60KPMX, St 
Charles, Missouri, USA). Cytokine levels in 24 hour tissue culture supernatants and serum 
samples were assessed using 96-well filter plates, on a Bio-Plex platform, Bioplex ™Bio-Rad 
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100 analyser (Bio-Rad Laboratories, Hercules, USA), according to the manufacturer’s 
instructions. Cytokine assays were performed on an 8-plex panel or 9-plex panels depending 
on whether the analytes required sample dilution. For IFN-γ, IL-10, IL-12p40, IL-2, IL-15, 
IL-13, IL-5, IL-4 the assay was performed on 8-plex panels with the samples assayed as neat. 
Samples were diluted 1:10 before measuring IL-8, IL-1β, MIP-1α, MIP-1β, IL-6, RANTES, 
TNF-α, GM-CSF, and IP-10 on a 9-plex panel.  Antibody-immobilised beads vials containing 
each of the analytes were vortexed before mixing them and making up the final volume of the 
bead mix to 3ml with Bead Diluent.  Before the assay, the 96-well filter plate was pre-wet by 
adding assay buffer into each well and incubating the plate. Assay buffer was then vacuumed 
out before adding 25µL of either standard or control to the appropriate wells. A similar 
volume of assay buffer was added to the sample wells, followed by 10% FCS RPMI where 
appropriate (for the diluted 9-plex plate). Sample was added into the appropriate wells, 
followed by 25µL of pre-mixed beads. Following incubation, excess fluid was removed by 
vacuum from the plate before washing with wash buffer. Detection antibody was added to 
each well followed by a further 30 minute incubation of the plate at RT. Without removing 
the contents, 25µL of Streptavadin-Phycoerytrin conjugate, the reporter molecule, was added 
to each well to complete the reaction. After incubating for 30 minutes, all contents were 
vacuumed out before a final wash. Sheath fluid was added to each well to resuspend beads 
before reading the plate on a Biorad Luminex platform.  
 
2.7.2 ELISA immuno-Assays 
2.7.2.1 Measurement of IL-17  
The quantitative determination of IL-17A protein levels were performed as per 
manufacturer’s recommendations using commercial eBioscience Human ELISA Ready-Set 
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Go Kit (Catalog numbers: 88-71760). NUNC Maxisorp 96 well plates were coated with 100 
µL of capture antibody diluted in coating buffer and incubated overnight. After washing off 
excess antibody, the wells were blocked with 200µL of assay diluent before the plate was 
incubated for 1 hour. Standards were prepared by a -fold dilution together with the samples 
added to the plate, followed by further incubation at RT for 2 hours. Detection antibody was 
added, followed by diluted Avidin-HRP and 30 minutes of incubation. After incubation, 
substrate solution was added and the reaction developed by incubating at room temperature. 
The reaction was stopped with 2M H2SO4 stop solution after 15 minutes and OD read at 
450nm on a microplate reader. The IL-17A had a sensitivity of 4pg/ml. 
2.7.2.2  Measurement of Interferon-γ 
Interferon-γ was measured using an in-house developed ELISA protocol using purified anti-
human IFN-γ antibody pairs from BD Pharmingen™ (Catalogue number: 551221).  A NUNC 
plate was coated overnight at 4°C with 50 µL per well of capture antibody. PBS-Tween wash 
buffer was used to wash the plates before blocking with 200 µL PBS/10% FCS and 
incubating for 2 hours at RT. Standards were serially diluted 1:3, added to the washed plate 
together with 100µL of sample per well and the plate incubated overnight at 4°C. Following 
incubation, the plate was washed, 100µL of biotinylated secondary antibody added, incubated 
at RT for 45 minutes and the excess antibody washed off before addition of diluted Avidin-
Peroxidase. After 30 minutes of incubation with OPD substrate solution, the reaction was 
stopped and OD measured on a plate reader at 490nm.  
2.7.2.3 Measurement of TGF-β1 
Transforming Growth factor beta-1 (TGF-β1) was measured using antibody pairs from R&D 
Systems (Catalog Number: DY240) as per manufacturer’s recommendations. The samples 
were not acid activated for this assay. A NUNC ELISA plate was coated with 100µL of 
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capture antibody diluted in PBS and incubated at RT overnight. After repeated washing of 
excess antibody with 400µL of wash buffer, 300µL of block buffer was added and the plate 
incubated for an hour. Following washing, samples and standards were added and the plate 
incubated for 2 hours. After incubation, 100µL of secondary antibody was added and the 
plate incubated for 2 hours at RT. After washing off excess antibody, streptavidin-HRP was 
added and the plate incubated for 20 minutes. Substrate solution was then added and the plate 
incubated at RT, after which, the reaction was stopped and optical density determined by 
reading in a microplate reader at 450nm. 
2.7.2.4 Measurement of Interleukin-22 
IL-22 protein was determined using the Human IL-22 Immunoassay Quantikine kit from 
R&D Systems (Catalog Number: D2200). Reagents and samples were prepared as per 
manufacturer’s instructions. Wells were pre-wet by dding 100µL of Assay diluent to each 
well, followed by 100µL of standard or sample to the appropriate wells. After 2 hours of 
incubation at RT, the plate was repeatedly washed  before adding 200µL of conjugate and 
incubating further for two hours. After washing off excess conjugate enzyme, 200µL of  
substrate solution was added, incubated for 30 minutes and the reaction stopped as soon as 
colour had  developed. The OD of the plate was  read on a microplate reader at 450nm. The 
assay had a sensitivity of 15.6pg/ml. 
2.7.2.5 Measurement of Interleukin-19 
IL-19 was determined using the Human IL-19 Immunoassay Quantikine Kit from R&D 
Systems (Catalog Number: D1900) as per manufacturer’s recommendations. Reagents, 
working standards and samples were prepared as instructed. Prior to the addition of 
standards, controls and samples, 100µL of assay diluent were added to each well, followed by 
incubation of the plate at RT for 2 hours. After repeated washing of the plate with 400µL, 
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200µL of IL-19 conjugate were added to each well. After a 2 hour incubation period at RT, 
substrate solution was added followed by further 30 minute incubation in the dark with 
monitoring. Soon after colour development, the reaction was stopped and OD determined on 
a microplate reader at 450nm. The assay had a sensitivity of 12.2 pg/ml. 
2.7.2.6 Measurement of Interleukin-21 
IL-21 protein concentration was determined using LEGEND MAXTM Human IL-21 ELISA 
kit (Catalogue Number: 433807) from BioLegend (San Diego, CA, USA) according to the 
manufacturer’s recommendations. Reagents were left to stabilise to RT and standards 
prepared as per manufacturer’s instructions. The pre-coated ELISA plate was washed  and 50 
µL of assay buffer added to pre-wet the plate, followed by addition of 50 µL of standards or 
samples to the appropriate wells. The plate was sealed and incubated for 2 hours at RT with 
constatnt shaking. Following this, the plate was washed and 100 µL of detection antibody 
added to each well, followed by a further 1 hour of incubation at RT with constatnt shaking. 
After repeade washing steps, 100 µL of Avidin HRP D solution was added to each well 
follwed by 30 minutes of incubation. Substrate solution was added and the reaction plate 
incubated for 30 minutes in the dark, followed by stopping solution and reading of the OD at 
450nm.  The sensitivity of this assay was 4.2 pg/ml 
2.7.2.7 Measurement of Interleukin-7 
IL-7 was analysed using the IL-7 quantikine High sensitivity (HS) assay (Catalogue number 
HS750) purchased from R&D Systems, (Minneapolis, USA) as per manufacture’s 
instructions. Reagents were brought to RT before being prepared and standards were 
reconstituted before serial dilutions to produce the standard curve. Fifty  µL of assay diluent 
were added to each well to solubilise the precoated antibody before addition of 200 µL of 
sample or standards to the appropriate wells. To maximise sensitivity, the plate was incubated 
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overnight for 20 hours at RT. The plate was then washed thoroughly with 400 µL of wash 
buffered 6 times, ensuring complete removal of residual buffer by inverting the ELISA plate 
on dry paper towels in between each wash. After the washing steps, 200 µL of IL-7 conjugate 
was added into each well before incubating the plate for a further 2 hours at RT, following 
which the wash steps were repeated.  Fifty µL of susbtrate solution were then added to each 
well and the plate incubated for 45 minutes. After this incubation, amplifier solution was 
added, followed by a further 45 minute incubation. After colour development, 50  µL of stop 
solution were added to stop the reaction. The optical density of each well was determined on 
a microplate reader set at 490 nm. This assay had a sensitivity of 0.6 pg/ml. 
 
2.8 Analysis of Matrix metalloproteinses(MMPs)  and their inhibitors  
Protein levels for the different MMPs and TIMPs as well as MMP/TIMP complexes in tissue 
culture supernatants and in serum samples were analysed using Luminex technology and 
ELISA protocols as outlined in this section. 
2.8.1 MMP Multiplex analysis  
Luminex assays for MMPs were performed on the BIO-RAD Bioplex 200 System using the 
Fluorokine MAP Kit Protocol (Catalogue Number LMP001, R&D Systems, Inc) as per 
manufacturer’s recommendations. The reaction plate was prepared by pre-wetting with 
100µL/well of wash buffer and then vacuuming out excess liquid. Diluted microparticle 
mixture (50µL) was added to each well followed by 50µL of sample or standard to each well. 
The plate was incubated for 2 hours at RT on a microplate shaker. For MMP-1, -2, -3, -7, -8, 
-12 and -13, samples were assayed undiluted. To measure MMP-9, the tissue culture 
supernatant was diluted 1:100 and was assayed on a separate plate from the rest of the 
analytes. The plate was washed three times by adding 100 µL of wash buffer and then 
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vacuuming out excess liquid. After washing, 50µL of diluted Biotin Antibody cocktail was 
added to all wells followed by 1 hour incubation at RT. Washing was repeated, followed by 
addition of Streptavidin-PE to all the wells. The plate was further incubated for 30 minutes 
before repeating the wash steps. The plate was then read on a Biorad Luminex analyzer 
within 90 minutes of preparation at both high and low PMT instrument settings. Extra 
dilutions were included at the lower end of standard curve for low RPMI readings and the 
machine recalibrated to capture analytes at low concentration. At all times, care was taken to 
protect microparticles from light. 
 
2.8.2 Human MMP-10 ELISA 
The concentration of MMP-10 protein in the tissue cultur  supernatants and serum samples 
was measured using the Human MMP-10 quantikine kit from R&D Systems (Catalogue 
number DM1000). This kit measures human pro-MMP10.  Reagents, working standards and 
samples were prepared and diluted as per manufacturer’s instruction. Assay diluent (100µL) 
was added to each well followed by 50µL of standard, control or sample to the appropriate 
wells. The plate was incubated for 2 hours on a plate shaker followed by washing with 400µL 
of wash buffer. Following washing, 200µL of MMP-10 conjugate was added to each well and 
the plate incubated at RT for a further 2 hours. Substrate solution was then added to each well 
followed by 30-minute incubation for colour development, after which the reaction was 
stopped and OD read on at 450nm. The assay has an average sensitivity of 4.13 pg/ml. 
 
2.8.3 Tissue inhibitors of Matrix Metalloproteinases (TIMP) Assays 
Levels of human TIMP-1 and TIMP-2 protein as well as TIMP-2/MMP-9 and TIMP-
1/MMP-2 complexes in tissue culture supernatants and serum samples were measured using 
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Duoset ELISAs from R&D Systems (catalog numbers: DY970, DY971, DY1453, DY1496 
respectively). Reagents and samples were prepared and diluted according to the 
manufacturer’s protocol. A 96 well microplate was coated with 100µL of diluted capture 
antibody and the plate incubated at RT overnight. The plate was washed twice with 400µL of 
wash buffer before blocking each well with 300µL of reagent diluent. Following a further 
one-hour of incubation the plate was washed again and this was followed by addition of 
samples and standards. After another wash step, and incubation with detection antibody for 2 
hours, excess antibody was washed off and 100µL of streptavidin-HRP was added to each 
well. After incubating with substrate solution at RT for 30 minutes, the reaction was stopped 
and optical density measured on a microplate reader set to 450nm. The TIMP-1 assay had a 
sensitivity of 11pg/ml while the TIMP-2 assay had a sensitivity of 18pg/ml.  
 
2.8.4 Gelatin Zymography  
Enzyme activity for MMP-9 was measured using an established gelatinase zymography 
method. This technique involves the electrophoresis of secreted protease enzymes through 
discontinous polyacrylamide gels containing enzyme substrate (which can be either type III 
gelatine or B-casein). After electrophoresis, removal of SDS from the gel by washing in 2.5% 
Triton X100 solution allows enzymes to renature and degrades the protein substrate. Staining 
of the gel with commassie blue allows the bands of proteolytic activity to be detected as clear 
bands of lysis against a blue background.   
 
Tanks and components sufficient for two gels were washed with distilled water and dried 
before assembly. Reagents and buffers for this assay are summarised in Appendix 2. A gel 
slab sandwich was constructed and locked into the base unit. The running gel was made and 
poured with a 25 ml pipette, and overlaid with 1ml of isopropanol at the top. The gel was left 
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to set for about 20 minutes, after which the isopropanol was poured off, combs inserted and 
stacking gel poured until overflowing and left to set for 30 minutes. After this, gels were 
assembled ready to place in tanks and running buffer poured to check for leaks, before 
placing in a large tank ready to run. Standards and samples were prepared and 20µL loaded 
into each well. The gel was left to run at 180V for 4 hours until the blue marker ran off the 
gel. After this, running buffer was poured off and the gel sandwich dismantled. The stacking 
gel was cut off and a top corner of the gel nipped off for orientation of the gel. The gel was 
incubated with 200 ml of 2.5% Triton X-100 for 1 hour at RT with gentle shaking to wash off 
the SDS. Collagenase buffer was then used to rinse and incubate the gel overnight (16 hours) 
at 37°C. The following day, collagenase buffer was poured off and the gel rinsed in distilled 
water before incubating it at RT with gentle agitation in staining solution for 2 hours. 
Staining solution was poured off and rinsed in distilled water before capturing an electronic 
image of the gel on a Syngene Bio Imaging GelDoc system (Syngene, Hong Kong). Scion 
image analysis software was used to analyse the images by determining densitometry of the 
clear bands to measure gelatinase activit  of MMP-9.  
2.9 Statistical Analysis 
The main comparisons were between TB-IRIS and non-IRIS contol patients. Comparisons 
were also made between prednisone treated and placebo treated TB-IRIS patients from the 
RCT. Data derived from gene expression studies is not normally distributed. However, 
logarithmic transformation should make the data more symmetric reducing the effect of 
outlier values and inter-experimental variations.  Based on preliminary studies, typical 
standard deviations for log-transformed gene expression data from exactly the same genes 
have a range of 0.4 to 1.4 (unpublished data). Using a sample size of 21 samples in each arm 
(i.e IRIS vesus non-IRIS) at a 95% confidence interval would give us a conventional power 
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of 80% , thus making the findings well-powered and generalisable. Based on these statitics, 
we used a sample size of 22 TB-IRIS cases and 22 non-IRIS controls for the cross sectional 
analysis. 
 
The delta delta (∆ ∆CT) method used was used for analysis of the RT-PCR data. In this 
method, ∆ CT is calculated by subtracting the Ct of the housekeeping gene from the Ct of the 
gene of interest. Beta actin was used as the housekeeping gene through out these experiments. 
The ∆ CT of the unstimulated sample was then subtracted from that of the stimulated sample 
to obtain ∆∆ CT. Fold induction was obtained by adding this value to the mathematical 
equation 2 -∆∆CT. This value was then log 10 transformed and used for the fold induction 
analyses.  
 
GraphPad Prism® Version 5.03 software for windows, and Mac was used for analysis 
(GraphPad Software, San Diego California USA). Normality of the data was assessed by the 
D'Agostino & Pearson omnibus normality test. Medians were quoted ± IQR and means ± SD. 
Paired parametric data was analysed by the student’s paired t-test, or repeated measures 
ANOVA. Paired non-parametric data was analysed by the Wilcoxon signed rank test or 
Friedman test. Unpaired parametric variables such as comparisons of Delta CT between IRIS 
and non-IRIS were assessed using the unpaired t-test for parametric data. The Mann Whitney 
U test was used for analysis of unpaired non-parametric data such as the Delta Ct values 
between stimulated and unstimulated patients. Comparisons between stimulated and 
unstimulates IRIS or non-IRIS patients were performed using the Wilcoxon matched-pairs 
signed rank test. RT-PCR fold induction data was analysed by using unpaired analyses 
(unpaired t-tests) and the data treate as continous variables. Cytokine and MMP 
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concentrations were treated as continous variables and were analysed by repeated measures 
ANOVA and paired t-tests 
 
Randomised-controlled trial (RCT) samples were analysed by one-way ANOVA using the 
Kruskal Wallis test with no post test correction to accommodate incomplete follow-up data 
sets. To factor multiple comparisons, p values were multiplied by n-1. Correlations were 
determined by non-parametric correlation (Spearman correlation) between the selected data 
sets such as INF-gamma ELISA versus luminex, Delta CT versus cytokine concentration and 
MMP versus cytokine concentrations.  
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3 CHAPTER 3: THE ROLE OF PRO- AND ANTI-
INFLAMMATORY CYTOKINES IN THE IMMUNOPATHOLOGY OF 
HIV-TB ASSOCIATED IRIS 
3.1 Introduction 
Apart from initiation of ART, the causes of immunopathology in IRIS occurrence in patients 
with tuberculosis remain incompletely understood. Initially recognised in the context of 
atypical mycobacterial infection and termed immune restoration disease (IRD) (French, 
Mallal et al. 1992), IRIS in the context of TB is clearly antigen load dependent; its risk 
factors also include a low nadir CD4 count, high HIV-1 viral load and short interval between 
commencement of antitubercular and cART therapies (Breen, Smith et al. 2004; Breton, 
Duval et al. 2004; Shelburne, Visnegarwala et al. 2005; Manosuthi, Kiertiburanakul et al. 
2006; Burman, Weis et al. 2007; Lawn, Myer et al. 2007). TB-IRIS presents temporally as 
two forms. Paradoxical TB-IRIS occurs in patients who are diagnosed with active TB prior to 
cART, are typically improving on TB treatment and then during early cART develop an 
immune-mediated paradoxical reaction with new or recurrent clinical and/or radiologic 
manifestations of TB and the less well defined: unmasking TB-IRIS.  
 
It is important to understand the immunopathogenesis of TB-IRIS in order to inform specific 
therapies. Past studies on this subject have tended to be either anecdotal or underpowered: 
particularly important considering the highly heterogenous nature of the condition. To this 
end, the pathogenesis of TB-IRIS remains ill-understood. Among the early features 
associated with TB-IRIS is the conversion of a negative TST to strongly positive after ART 
(Narita, Ashkin et al. 1998). Remarkable (Hengel, Allende et al. 2002) expansions of 
terminally differentiated tuberculin PPD specific CD4 T cells by flow cytometric analysis in 
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TST positive patients during ART in the absence of TB-IRIS have also been reported. Further 
work has documented highly dynamic M. tuberculosis antigen specific Th1 T cell expansions 
are clearly associated with cART mediated immune restoration in TB co-infected persons 
(Bourgarit, Carcelain et al. 2006; Meintjes, Wilkinson et al. 2008; Elliott, Vohith et al. 2009), 
although their absence from some patients with TB-IRIS and their presence in similar 
patients without the syndrome brings into question whether the association is causal 
(Meintjes, Wilkinson et al. 2008; Elliott, Vohith et al. 2009). One possibility is that such Th1 
expansions are associated with defective restoration of regulatory T cell function. However 
TB-IRIS patients had no difference in the numbers of CD4+FoxP3+ positive cells (assumed 
regulatory) when compared to similar patients who did not develop the syndrome(Meintjes, 
Wilkinson et al. 2008), an observation subsequently been replicated by others (Tan, Yong et 
al. 2008; Seddiki, Sasson et al. 2009). TB-IRIS has also been associated with Killer 
Immunoglobulin receptor (KIR) -negative gamma delta T cells and anti phenolic glycolipid 
antibodies (Simonney, Dewulf et al. 2008; Bourgarit, Carcelain et al. 2009) and, in a small 
subset analysis, with a peak of non-specific inflammatory cytokines/chemokines (TNF, IL-6, 
IL-1Beta, IL-10, RANTES and MCP-1) (Bourgarit, Carcelain et al. 2006). This has lead to 
the comment that, like H5N1 influenza infection and experimental anti-CD28 therapy, TB-
IRIS may be associated with a cytokine release syndrome (de Jong, Simmons et al. 2006; 
Suntharalingam, Perry et al. 2006). 
 
For this study, I hypothesized that TB-IRIS may be associated with a cytokine release 
syndrome (Ruhwald and Ravn 2007). To investigate this hypothesis, I performed a study to 
evaluate the role of pro-and anti-inflammatory cytokines in the pathogenesis of TB-IRS.  to 
investigate this hypothesis in greater depth. To investigate this hypothesis in greater depth, I 
conducted a case-control study comparing cytokine gene expression and secretion in vitro, 
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and serum cytokine levels in vivo for 22 paradoxical TB-IRIS and 22 non-IRIS control 
patients. 
3.2 Results 
3.2.1 Summary of baseline characteristics of TB-IRIS and control patients for the 
cross-sectional study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TabTable 5 Summary of baseline characteristics of 22 TB-IRIS and control patients  
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le 5 shows a summary of the baseline and clinical characteristics of the patients analysed for 
this cross-sectional analysis. For most of the variables analysed, there was no significant 
difference in the baseline characteristics including age, gender, baseline CD4 count, median 
days between starting cART and TB treatment.  However, TB-IRIS patients tended to have 
more smear or culture confirmed TB disease (p=0.045) than the non-IRIS controls. 
 
3.2.2 Transcript abundance of cytokine genes 
Transcript abundance was calculated by subtracting the cycle threshold of beta-Actin from 
that of the gene of interest to obtain a delta Ct (Δ Ct). At 6 hours the RNA for several genes 
(e.g. IL-13, IL-15 and IL-17A) in unstimulated cells from non-IRIS patients tended to be 
slightly but significantly higher than TB-IRIS (Table 6). Stimulation with MTB increased the 
abundance of all transcripts studied in both groups with the exception of TGF-b. After 
Bonferroni (n-1, 15) correction of multiple comparisons, the abundance of IL-17A was 
significantly greater in stimulated TB-IRIS cultures. At 24 hours the RNA for IL-5 in 
unstimulated cells from non-IRIS patients was significantly higher than TB-IRIS and 
conversely the levels of IL-2, IL-15 and TNF higher in TB-IRIS (Table 7). Stimulation with 
MTB increased the abundance of all transcripts studied in both groups with the exception of 
IL-18 and TGF-b (whose level significantly decreased in non-IRIS). The abundance of IL-1b, 
IL-5, IL-6, IL-10, IL-13, IL-17A, IFN-g, GM-CSF and TNF were significantly greater in 
stimulated TB-IRIS cultures. 
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Table 6 Delta CT values for cytokine genes after 6 hours of in vitro culture in the presence or absence of heat killed M. tuberculosis 
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Table 7 Delta CT values for cytokine genes after 24 hours of in vitro culture in the presence or absence of heat killed M. tuberculosis 
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3.2.3 Fold induction analysis of Cytokine genes 
The fold induction of genes was calculated by the Delta delta Ct method and values 
normalised by log10 transformation (Figure 7). In TB-IRIS patients at 6 hours IL-1b, IL-5, IL-
6 and GM-CSF were more than 100 fold induced and IL-2, IL-8, IL-12p40, IL-13, IL-17A, 
IFN-g and TNF more than 10-fold. Gene induction was higher in TB-IRIS than in non-IRIS 
controls for IL-1b, IL-2, IL-4, IL-6, IL-10, IL-13, IL-15, IL-17A, IFN-gamma, GM-CSF and 
TNF (p ≤ 0.05). Bonferroni correction of p values indicated the differences in IL-6 (mean log 
difference 0.78 ± 0.23, pcorr = 0.033), IL-12p40 (mean log difference 0.81 ± 0.26, pcorr = 
0.047), IL-13 (mean log difference 1.16 ± 0.23, pcorr < 0.01), IL-17A (mean log difference 
1.08 ± 0.33, pcorr = 0.041) and IFN-g (mean log difference 0.78 ± 0.21, pcorr = 0.011) to be 
most significant. At 24 hours the fold induction in TB-IRIS patients (with the exception of 
IL-2, IL-15 and IL-18 which showed a reduction) tended to be similar to the 6-hour time 
point. However fewer differences between TB-IRIS and non-IRIS were observed due to 
increases that occurred between 6 and 24 hours in the latter group. Significant differences 
between TB-IRIS and non-IRIS controls persisted, however for IL-8 (mean log difference 
0.64 ± 0.24, p = 0.011), IL-10 (mean log difference 0.74 ± 0.18, p = 0.002), IL-15 (mean log 
difference -0.29 ± 0.12, p = 0.021) and TGF-b1 (mean log difference 0.36 ± 0.12, p = 0.006). 
TGF-b1 tended to be minimally influenced by the presence of MTB and all fold values were 
close to baseline. 
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Figure 7 A
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3.2.4 Cytokines secreted into cell culture supernatant 
The corresponding tissue culture supernatants for 20 of the IRIS and 19 non-IRIS patients 
were assayed for cytokine content by multiplex analysis. Beads for TGF-Beta and IL-18 were 
unavailable. IL-5 and IL-15 protein were undetectable except in small quantities in 3 samples 
in the case of IL-5. IL-4 and IL-17, whose levels were close to lower detection limits, did not 
differ between TB-IRIS and non-IRIS (Figure 8). Otherwise levels were consistently and 
significantly higher in TB-IRIS. After correction of p-values for multiple comparisons the 
largest and significant fold differences were in IL-12p40 (~ 40-fold: 40 pg/ml, IQR 4-300 
versus 0, IQR 0-16, pcorr = 0.01), IL-1b (22-fold: 2616 pg/ml, IQR 399-4788 versus 118, IQR 
23-240, pcorr = 0.001), GM-CSF (9.6-fold 721 pg/ml, IQR 254-6129 versus 75, IQR 45-170, 
pcorr = 0.001), TNF (8.6-fold 6.79 ng/ml, IQR 4.62-12.67 versus 0.78, IQR 0.25-1.41, pcorr = 
0.001), IL-10 (6.4-fold 876 pg/ml, IQR 267-3070 versus 137, IQR 75-287, pcorr = 0.004), IL-
6 (6.3-fold 17.7 ng/ml, IQR 5.64-34.25 versus 2.81, IQR 0.73-5.56, pcorr = 0.01), IL-2 (3.5-
fold 283 pg/ml, IQR 100-898 versus 80, IQR 9-128, pcorr = 0.04) and IL-8 (1.4-fold 133.4 
ng/ml, IQR 117.8-144.0 versus 96.1, IQR 65.7-107.6, pcorr = 0.001). Of these cytokines only 
IL-2 is exclusively of lymphoid origin, the others being predominantly the products of 
myeloid cells. 
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Figure 8 Cytokine content of tissue culture supernatants for the most differentially upregulated 
cytokine genes 
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3.2.5 Correlation of Transcript Abundance versus Cytokine Concentrations in TB-
IRIS and non-IRIS patients 
To investigate the relationship between the mRNA levels or transcript abundance and the 
secreted cytokine concentration in the corresponding tissue culture supernatants, delta CT 
values (6 and 24 hours for TB-IRIS and non-IRIS patients) were correlated with cytokine 
concentrations. Table 8 shows a summary of the correlations of the Delta Ct versus protein 
concentrations i.e. is Spearman correlation (r) and p-values. The lower the delta Ct value the 
more abundant the transcript is; hence the negative values of the Spearman r values indicate a 
negative correlation with lower delta Ct values (more abundant transcript) expressing higher 
concentrations of cytokines. In general, there was a good correlation between transcript levels 
and cytokine concentration for many of the cytokines particularly for both 6 and 24-hour 
cultures after MTB-stimulation (Table 8). For IL-1b, IL-2, IL-4, IL-6, IL-10, IFN-gamma, IP-
10, IL-13 and GM-CSF there was a negative spearman correlation coefficient and significant 
p-values (p≤0.05) in the stimulated 6 and 24-hour cultures. However, IL-15 transcript did not 
correlate well with tissue culture supernatant protein secretion as show by the p value, which 
was not statistically significant fo  both 6 and 24 hours.  
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Table 8 Spearman Correlation and p-values of Cytokine gene expression versus secreted 
cytokine concentrations  
 
 
 
 
 
 
 
 
 
unstim	  6hrs unstim	  24	  hrs stim	  6hrs stim	  24	  hrs
spearman	  r p-­‐value spearman	  r p-­‐value spearman	  r p-­‐value spearman	  r p-­‐value
IL-­‐1b -­‐0.435 0.006 -­‐0.246 0.131 -­‐0.593 <0.0001 -­‐0.797 <0.0001
IL-­‐2 -­‐0.173 0.292 -­‐0.231 0.158 -­‐0.894 <0.0001 -­‐0.648 <0.0001
IL-­‐4 -­‐0.274 0.092 0.043 0.793 -­‐3.810 0.017 -­‐0.337 0.036
IL-­‐6 -­‐0.525 0.001 -­‐0.199 0.224 -­‐0.599 <0.0001 -­‐0.839 <0.0001
IL-­‐8 -­‐0.310 0.055 -­‐0.171 0.298 -­‐0.308 0.056 -­‐0.552 0.003
IL-­‐10 -­‐0.282 0.082 -­‐0.529 0.001 -­‐0.625 <0.0001 -­‐0.798 <0.0001
IL-­‐12 0.118 0.481 -­‐0.331 0.039 -­‐0.568 0.0002 -­‐0.275 0.090
IL-­‐15 -­‐0.249 0.126 0.029 0.860 -­‐0.112 0.496 -­‐0.147 0.371
IFN-­‐g 0.090 0.587 0.304 0.060 -­‐0.746 <0.0001 -­‐0.722 <0.0001
IP-­‐10 -­‐0.429 0.006 -­‐0.477 0.002 -­‐0.528 0.001 -­‐0.700 <0.0001
TNF 0.117 0.480 0.015 0.928 -­‐0.780 <0.0001 -­‐0.884 <0.0001
IL-­‐13 0.020 0.902 0.229 0.161 -­‐0.519 0.001 -­‐0.731 <0.0001
GM-­‐CSF -­‐ -­‐ -­‐0.771 <0.0001 -­‐ -­‐ -­‐0.848 <0.0001
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3.2.6 Internal validity of IFN-gamma determination by luminex determination  
Luminex analysis is a convenient and powerful technology but has on occasions been 
reported to correlate poorly with ELISA (arbitrarily defined as gold standard). There was 
insufficient sample to secondarily test all analytes. However the same supernatant and cells 
were additionally assayed for IFN-g secretion by both ELISA and ELISpot using the same 
stimulus, MTB H37Rv. Correlation between ELISA and Luminex values for IFN-gamma 
was very strong as shown in Figure 9 (Spearman r = 0.701, p < 0.0001).  However, Luminex 
analysis consistently rendered higher values.  
 
Figure 9 Correlation between ELISA and Luminex analysis for IFN-gamma in tissue culture 
supernatants 
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3.2.7 Cytokine concentrations in serum samples 
Based upon the quantitative RT-PCR and supernatant results we next assayed the level of the 
most consistently discriminatory cytokines in serum samples taken from the same patients at 
the same time i.e. IL-1β, IL-2, IL-6, IL-8, IL-10, IL-12p40, IL-13, TNF, IFN-γ, IP-10 and 
GM-CSF. Serum concentrations of IL-1b, IL-2, IL-13 and GM-CSF were consistently close 
to the lower limit of assay detection and did not significantly differ between TB-IRIS and 
Non-IRIS groups.  The serum concentrations of IL-6, IL-8, IL-10, IL-12p40, IFN-g and TNF 
were significantly higher in the serum of TB-IRIS patients (Figure 10). After correction of p-
values for multiple comparisons (multiplied by n-1), the largest a d significant fold 
differences were in TNF (3.3-fold 90 pg/ml, IQR 17-156 versus 27, IQR 10-45, pcorr = 0.002), 
IL-6 (7.3-fold 44 pg/ml, IQR 22-64 versus 6, IQR 0-21, pcorr = 0.001), and IFN-g (~ 22-fold 
22 pg/ml, IQR 10-79 versus 0, IQR 0-8, pcorr = 0.02). Next, I stratified the IRIS patients on 
the basis of severity of IRIS. Most TB-IRIS patients in this study had either disseminated TB 
or evidence of multiple organ involvement (Table 5). However four of these patients were 
classified as having clinically localized (usually lymphadenopathic) disease, which may be 
regarded as less severe IRIS. In these patients a clear trend towards lower serum cytokine 
levels was seen with 22/24 (92%, 95%CL 74-97%) cytokine values falling on or below the 
median (shown as grey circles in Figure 10). Thus the elevation or otherwise of cytokines 
appears to relate partially to TB-IRIS severity. However, it is important to note that this study 
was underpowered to make adequate conclusions on the association of TB-IRIS severity with 
cytokine levels. Future studies could be performed to further explore this association.  
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Figure 10 Serum cytokine levels in IRIS and non-IRIS control patients for the most consistently 
discriminatory cytokines  
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3.2.8 Analysis of IL-7 in TB-IRIS and non-IRIS control patients 
Recent studies have reported higher serum IL-7 levels and suggested that IL-7 could be used 
as a biomarker of IRIS. To investigate the role of IL-7 in TB-IRIS, I analysed mRNA 
expression by quantitative RT-PCR in a subset of TB-IRIS and appropriate control patients. 
IL-7 protein expression was also measure in the plasma samples of TB-IRIS and control non-
IRIS patients. IL-7 mRNA expression was generally very low in both patient groups and did 
not show any distinct differences between TB-IRIS and non-IRIS patients. Similarly there 
was no significant difference noted between IRIS and non-IRIS patients over a 3-week period 
of follow-up (Figure 11). The median levels of IL-7 were 10.7, 10.1 and 8.3 pg/ml at week 0 
(cART commencement), week 2 (IRIS onset time) and week 3 respectively. In the control 
arm, the median levels of IL-7 were 11.6, 12.6 and 10.5 pg/ml respectively at these same time 
points. Thus in these patients, although high levels of IL-7 were expressed, there was no 
significant difference in the levels of this cytokine between IRIS and non-IRIS patients. 
 
Figure 11 Log fold induction and IL-7 concentrations in TB-IRIS and non-IRIS control 
patients 
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3.2.9 Effect of cortecosteroid therapy on cytokine concentrations in serum samples 
Expert opinion favours the use of adjunctive corticosteroid therapy in some cases of TB-IRIS, 
an opinion recently provided greater evidence by the randomized placebo-controlled trial of 
prednisone in TB-IRIS that showed this therapy was associated with more rapid resolution of 
symptoms (Meintjes, Wilkinson et al. 2010). To better explore cause and effect, I analysed 
serum cytokine levels in a subset of 10 TB-IRIS trial participants who were randomised to 
receive corticosteroid therapy (1.5mg/kg daily for 2 weeks then 0.75 mg/kg for a further 2 
weeks) or placebo treatment for four weeks. The levels of IL-6 (week zero 40 pg/ml IQR 19-
51, week 2 11 pg/ml IQR 8-13, week 4 10 pg/ml IQR 6-22, p = 0.006) a d TNF (week zero 
144 pg/ml IQR 63-219, week 2 40 pg/ml IQR 24-92, week 4 29 pg/ml IQR 24-101, p = 
0.038) significantly declined whereas no effect on IFN-g levels was observed (Figure 12). 
Figure 12 shows the changes in the concentrations of IL-6, IL-10 and TNF (pg/ml) in serum 
samples for 10 TB-IRIS patients who were prednisone-treated and were longitudinally 
followed up for 4 weeks.  
 
 
Figure 12 Longitudinal follow-up of prednisone treatment on serum cytokine levels in TB-IRIS 
patients 
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Figure 13 Comparison of prednisone vs placebo treatment on serum cytokine levels in TB-IRIS patients 
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Figure 13 shows the comparison of cytokine levels between prednisone and placebo treated 
patients for IL-6, IFN-gamma, IL-10, IL-12p40, IL-8 and TNF. While there was a significant 
decrease in the levels of IL-6, IL-12p40 and TNF in the prednisone treated patients, there was 
no change in the levels of these cytokines over the same period in the placebo treated 
patients. For IL-8, IL-10 and IFN-gamma, there was no difference between prednisone and 
placebo treated patients, just like in the longitudinally followed-up patients. 
 
3.2.1 Summary of analyses of cytokines in TB-IRIS 
 
 
 
Figure 14 Summary of pro- and anti-inflammatory cytokines that were differentially higher in 
TB-IRIS  
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3.3 Discussion 
Stimulation of PBMC with M. tuberculosis increased the abundance of the majority of 
transcripts with IL-1Beta, IL-5, IL-6, IL-10, IL-13, IL-17A, IFN-g, GM-CSF and TNF being 
significantly greater in stimulated TB-IRIS cultures at either the 6 or 24-hour time points.  
MTB-stimulated gene induction in vitro was significantly greater in TB-IRIS patients for IL-
6, IL-10, IL-12p40, IL-13, IL-17A and IFN-γ. In tissue culture supernatants, the levels of IL-
12p40, IL-1Beta, IL-2, IL-6, IL-8, IL-10, IL-12p40, IFN-γ, GM-CSF and TNF were higher in 
TB-IRIS patients. In serum samples, significantly higher levels in TB-IRIS patients were 
observed for TNF, IL-6, and IFN-gamma and the serum levels of IL-6 and TNF decreased 
during prednisone therapy of TB-IRIS. Thus many pro- and anti-inflammatory cytokine 
transcript and protein levels are elevated in TB-IRIS patients, strongly suggesting that 
cytokine release contributes to pathology and symptoms in this condition. IL-6 and TNF were 
elevated under all conditions and decreased in serum during corticosteroid therapy such that 
blockade of these cytokines may be a novel and rational approach to immunomodulation in 
TB-IRIS. 
 
The observations that higher levels of cytokines were consistently detected by luminex versus 
by ELISA indicate that luminex could be a potentially more sensitive technique than ELISA. 
The assay detection limits were much lower for luminex, and so lower levels of protein, 
which may not have been detected by standard ELISA. These observations are in agreement 
with findings previously published on the evaluation of different commercial bead-based kits, 
where higher levels of the assessed cytokines were detected by commercial bead-based 
methods as compared to ELISA (Djoba Siawaya, Roberts et al. 2008) 
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However, TB-IRIS patients tended to have more smear or culture confirmed TB disease 
(p=0.045) than the non-IRIS controls. These observations are consistent with the recent 
findings by Day et al (Day, Abrahams et al. 2011) which reported progressive changes and 
associations between Mycobacterium tuberculosis-specific T cell functional capacity and 
mycobacterial load in the context of tuberculosis infection and  disease. Thus the sputum load 
in the TB-IRIS patients who tended to have smear or culture positive TB in these patients 
may have had a confounding as these patients were likely to have more polyfunctional T cell 
subsets, and hence produce more cytokines. However, while ESAT-6 and CFP-10 antigens 
were used to restimulate the PBMC, for the work presented in this thesis, cells were 
restimulated by heat killed H37Rv M.tb. 
 
The cytokine release syndrome (sometimes referred to as a cytokine storm or 
hypercytokinaemia) occurs in a number of infectious and non-infectious diseases including 
graft versus host disease (GVHD) (Holler, Kolb et al. 1990), acute respiratory distress 
syndrome (ARDS) (Belperio, Keane et al. 2006), sepsis (Lappin and Ferguson 2009), H5N1 
influenza (de Jong, Simmons et al. 2006) and the systemic inflammatory response syndrome 
(SIRS) (Lenz, Franklin et al. 2007). The experimental drug TGN1412 also caused serious 
acute illness likely to be driven by cytokines when given to six participants in a Phase I trial 
(Suntharalingam, Perry et al. 2006). The syndrome does not appear to have a quantitative 
definition but is characterised as including fever, hypotension, increased endothelial 
permeability, oedema and vasodilatation. TB-IRIS can be of acute onset especially the 
unmasking form and fatal ARDS as has been previously described (Goldsack, Allen et al. 
2003; Lawn, Wilkinson et al. 2008; Lawn, Wainwright et al. 2009). Patients with paradoxical 
TB-IRIS frequently have prolonged fever and tachycardia and are at increased risk of venous 
thromboembolism (Meintjes, Rangaka et al. 2009; Pepper, Rebe et al. 2009). Whilst the 
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levels of serum cytokines observed in the current study are not as high as those reported in 
the TGN1412 trial for example or in H5N1, the exaggerated cytokine responses we observed 
in TB-IRIS patients compared to similar patients who do not experience the syndrome may 
contribute substantially to pathogenesis. 
 
Anti-retroviral therapy effectively suppresses HIV-1 replication and thereby allows recovery 
of CD4 numbers and function with the most rapid CD4 rise occurring early in therapy. It is 
thus logical to investigate whether dysregulated CD4 responses contribute to TB-IRIS. Very 
large antigen specific Th1 CD4 expansions accompany cART mediated immune restoration 
in both TB-IRIS patients and similar co-infected persons who do not develop the syndrome 
(Bourgarit, Carcelain et al. 2006; Meintjes, Wilkinson et al. 2008). In keeping with these 
observations an increase in IFN-gamma transcript abundance, fold induction and both 
secreted and serum cytokine in TB-IRIS patients was observed (Tables 6 and 7 and Figures 
7). Increased IL-12p40 fold induction and secreted cytokine and also increased IL-2 in tissue 
culture supernatants from TB-IRIS patients were also observed. However these observations 
suggest that other lymphocyte subsets other than Th1 may also contribute. Thus transcript 
from the ‘Th2’ genes, IL-5 and IL-13 were elevated in TB-IRIS patients although that did not 
translate into protein differences. 
 
 It is also interesting to note that the transcript of IL-17A was, after correction for multiple 
comparisons, the only significantly elevated in TB-IRIS patients at 6 hours; a difference 
reflected at 24 hours and in fold induction. However, IL-17A protein levels were low and did 
not differ between groups. IL-17 is markedly pro-inflammatory and has been implicated in 
the early protective immune response to tuberculosis (Khader, Bell et al. 2007). In humans 
IL-17 secretion in response to tuberculosis appears mediated by a distinct T cell subset with 
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phenotypic characteristics of long-lived central memory cells (Scriba, Kalsdorf et al. 2008). 
The lack of protein secretion we observed might have been due to IFN-gamma mediated 
suppression of IL-17 in vitro (Harrington, Hatton et al. 2005). IL-17 is indirectly chemotactic 
for neutrophils (Laan, Cui et al. 1999) and the cold abscesses that occur in TB-IRIS are 
characterised by the presence of neutrophils. Future work on the potential for early IL-17 
production to contribute to inflammation in TB-IRIS may therefore be of interest.  
 
IL-6 and TNF secretion was identified as elevated in all circumstances and potentially 
amenable to immune modulation, which is consistent with the finding that polymorphism in 
these genes may associate with the risk of IRIS (Price, Morahan et al. 2002). IL-6 is a key 
driver of the acute phase response and we have previously documented that the C-reactive 
protein (CRP) is invariably elevated at presentation of TB-IRIS (Meintjes, Rangaka et al. 
2009). Thus blockade of IL-6 or TNF may be a rational approach to immunomodulation in 
this condition.  
TNF has consistently been associated with both protection and pathology in tuberculosis 
(Bekker, Maartens et al. 1998; Keane, Gershon et al. 2001; Wilkinson, DesJardin et al. 2001). 
Recent case reports have documented a beneficial effect of TNF blockade on paradoxically 
deteriorating TB in HIV-1 uninfected patients (Blackmore, Manning et al. 2008; Wallis, van 
Vuuren et al. 2009). However a clinical study of anti-TNF antibodies in TB-IRIS would face 
a number of difficult issues because it is recognised this therapy has a prolonged half-life and 
also leads to the reactivation of tuberculosis (Keane, Gershon et al. 2001).  
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4 CHAPTER 4: MATRIX METALLOPROTEINASES 
INVOLVEMENT IN THE TISSUE DAMAGE ASSOCIATED WITH 
HIV-TB IRIS 
4.1 Introduction  
Matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases capable of degrading 
all components of the extracellular matrix at neutral pH including fibrillar type I collagen, a 
key structural fibril which is otherwise highly resistant to enzymatic degradation (Parks and 
Shapiro 2001). The lung matrix is supported by highly stable fibrillar collagens (Brinckerhoff 
and Matrisian 2002; Elkington, O’Kane et al. 2005; Elkington, D'Armiento et al. 2011). MMPs 
re known to perform tissue remodelling, repair and modulation of immune responses (Park, 
Hwang et al. 2005; Gueders, Foida et al. 2006; Taylor, Hattle et al. 2006; Sheen, O’Kane et 
al. 2009). MMPs are rarely expressed in healthy tissues while their biological activity is 
highly regulated (Chang, Wysock et al. 1996; Shapiro 1998). Excessive MMP production has 
been reported in diverse inflammatory conditions such cancer, Chronic Obstructive 
Pulmonary Disease (COPD), sarcoidosis, interstitial lung disease, arthritis and atherosclerosis 
(Shapiro and Senior 1999; Manicone and McGuire 2008).  
 
Emerging data suggests an association of MMP activity with pathology in various states of 
tuberculosis. Advanced pulmonary tuberculosis is associated with a locally destructive 
process of cavitation which plays an important part in transmission of disease whose 
pathogenesis remains incompletely understood (Elkington, O’Kane et al. 2005; Taylor, Hattle 
et al. 2006; Friedland 2008; Elkington, D'Armiento et al. 2011). TB-IRIS is a cART and 
immune-mediated deterioration which occurs in patients diagnosed with tuberculosis who are 
responding to anti-TB treatment but develop subsequent clinical deterioration on cART 
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(Dhasmana, Dheda et al. 2008). Paradoxical TB-IRIS is the best-characterised form of this 
condition. Characteristic features of the condition include swelling and suppurative lymph 
nodes, chest-x-ray infiltration with cavitations, weight loss and formation of tissue abscess 
(Meintjes, Lawn et al. 2008). Central to these features is immune-mediated tissue destruction 
and breakdown of the normal extracellular matrix structure.  
 
Advanced pulmonary tuberculosis is associated with a locally destructive process of 
cavitation which plays an important part in transmission of disease (Elkington, O’Kane et al. 
2005; Taylor, Hattle et al. 2006; Friedland 2008; Elkington, D'Armiento et al. 2011). Recent 
work by Volkman et al has demonstrated that disruption of MMP-9 function attenuated 
granuloma formation and bacterial growth, suggesting that targeting of MMP-9 production 
could be a promising host-targeting tuberculosis therapy (Volkman, Pozos et al. 2010). TB-
IRIS is associated with a tissue degrading phenotype. Little is known about the 
immunopathology of tissue damage in TB-IRIS. Matrix metalloproteinases (MMPs) have the 
unique ability to degrade components of the Extracellular Matrix (ECM). A tissue degrading 
phenotype is evident in TB-IRIS. I hypothesized that MMPs may play a role in tissue 
degradation in HIV-associated TB-IRIS. MMP gene expression and concentrations of 
secreted protein (in vitro) were analyzed in M.tuberculosis stimulated PBMC cultures from 
TB-IRIS controls. To investigate the role of these tissue-degrading enzymes in the 
immunopathogenesis of TB-IRIS, I analyzed MMP gene expression and protein secretion in 
paradoxical TB-IRIS participants and similar controls that did not develop TB-IRIS.  
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4.2 Results 
4.2.1 Baseline characteristics of Study Participants 
The baseline characteristics of the patients used for this cross-sectional analysis were 
previously described in Table 5. Twenty-two TB-IRIS and 22 non-IRIS participants were 
included in the analysis. There were no significant differences in age, gender and baseline 
CD4 counts between the two groups. Baseline viral loads were not routinely measured in this 
study. The median time from starting TB treatment and that to cART commencement, 
reporting of TB-IRIS and sample collection was similar in both groups of participants (Table 
5). However, a greater proportion (86%) of participants in the TB-IRIS compared to 59% of 
the non-TB-IRIS control group had either culture or smear confirmed TB disease (p =0.045).  
 
A second group of participants originated from a randomized placebo-controlled trial of 
prednisone (RCT) of TB-IRIS patients which has been reported previously (Meintjes, 
Wilkinson et al. 2010). Table 9 is a summary of these baseline and clinical characteristics for 
the subset of RCT patients analysed in this study. There were no significant differences in 
gender or baseline CD4 count between the prednisone and placebo treated groups. The 
proportion of participants with previous TB infection, extrapulmonary TB, and IRIS 
manifestation were also similar between the two groups. However, a difference of marginal 
statistical significance in the median days of TB treatment prior to cART between the 
placebo-treated and prednisone treated group (p=0.04) was observed.  
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Table 9 Baseline characteristics of TB-IRIS prednisone vs. placebo treated patients 
 
 
 
Prednisone Placebo treated p-value 
treated 
n 16 12 NA 
Female n (%) 10 (63) 5 (42) 0.45 
Baseline CD4/rlL 48 68 .5 0.67 
[13-181] [5-156] 
Median days of TB 67 30 0.04 
treatment pnor to [22-180] [13- 115] 
cART 
Median days of cART 14 7 0.08 
to IRIS onset [5-23] [3-32] 
Previous TB? (%) 3 (19) 2 (17) 1.00 
Basis ofTB Diagnosis 0.71 
Culture confirmed 9 8 0.71 
Smear only 4 2 0.67 
Clinical TB 3 2 1.00 
TB Disease Form 
Pulmonary only 9 4 0.28 
Extrapulmonary 7 8 0.44 
IRIS manifestation n 
(%) 
New Lymph nodes 6 (38) 3 (25) 0.69 
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4.2.2 Transcript abundance of MMP genes 
Transcript abundance of MMP genes in the PBMC cultures of 22 TB-IRIS and 22 non-IRIS 
control patients was assessed after 6 and 24 hours of stimulation with M.tuberculosis (shown 
in Tables 10, table 11 and table 12). Table 10 shows a summary of the effect of 
M.tuberculosis stimulation in either TB-IRIS patients or controls at 6 and 24 hours. In 
general, stimulation of PBMC increased the transcript abundance for multiple MMPs in both 
the TB-IRIS and non-IRIS groups. In particular, MMP-1, and MMP-10 transcripts increased 
on stimulation in the TB-IRIS and control groups at both 6 and 24 hour time points while 
MMP-7 transcript increased in the TB-IRIS group only. MMP-2, MMP-11 and TIMP-2 
transcripts were down regulated on stimulation in both patient groups. 
 
When TB-IRIS participants were compared with controls in the unstimulated samples, 
MMP-3, -7, -10 transcripts were more abundant in non-IRIS controls (p ≤ 0.01).  A six-hour 
stimulation did not result in any significant difference in the transcript levels between TB-
IRIS and controls (Table 11). In the 24-hour cultures, MMP-1, MMP-7, MM-10 and TIMP-1 
transcripts were significantly higher in the TB-IRIS compared to controls (Table 12) (p ≤ 
0.02). MMP-12 transcript was higher in controls in the unstimulated 24-hour cultures.  Thus, 
stimulation of PBMC with M.tuberculosis clearly increased transcript levels for multiple 
MMP genes, particularly at the 24-hour time point. 
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Table 10 Comparison of the differences in transcript abundance between heat killed M. 
tuberculosis stimulated and unstimulated IRIS and non-IRIS PBMC cultures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
unstim stim unstim stim unstim stim unstim stim
mRNA IRIS IRIS p-value non-IRIS non-IRIS p-value IRIS IRIS p-value non-IRIS non-IRIS p-value
MMP-1 15.0 10.2 < 0.001 14.8 10.3 < 0.001 15.6 5.6 < 0.001 15.4 9.8 <0.001
MMP-2 7.5 8.0 0.07 7.7 7.4 0.41 7.2 9.4 < 0.001 6.3 9.4 <0.001
MMP-3 20.3 15.9 < 0.001 18.8 17.3 0.06 19.0 20.1 0.56 18.7 17.2 0.81
MMP-7 10.3 9.1 0.002 9.2 9.3 0.72 9.4 6.8 < 0.001 9.3 8.7 0.05
MMP-8 19.8 18.8 0.19 18.9 19.3 0.63 19.0 19.5 0.08 18.9 17.2 0.88
MMP-9 2.5 1.7 0.14 1.3 1.4 1.00 2.8 0.3 < 0.001 2.3 0.7 <0.001
MMP-10 17.9 11.3 < 0.001 16.3 13.5 0.004 18.3 10.5 < 0.001 18.1 13.4 <0.001
MMP-11 14.4 18.5 < 0.001 13.7 19.0 < 0.001 18.5 16.0 0.93 15.5 19.3 0.14
MMP-12 19.8 19.3 0.82 18.9 19.0 0.63 20.2 13.8 < 0.001 18.7 14.9 0.002
TIMP-1 2.7 2.2 0.02 2.8 2.6 0.30 3.0 2.6 0.13 3.5 3.4 0.68
TIMP-2 2.6 4.0 < 0.001 2.5 3.7 < 0.001 2.3 3.7 0.04 2.1 3.7 <0.001
Median 6 hour delta CT values Median 24 hour delta CT values
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Table 11 Median Transcript abundance as measured by delta CT values for MMP genes after 6 
hours of in vitro culture in the presence or absence of heat killed M. Tuberculosis.  
 
 
 
 
 
Table 12 Transcript abundance as measured by delta CT values for MMP genes after 24 hours 
of in vitro culture in the presence or absence of heat killed M. Tuberculosis.  
 
 
 
 
 
unstimulated
mRNA IRIS IQR non-IRIS IQR p-value IRIS IQR non-IRIS IQR p-value
MMP-1 15.0 12.9-18.5 14.8 11.6-17.9 0.50 10.2 6.7-12.2 10.3 8.6-12.9 0.33
MMP-2 7.5 6.9-8.1 7.7 6.46-8.50 0.72 8.0 7.2-8.9 7.4 7.1-9.3 0.51
MMP-3 20.3 19.3-20.8 18.8 16.8-19.3 <0.001 15.9 14.2-19.0 17.3 14.9-18.8 0.49
MMP-7 10.3 9.1-11.1 9.2 8.1-10.2 0.01 9.1 7.9-10.1 9.3 7.8-10.9 0.75
MMP-8 19.8 17.8-20.8 18.9 17.2-19.4 0.14 18.8 11.5-19.5 19.3 16.2-19.6 0.37
MMP-9 2.5 1.4-3.1 1.3 0.7-2.5 0.05 1.7 1.1-3.2 1.4 0.5-2.9 0.31
MMP-10 17.9 16.5-20.2 16.3 14.4-17.7 0.01 11.3 7.4-14.2 13.5 11.2-14.9 0.06
MMP-11 14.4 13.2-16.3 13.7 12.5-14.4 0.10 18.5 15.4-19.5 19.0 17.9-19.9 0.21
MMP-12 19.8 18.8-21.1 18.9 18.0-19.7 0.17 19.3 18.8-19.9 19.0 18.2-19.9 0.50
TIMP-1 2.7 2.1-3.1 2.8 2.0-3.5 0.47 2.2 1.6-2.9 2.6 2.2-2.9 0.09
TIMP-2 2.6 2.3-2.9 2.5 2.1-3.3 0.87 4.0 3.5-4.4 3.7 2.9-4.7 0.45
stimulated
Median 6 hour delta CT values
mRNA IRIS IQR non-IRIS IQR p-value IRIS IQR non-IRIS IQR p-value
MMP-1 15.6 10.8-16.9 15.4 13.4-18.1 0.61 5.6 2.0-8.5 9.8 7.0-11.6 0.002
MMP-2 7.2 5.5-8.3 6.3 5.1-8.0 0.40 9.4 8.4-10.5 9.4 6.9-10.5 0.66
MMP-3 19.0 14.2-20.1 18.7 18.0- 19.4 0.66 20.1 10.2-20.8 17.2 16.9-19.6 0.35
MMP-7 9.4 8.3-10.4 9.3 8.0-10.0 0.80 6.8 4.8-8.6 8.7 7.34-9.66 0.01
MMP-8 19.0 13.4-20.3 18.9 17.6-20.6 0.74 19.5 15.0-20.2 17.2 14.1-19.8 0.56
MMP-9 2.8 1.5-3.3 2.3 1.4-3.9 0.82 0.3  -0.2 -1.4 0.7 0.1-1.9 0.25
MMP-10 18.3 12.4-19.0 18.1 16.1-18.8 0.95 10.5 7.1-11.6 13.4 12.1-16.3 <0.001
MMP-11 18.5 14.2-19.6 15.5 14.5-18.8 0.35 16.0 14.6-19.6 19.3 14.8-20.2 0.45
MMP-12 20.2 19.0-21.5 18.7 17.5-19.9 0.01 13.8 10.3-19.9 14.9 11.1-19.6 0.56
TIMP-1 3.0 2.4-3.5 3.5 3.1-4.2 0.02 2.6 1.6-3.0 3.4 2.4-4.4 0.02
TIMP-2 2.3 1.7-4.4 2.1 1.6-2.8 0.49 3.7 3.2-3.9 3.7 2.8-4.0 0.88
stimulatedunstimulated
Median 24 hour delta CT values
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4.2.3 Fold induction analysis of MMP genes 
The delta delta (∆ ∆CT) method used was used for analysis of RT-PCR data. Beta actin was 
used as the housekeeping gene through out these experiments. Delta CT was obtained by 
calculating the difference of the Ct of Beta Actin from the CT of the MMP gene of interest.  
Delta delta CT was then calculated by subtracting the delta CT of the unstimulated sample 
from the delta CT of the stimulated sample to obtain a delta delta   (∆ ∆) Ct. This value was 
then substituted into the mathematical equation 2-ΔΔCT to obtain the fold induction/repression 
before log 10 transformation in order to normalise the data (Figure 15). Figure 15 shows a 
summary of the log fold induction of cytokine genes by heat killed M. tuberculosis for TB-
IRIS and non-TB-IRIS control participants. At 6 hours, induction was significantly higher in 
TB-IRIS than in controls for MMP-3, MMP-7 and MMP-10 (p ≤ 0.05). At 24 hours 
significant differences existed between TB-IRIS and non-IRIS for MMP-1, MMP-7, MMP-
10, and MMP-12.  Thus, MMP-7 and MMP-10 were consistently higher at both 6 and 24 
hours in TB-IRIS patients compared to controls. By contrast as with the transcript levels, the 
genes for MMP-2, MMP-8, TIMP-2 and MMP-11 were down regulated by M. tuberculosis 
stimulation at both 6 and 24 hou s in both the TB-IRIS and non-IRIS control groups. MMP-
12 was undetectable in 6-hour cultures but was marginally induced in TB-IRIS at 24 hours.  
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4.2.4 MMP protein secretion (in vitro) into tissue culture supernatant  
MMP levels were assayed in the tissue culture supernatants arising from 20 IRIS and 20 non-
IRIS patients (based on sample availability). MMP protein secretion into corresponding tissue 
culture supernatants from the 24-hour M. tuberculosis stimulated PBMC was assessed mainly 
by luminex with the exception of MMP-10 and TIMP-1/2 concentrations which were 
measured by ELISA. Consistent with the gene expression data, secretion of MMP-1, -3, -7, 
and -10 protein was significantly higher in the tissue culture supernatants from TB-IRIS 
when compared to the controls (p ≤ 0.05) (Figure 16). While TIMP-1 was expressed in very 
small amounts in both groups, TIMP-2 was completely undetectable in these cultures. MMP-
2 was down regulated in both TB-IRIS and controls with no significant difference between 
the two groups. Although large amounts of MMP-9 were detected in these cultures, this did 
not differ significantly between TB-IRIS and non-IRIS controls. 
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Figure 16 MMP protein secreted into tissue culture supernatants 
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4.2.5  Correlation of MMP transcript vs. Protein secretion 
To determine the correlation between transcript and protein secretion, MMP transcript levels 
(Δ Ct values) for 6 and 24 hours were correlated (Spearman correlation) with the 
corresponding 24 hour tissue culture supernatant concentrations (pg/ml) for both TB-IRIS 
and non-IRIS controls. Figure 17 and 18 show a summary of these correlations at 6 and 24 
hours respectively. In general there was an inverse correlation with higher transcript 
abundance (represented by smaller ΔCt values) corresponding to higher concentrations of 
protein secreted. There was a good correlation between MMP transcript and protein for 
MMP-2, MMP-7 and MMP-9 (Figure 17 and Figure 18) at both 6 and 24 hours. MMP-1 
transcript correlated with protein secretion in the unstimulated 6-hour and the 24 hour 
stimulated samples only. For MMP-3 the correlation with secreted protein was significant 
with the 6 hour cultures on stimulation but not with the others. MMP-10 was not detected in 
non-IRIS patients and was detected only in very few IRIS patients. Corrections were not 
performed for multiple comparisons in this figure. 
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 Figure 17 Correlation of MMP transcript with secreted protein in 24 hour tissue culture supernatants  
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4.2.6 Enzymatic activity of MMP-9 as determined by gelatin zymography 
 
 
 
Figure 19a 
 
 
Figure 19b 
Figure 18 Representative Gelatin zymograms 
 
Figure 19a and 19b show two representative gelatin zymograms performed on 24 hour tissue 
culture supernatants. The intensity of the clear bands was determined by Scion Image 
analysis to give area under the curve. Corresponding luminex results in pg/ml these TB-IRIS 
MMP-9 MMP-9 NI 1 U NI 1 S I 1 U I 1 S NI 2 U NI 2 S I 2 U I 2 S
MMP-9  
pg/ml - - 38209 72369 26662 101281 43655 36660 48451 38597
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under 
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MMP-2 NI 3U NI 3S I 3 U I 3 S NI 4 U NI 4 S I4 U I4 S NI 5 U NI 5 S I 5 U I 5 S MMP-9
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patients (I) and non-IRIS controls (NI), U= unstimulated sample, S= stimulated sample, ND= 
not detected. MMP-2 and MMP-9 on these figures represent positive controls. MMP protein 
retained potential for proteolytic activity despite there being no distinct differences between 
IRIS and non-IRIS in the area under the curve, hence in the level of MMP activity  
 
MMP-9 protein levels measured by luminex tended to relate well to the area under the curve 
(measured by gelatin zymography) in the same sample although there were no significant 
differences noted between TB-IRIS and non-IRIS control samples.  Luminex measures total 
protein in a sample (in this case MMP-9), while zymography measures enzymatically active 
MMP-9 by measuring the intensity of the clear lysed band on the zymogram.  
 
4.2.7 MMP levels in serum (in vivo) 
To confirm whether the increased MMP expression and secretion detected in the stimulated 
PBMC was reflected in vivo, we analyzed circulating MMPs in corresponding serum samples 
of the TB-IRIS and control participants. MMP levels were assessed in 22 TB-IRIS and a 22-
non-IRIS control by luminex while MMP-10 protein was measured by ELISA. MMP-7 was 
significantly higher in the serum of TB-IRIS participants compared to controls (p=0.001). 
Levels of TIMP-1 were also higher in the IRIS group (p=0.003). Of the other MMPs analysed 
including MMP-3, MMP-10 and TIMP-2, no differences were noted in the serum MMP 
levels between TB-IRIS participants and controls. Figure 20 shows a summary of these 
results. Corrections were not made for multiple comparisons in this figure. 
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Figure 19 Summary of MMP protein levels in the serum samples of TB-IRIS and non-IRIS 
patients. 
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Figure 20 Serum (in vivo) levels of TIMP complexes  
 
The concentrations of TIMP-2 complexed with MMP-9 (TIMP-2/MMP-9) and TIMP-1 
complexed with MMP-2 (TIMP-1/MMP-2) circulating in serum samples were also assessed. 
The concentrations of the TIMP-1/MMP-2 and TIMP-2/MMP-9 complexes were observed to 
be higher in TB-IRIS than in non-IRIS patients. The concentrations of TIMP-1/MMP-2 and 
TIMP-2/MMP-9 complexes were ignificantly higher in the serum of TB-IRIS compared to 
non-IRIS patients (Figure 21). 
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4.2.8 Effect of Corticosteroid therapy on gene expression and serum levels in TB-IRIS  
Corticosteroid therapy has been shown to improve clinical outcomes in patients presenting 
with paradoxical TB-IRIS (Meintjes, Wilkinson et al. 2010). To determine the effect of 
corticosteroid therapy on levels of MMP protein in the serum (in vivo) of TB-IRIS patients 
who were enrolled in the prednisone-placebo RCT and were treated with either a 4-week 
course of prednisone or placebo were compared. MMP-1, MMP-3, MMP-7 and MMP-10 
gene expression was analysed by quantitative RT-PCR in M. tuberculosis-stimulated PBMC 
cultures from 16 TB-IRIS participants treated with prednisone therapy compared to 12 who 
were placebo-treated. Figure 22 and 23 show a summary of these analyses in the 6 and 24-
hour cultures respectively.  
 
Prednisone treatment did not significantly modulate MMP gene expression in the 6-hour 
cultures (Figure 22). However, in the 24-hour cultures, MMP-7 and MMP-10 were 
significantly suppressed in the prednisone-treated but not in the placebo-treated group (Figure 
23). Prednisone therefore significantly suppressed MMP-7 gene expression over the 
treatment course (p=0.006). MMP-10 was also marginally suppressed (p=0.045). MMP-1 and 
MMP-3 genes were not modulated by either prednisone or placebo treatment over the 
treatment course.  
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Figure 21 Effect of Prednisone on MMP gene induction/repression at 6 hours 
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Figure 22 Effect of Prednisone on MMP gene induction/repression at 24 hours 
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4.2.9 Effect of corticosteroid therapy on the levels of circulating MMPs  
Finally the levels of circulating MMP-7 in the corresponding serum samples of these RCT 
participants over 4 weeks of treatment were analysed. Prednisone tended to significantly 
suppress circulating MMP-7 levels (p=0.046) between week 0 and week 2 (Figure 24). In the 
placebo treated group, there was no difference in the MMP-7 levels over the treatment 
course. MMP-1 and MMP-3 levels did not appear to be modulated by prednisone or placebo 
in these patients. 
 
 
 
Figure 23 Analysis of the effect of prednisone treatment on MMP levels in TB-IRIS  
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4.3 Discussion 
In summary, this chapter presents a comprehensive series of studies that was conducted to 
investigate the role of tissue degrading enzymes (MMPs) in participants who developed 
paradoxical TB-IRIS. The findings show that M. tuberculosis stimulation of PBMC increased 
the transcript levels for MMP-1, MMP-7, MMP-10, and TIMP-1 genes in paradoxical TB-
IRIS participants in 24-hour cultures (p ≤ 0.02).  Fold induction was significantly higher in 
TB-IRIS than in controls for MMP-3 at 6 hours, while in the 24-hour cultures MMP-1 and 
MMP-12 were differentially induced in TB-IRIS. MMP-7 and MMP-10 were differentially 
induced in TB-IRIS at both 6 and 24 hours.  
 
There was consistency between gene expression and supernatant results with higher MMP 
protein levels being observed in the tissue culture supernatants for MMP-1, -3, -7 and -10 
genes which were higher in TB-IRIS. This was also supported by the results of the Spearman 
correlation analysis (correlation coefficients and the significant p values) for these MMPs, 
which indicates that control is mainly transcriptional.  The up-regulation of MMP-1, -3, -7 
and -10 by M. tuberculosis is consistent with previous reports in primary human 
macrophages, monocytes (Harris, Green et al. 2007; Elkington, Green et al. 2009) and 
PBMC. MMP-7 is expressed in macrophages within TB granulomas. Analysis of serum 
samples showed MMP-7 and TIMP-1 protein levels to be higher in vivo for TB-IRIS 
compared with controls. Prednisone has been shown to improve clinical outcomes in TB IRIS 
patients (Meintjes, Wilkinson et al. 2010) . In a subset of paradoxical TB-IRIS participants 
randomised to prednisone or placebo treatment, MMP-7 and MMP-10 genes were shown to 
be significantly down regulated in steroid but not in the placebo treated participants. Analysis 
of the concentrations of circulating MMP-7 showed a significant decrease over the first two 
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weeks of treatment in the prednisone but not in the placebo treated group. Taken together, 
these data implicate MMP-7 in the immunopathology of TB-IRIS. 
The involvement of matrix metalloproteinases in lung biology and in the tissue degrading 
phenotype of pulmonary tuberculosis has been reported previously (Parks and Shapiro 2001; 
Parks, Wilson et al. 2004; Elkington and Friedland 2006). MMP-7 has been shown to be 
highly expressed in macrophages within TB granulomas (Elkington, Nuttall et al. 2005; 
Elkington, Shiomi et al. 2011). However, this is the first study to investigate the involvement 
of these tissue-degrading enzymes in paradoxical TB-IRIS.  The clinical features and 
symptoms observed in patients presenting with TB-IRIS suggest an association of this 
condition with tissue damage. I have shown that stimulation of PBMC with M. tuberculosis 
upregulates several of the MMP genes in TB-IRIS patients. These findings corroborate 
related findings on analysis of gene expression and secretion following direct M. tuberculosis 
infection of human microglia in a cellular model of CNS TB (Green, Tran et al. 2009). My 
findings suggest that MMPs are involved in TB-IRIS pathogenesis and that infection with 
MTB promotes a tissue damaging phenotype, which is evident in TB-IRIS (Meintjes, Lawn 
et al. 2008).  
 
While MMP-9 was highly expressed in the patients analysed in these studies, there was no 
difference in the levels of this MMP in both the mRNA and secreted protein between TB-
IRIS and non-IRIS. Analysis of MMP-9 enzymatic activity by zymography showed the 
presence of active MMP-9 in both patient groups and this tended to relate well to the MMP-9 
levels as measured by luminex. MMP-9 has been implicated in tuberculosis 
immunopathology (Friedland, Shaw et al. 2002; Sheen, O’Kane et al. 2009). More recently, 
MMP-9 has been implicated in the regulation of monocyte recruitment in granuloma 
formation and bacterial growth in the M. marinum model of infection in zebra fish, 
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suggesting a potential host-targeting tuberculosis therapeutic approach targeting the 
disruption of MMP-9 function (Volkman, Pozos et al. 2010). I did not demonstrate divergent 
MMP-9 gene expression or secretion between the IRIS and non-IRIS patients.  Thus, while 
MMP-9 may be associated with the pathogenesis of tuberculosis, it does not appear to be 
specifically associated with the immunopathology that is evident in TB-IRIS.  
 
 MMP-7 correlated closely with IRIS and was suppressed by prednisone treatment. MMP-7 
may act as a regulator of the immune response as opposed to directly cleaving fibrils of the 
extracellular matrix (Parks, Wilson et al. 2004). MMP-7 is a multifunctional MMP, which is 
required for activation of defensins (Wilson, Ouellette et al. 1999). For example, MMP-7 
regulates neutrophil eggression into the lung by cleaving syndecan-1 to then generate a 
chemotactic gradient (Li, Park et al. 2002) and can also release pro-TNF alpha from the cell-
surface (Haro, Crawford et al. 2000). In other studies, MMP-7 has been shown to regulate the 
lung localisation of dendritic cells to limit inflammation and inhibit fibrosis (Manicone, 
Huizar et al. 2009). MMP-7 activity has also been previously implicated in the pathogenesis 
of aberrant lung remodelling in pulmonary fibrosis (Zuo, Kaminski et al. 2002; Rosas, 
Richards et al. 2008).  
 
Tissue inhibitors of matrix metalloproteinases (TIMPs) are known to down-regulate MMP-
activity by binding to latent and active forms of MMPs. While TIMPs are constitutively 
expressed in many tissue fluids, including CSF (Rosenberg 2002), the peripheral 
measurement of these inhibitors may not always reflect tissue effects (Price, Farrar et al. 
2001) . This may explain the finding in this study that the TIMP genes were generally not 
regulated by M. tuberculosis at both the mRNA and tissue culture supernatants levels, but 
were then found elevated in the serum of TB-IRIS participants. The presence of TIMP-
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1/MMP-2 and TIMP-2/MMP-9 complexes in significantly higher levels in the serum of IRIS 
patients than detected in vitro may suggest that active forms of these MMPs are present in 
vivo as complexes with these tissue inhibitors. Endogenous inhibitors including α -
macroglobulin and other TIMPs exert their effect in vivo by trapping active MMPs, with 
MMP-1 known to be rapidly inhibited by α2-macroglobulin which is particularly abundant in 
serum (Visse and Nagase 2003). Thus, the regulatory mechanisms associated with controlling 
the potentially destructive nature of MMPs by binding active MMPs with their endogenous 
inhibitors may complicate the study and quantification of MMPs in biological samples. While 
I showed high levels of various MMP proteins in vitro, but not in vivo, I detected the 
presence of MMP-2/TIMP-1 and MMP-9/TIMP-2 complexes. These findings suggest a 
possible inhibition of active MMPs by TIMPs in the serum samples, and hence their 
availability and subsequent detection as complexes.  
 
In summary, the findings documented in this chapter show that stimulation with M. 
tuberculosis differentially up-regulates multiple MMPs in TB-IRIS patients. MMP-7 was 
consistently expressed in increased levels in participants with TB-IRIS and was suppressed 
by prednisone.  However, since steroids have multiple deleterious immunological effects and 
may be harmful in the context of drug-resistant TB, more specific immunomodulatory 
approaches are needed in TB-IRIS. Dysregulated MMP activity may represent a therapeutic 
target to reduce immunopathology without causing steroid-related immunocompromise. 
These findings indicate an involvement of MMPs, particularly MMP-7 and MMP-10 in the 
immunopathology of paradoxical TB-IRIS.  Modulation of dysregulated MMP-7 activity 
during TB-IRIS may represent a novel therapeutic approach to alleviate this condition. 
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5 CHAPTER 5: MMPS AS MODULATORS OF INFLAMMATION 
IN THE IMMUNOPATHOLOGY OF HIV-TB IRIS 
5.1       Introduction 
The role of MMPs was originally believed to be restricted to the degradation of the 
extracellular matrix (ECM) to permit normal remodelling and contribute to pathological 
tissue destruction (McCawley and Matrisian 2001). However, recent evidence, particularly 
from MMP-deficient mice shows the involvement of MMPs in modifying other non-matrix 
substrates such as chemokines, growth factors, receptors and or cytokines (Van Lint and 
Libert 2007). Thus MMPs can influence the progression of various physiological and 
inflammatory processes. Inflammation, though essential for host defence and tissue repair, 
can contribute to ongoing tissue injury (Manicone and McGuire 2008). Inflammatory and 
tissue destroying conditions such cancer, rheumatoid arthritis and periodontitis have been 
shown to be associated with dysregulated and often increased levels and activities of several 
MMPs (Parks, Wilson et al. 2004).  
 
In general, MMPs contribute to various inflammatory processes by modulating inflammatory 
mediators, establishing chemokine gradients in inflamed tissues (McCawley and Matrisian 
2001; Manicone and McGuire 2008). Thus MMPs can either protect or contribute to 
immunopathology in inflammatory processes by facilitating leucocyte recruitment, 
chemokine activation, generation of chemokine gradients and cytokine processing (Woessner 
and Nagase 1999; Visse and Nagase 2003). Leucocyte migration is a hallmark of 
inflammation which is primarily triggered and regulated by chemoattractant chemokines 
(RodrÌguez, Morrison et al. 2010). Precise MMP processing can inactivate, enhance or 
antagonise the chemotactic properties of chemokines, thus influencing the final outcome of 
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inflammation.  MMP-mediated proteolysis of chemokines is one way by which MMPs have 
been shown to influence leucocyte trafficking. The proteolysis of chemokines by MMPs may 
inactivate the chemokines, generate antagonistic derivatives or produce more potent 
chemoattractant products than the full-length molecules but may also lead to the inactivation 
of other chemokines (Van den Steen, Proost et al. 2000; Van Lint and Libert 2007). For 
example, cleavage of IL-8 by MMP-9 (gelatinase B) has been show to produce a truncated 
product of IL-8 which has ten-fold greater activity (Opdenakker, Van den Steen et al. 2001) 
than the original product.  MMPs may also indirectly control influx of inflammatory cells by 
cleaving proteins in the pericellular environment that binds chemokines. Some studies have 
shown that MMP-7 is required to generate a chemokine gradient, while MMP-8 and MMP-9 
have also been shown to promote neutrophil migration (Li, Park et al. 2002; Corry, Kiss et al. 
2004; Van Lint, Wielockx et al. 2005). 
 
The processing of cytokines may lead to the formation of more potent intermediates of the 
cytokines with altered bioavailability and activity by direct proteolytic processing or 
sometimes by shedding their receptors (Van Lint and Libert 2007). TNF, IL-1beta, IL-2 and 
TGF-Beta are some of the inflammatory cytokines whose activity has been shown to be 
amenable to MMP proteolysis. Several MMPs including MMP-1, -2, -3, -9, -7 and -12 have 
been shown to have the ability to convert pro-TNF to the potent pro-inflammatory cytokine, 
TNF in activated macrophages (Mohan, Seaton et al. 2002). Similarly, MMP-2, -3, and -9 has 
been shown to convert the IL-1β precursor to the active form of the enzyme (Schonbeck, 
Mach et al. 1998). Interestingly, MMP-3, MMP-1, -2 and -9 have been shown to degrade the 
active IL-1β, suggesting opposing roles of MMPs in either repressing or promoting IL-1β 
effects (Ito, Mukaiyama et al. 1996). The role of MMPs in modulating inflammatory 
responses is complex and requires further investigation. Whether MMPs can influence the 
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outcome of inflammation and how they exert their function is a question that remains 
incompletely understood. Understanding this mechanism will help in developing effective 
drug targets to modulate MMP activity in inflammatory conditions (Van Lint and Libert 
2007).  
 
Tuberculosis-associated immune reconstitution inflammatory syndrome has been reported to 
be associated with exacerbated inflammation (Meintjes, Wilkinson et al. 2008).  In general, 
the results reported in chapter 3 and 4 of this thesis showed distinctly higher levels for 
various cytokines and MMPs at different levels of analysis. I hypothesized that there may be 
correlations between the high levels of cytokines and MMPs in these patients. To synthesize 
these results and assess any relationship between high levels of cytokines and MMPs in these 
patients, the concentrations (those that were highly expressed in the 24 hour tissue culture 
supernatants) of different pro- and anti-inflammatory cytokines and chemokines were 
correlated with the concentrations of MMPs. This analysis is presented in this chapter. Table 
13 below shows a summary of some of the functions of the established functions of MMPs in 
modulating inflammation. 
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5.2 Results 
To assess the immunomodulatory role of MMPs have in inflammation in TB-IRIS, 
correlations were determined between MMPs and various pro-and anti-inflammatory 
cytokines that were expressed in appreciable concentrations in the 24-hour tissue 
supernatants. The concentrations of 10 cytokines (IL-1β, IL-2, TNF, IL-6, IFN-gamma, IL-
10, IL-12, IL-13, IL-10, GM-CSF) and 4 chemokines (IL-8, MIP-1α MIP-1β and RANTES) 
were correlated with 5 MMPs (MMP-1, MMP-2, MMP-3, MMP-7, MMP-10) and TIMP-1. 
For these analyses, all the concentrations were background subtracted before analysis by 
subtracting the concentration of the unstimulated sample from the stimulated sample. Thus, 
all analysis was done on the background-subtracted concentrations, hence explaining the 
negative concentrations for some of the samples (i.e in cases where the unstimulated value 
was higher than stimulated value). Spearman correlations were performed and the significant 
Spearman correlation coefficients (r) and the corresponding p-values are shown on the 
graphs. 
5.2.1 Correlation of MMP with cytokine concentrations  
Except for MMP-10 (where the correlation was on IRIS patients data since MMP-10 was 
only detected in tissue culture supernatants of some IRIS patients), the correlations shown in 
Figure 25 were on pooled data of IRIS and non-IRIS patients. Figure 25 shows a summary of 
the correlation of MMP-1 with the different pro and anti-inflammatory cytokines. There was 
a significant correlation between MMP-1 and IL-1β, TNF, IL-6, and IL-13 (p< 0.013) but not 
with IFN-gamma. ΜΜP-2 (gelatinase A) was positively and significantly correlated (Figure 
25) with IL-1β, TNF, IL-6, IL-10 and GM-CSF but not significantly correlated with IFN-
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gamma. Although large amounts of (MMP-9) gelatinase B were detected in these cultures 
there were no significant correlations detected between MMP-9 and the various cytokines 
analysed. When the concentrations of MMP-3 were correlated to cytokine concentrations, 
positive and significant correlations were observed between MMP-3 and IL-1β, TNF, IL-6 
and IL-10 but not IFN-gamma (Figure 26 and Figure 27). MMP-7 and MMP-10 correlated 
positively with IL-1β, GM-CSF, IL-13, TNF, IL-6 and IL-10 and this was highly significant 
(Figure 28 and Figure 29). Although large amounts of the neutrophil collagenase (MMP-8) 
were detected in these cultures, this did not show distinct correlations with any of the pro- or 
anti-inflammatory cytokines. While appreciable higher concentrations of TIMP-1 were 
observed in these cultures, there were no significant correlations of TIMP-1 with any of the 
cytokines that were analysed. 
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Figure 24 Correlation of MMP-1 vs. pro- and anti-inflammatory cytokines 
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Figure 25 Correlation of MMP-2 vs. pro-and anti-inflammatory cytokines 
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Figure 26 Correlation of MMP-3 vs. pro-and anti-inflammatory cytokines 
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Figure 27 Correlation of MMP-7 vs. pro-and anti-inflammatory cytokines 
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Figure 28 Correlation of MMP-10 vs. pro- and anti-inflammatory cytokines 
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5.2.2 Correlation of MMPs with chemokines 
To assess the correlation between MMP chemokine expression MMP concentrations were 
correlated with the concentrations of IL-8, RANTES, MIP-1α, and MIP-1 beta. Figure 30 
shows a summary of those correlations that were significantly different between MMPs and 
chemokines before corrections for multiple comparisons were made. The values in this figure 
were not corrected for multiple comparisons. There was a statistically significant positive 
correlation between between IL-8 and MMP-1, -2, -3, -7 and MMP-8 but not with MMP-10. 
When the concentration of MIP-1α was correlated with that of MMPs, a significant positive 
correlation was also observed with MMP-1, -3, MMP-7 and MMP-8. For MIP-1β and 
RANTES, no significant correlations were observed with any of the MMPs analysed.  
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 Figure 29 Summary of significant correlations between chemokines and MMPs 
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5.2.3 Summary of multiple comparisons of correlations stratified IRIS vs. non-IRIS  
To further elucidate the significance of the statistical differences outlined in 5.2.1 and 5.2.2, I 
stratified the IRIS vs. non-IRIS patients and then corrected the p-values for multiple 
comparisons using the Bonferonni correction (multiplying the p values by n-1). Table 14 
shows a summary of the stratified and corrected p-values. The positive significant 
correlations are highlighted in red while the blue highlighting shows the negative but 
significant correlations. After correcting for multiple comparisons the correlation between 
MMP-1 and IL-1β, IL-10 and MIP-1α remained statistically significant in the TB-IRIS 
group. MMP-2 correlated negatively to IL-10 and GM-CSF in IRIS patients and this 
remained statistically significantly but not with the other cytokines or chemokines. The 
correlation between MMP-3 and IL-1β, IL-6, IL-10, TNF and GM-CSF was statistically 
significant in IRIS patients even after multiple comparisons. MMP-3 showed significant 
correlation with IL-1β, TNF, and GM-CSF (p<0.05) in TB-IRIS after correction. 
Interestingly, MMP-7 even after multiple c mparisons in the stratified datasets, there was a 
significant correlation between MMP-7 and IL-1β, IL-6, IL-10, GMC-SF, MIP-1α and IL-8. 
Similarly, MMP-10 showed significant correlation with many of the cytokines including IL-
1β, IL-10, IL-13, GM-CSF and IL-8. MMP-10 was not expressed in the tissue culture 
supernatants of non-IRIS patients and is not shown in this summary table. It is interesting to 
note that while most of the correlations in this data were observed in TB-IRIS patients, even 
after multiple comparisons, many of these correlations remained significant in the TB-IRIS 
group and were practically absent in the non-IRIS controls.  
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Table 14 Summary of correalation p values stratified IRIS vs IRIS and then corrected for multiple comparison by 
Bonferonni correction (n-1) 
 
MMP-l MMP-2 MMP-3 MMP-7 MMP-8 MMP-9 MMP-IO 
IL-l ~ IRIS 0,033 0,330 0,022 0,001 5,610 4 ,620 0,022 
Non-IRIS 2,530 1,228 1,232 10,076 3,861 9,845 N/A 
TNF IRI S 0,209 0,396 0,011 0,055 3,652 5,940 0,099 
non-IRIS 0,286 5,555 0,781 8,228 7,821 6,237 N/A 
IL-6 IR IS 0, 143 0,088 0,033 0,033 3,3 77 4 ,9 17 0,050 
non-IRIS 0,693 4,807 0,132 8,162 6,413 5,753 N/A 
IFN-g IRIS 0, 154 4,4 11 0,090 1,485 0,385 7,656 0,077 
non-IRIS 5,401 7,986 6,094 10,252 5,379 5,104 N/A 
IL-2 IR IS 0, 165 3,553 0,572 1,353 3,949 1,672 0,737 
non-IRIS 1,650 2,530 9,042 9,581 9,856 5,885 N/A 
IL-IO IRIS 0,011 0,011 0,070 0,001 0,495 0,330 0,001 
non-IRIS 0,066 11 ,000 0,770 7,590 1,243 3,344 N/A 
IL-12 IRIS 0,781 4,510 0,968 2,398 2,717 1,22 1 2,970 
non-IRI S 2,431 8,965 0,957 5,698 8,8 11 0,78 1 N/A 
IL-13 IRIS 1,903 7,27 1 2,475 8,547 1,067 8,074 3,091 
non-IRIS 4,345 10,263 3,740 8, 162 2,090 10,263 N/A 
GM-CSF IRIS 0,055 0,044 0,001 0,001 1,034 1,738 0,001 
non-IRIS 0,605 6, 149 0,264 9,295 10,219 4 ,994 N/A 
MIP-Ia IR IS 0,022 0,308 0,220 0,003 7,843 2,497 0,080 
non-IRIS 1,243 9,471 3,641 10,428 8,503 6,72 1 N/A 
IL-8 IRI S 0,286 0,088 3,520 0,001 1,507 0,352 0,001 
non-IRIS 2,552 6,6 11 4,389 4,389 6,611 6,72 1 N/A 
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Figure 30 Schematic diagram showing the corrected p-values for correlations in IRIS 
 
Figure 31 shows a schematic diagram summarising the Spearman correlation p values in 
IRIS patients between the different immune mediators after correcting for multiple 
comparisons. Positive significant correlations are highlighted while the negative significant 
correlations are highlighted in blue. The grey highlighting shows those correlations that were 
not significant. There were no significant correlations in non-IRIS (Table 14) hence, the non-
IRIS correlations (p-values) are not show in this summary schematic diagram. 
 
 
 
 
 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 119 
5.3 Discussion 
In summary, the concentration of MMP-1, correlated significantly with IL-1β, IL-6, IL-10, 
IL-13, and TNF in the combined data sets. After stratification and correction for multiple 
comparisons, only IL-1β, IL-10 and MIP-1β remained significantly correlated with MMP-1. 
MMP-2 correlated significantly with IL-1β, MMP-2, IL-10, IL-6 and GM-CSF in the 
combined data sets. However, after stratifying IRIS versus non-IRIS and correcting for 
multiple comparisons, only IL-10 and GM-CSF in the IRIS group remained significantly 
correlated with MMP-2. The correlation of MMP-3 with IL-1β, TNF, IL-6, IL-10 and GM-
CSF was significant in the combined data but was mainly emanating from the IRIS patients. 
This was shown after stratifying IRIS versus non-IRIS as only the correlations in IRIS were 
shown to be significant. There were no significant correlations observed between IL-12 and 
IFN-gamma and any of the MMPs either in IRIS or in non-IRIS patients.   
 
MMP-7 and MMP-10 were significantly correlated to the cytokines IL-1β, GM-CSF, IL-13, 
TNF, IL-6 and IL-10. After correction for multiple comparisons, MMP-7 and MMP-10 
remained consistently correlated with the pro-inflammatory cytokine IL-1β in IRIS patients. 
When chemokines were correlated with MMP levels, MMP-7 and MMP-10 showed 
significant correlation with IL-8 in IRIS patients, while MIP-1α significantly correlated with 
MMP-1 and MMP-7 in the IRIS group. The macrophage inflammatory proteins are 
chemoattractant cytokines crucial for immune responses towards infection and inflammation 
and are produced primarily by macrophages (Ren, Guo et al. 2010). MIP-1β and RANTES, 
which was expressed at very high levels, did not appear to correlate with the MMPs that were 
analysed in these cultures. The results presented here show evidence that the co-expression of 
MMPs in TB-IRIS may be exacerbating the inflammatory response evident in this condition. 
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The upregulated expression of MMPs upon MTB stimulation corroborates earlier findings 
from other workers who have showed that MMPs are induced by M. tuberculosis in different 
immune cells including monocytes and macrophages (Elkington, Nuttall et al. 2005; Harris, 
Green et al. 2007; Green, Elkington et al. 2010) The positive correlations observed in many 
of the pro-inflammatory cytokines and MMPs analysed in this study support the presence of a 
feedback mechanism where elevated levels of cytokines may be driving MMP expression. In 
turn, cytokines to some extent are known substrates of MMPs, and thus prone to degradation 
or cleavage by MMPs as well as stimulating MMP expression. GM-CSF has been shown to 
enhance TNF and IL-1β stimulated secretion of MMP-9 by THP-1 cells (Zhang, McCluskey 
et al. 1998).  
 
It has been previously suggested that inflammation is a result of dyregulation and over 
expression of MMPs without a balance in the endogenous inhibitors, TIMPs, although this 
has proven difficult to show experimentally (Price, Farrar et al. 2001; Price, Gilman et al. 
2003). While levels of TIMP-1 were detected to be distinctly higher in TB-IRIS patients in 
this work (Chapter 4), there was no significant correlation between TIMP-1 and any of the 
cytokines analysed in this study.  
 
While the normal tissues contain little MMP activities, the production of pro-MMP-1, pro-
MMP-3, pro-MMP-7 and pro-MMP-9 has been shown to be enhanced by IL-1β that is 
secreted from activated macrophages and many other cells (Ito, Mukaiyama et al. 1996). 
Once secreted and activated, these MMPs can then control the activity of IL-1β. The findings 
in this analysis showed consistent and significant correlations of IL-1β with many of the 
cytokines in IRIS, even after correction for multiple comparisons. Thus, it is possible that the 
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inflammatory mediators produced in IRIS (IL-1β included) are driving the production of 
MMPs which, once activate, will in turn degrade IL-1β as a way of modulating inflammation.  
 
TNF and IL-1β have bee previously shown to enhance the production of MMP-9 by 
monocytes but had no effect on MMP-1, while combinations of IL-1β, TNF and GM-CSF 
have been shown to induce the synthesis of MMP-1 and enhance TIMP-1 production (Zhang, 
McCluskey et al. 1998). Individually, these cytokines were noted to induce MMP-9. IFN-
gamma, IL-4, and IL-10 have been shown to inhibit the production of MMPs (Birkedal 
Hansen 1993). MMP-9, which has been implicated in TB immunopathology, although 
detected in very high levels in these patients, did not correlate significantly with any of the 
cytokines that were analysed. Thus while MMP-9 has been implicated in tuberculosis, its 
involvement in the inflammation or modulation of the inflammation associated with TB-IRIS 
does not seem apparent, form this data, but may be contributing to immunopathology in other 
ways. 
 
The biological significance of MMP-2 (gelatinase B) on IL-1β degradation is still unclear 
and the results presented in this chapter also did not show any significant association between 
MMP-2 and IL-1β. However, MMP-2 correlated negatively and significantly with several 
cytokines and after comparison for multiple comparisons, IL-10 and GM-CSF remained 
significantly correlated in the IRIS group. This may imply that MMP-2 could be involved in 
immunomodulation. The significance of this however remains vague as no significant 
differences were observed between IRIS and non-IRIS when MMP-2 was analysed (chapter 
4). 
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While these in vitro analyses have shown significant correlations between MMPs and 
cytokines, it would be of interest to further investigate if these relationships and expression 
levels were present in site of disease samples such as Bronchoalveolar Lavage (BAL). This 
could improve our understanding on the interaction between MMPs and TIMPs in 
inflammatory conditions such as TB-IRIS. The use of MMP inhibitors could also clarify the 
involvement of MMPs in this condition.  Further more, in vitro assays such as tissue culture 
experiments could clarify and enhance our understanding on the involvement of MMPs in 
regulating inflammation in TB-IRIS. In summary, the analyses presented in this chapter 
demonstrate an association between the high levels of tissue degrading enzymes, MMPs and 
inflammatory mediators observed in these studies suggesting a potential role for MMPs in 
promoting or regulating inflammation in the inflammatory condition, TB-IRIS. 
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6 CHAPTER 6: ROLE OF IL-10 RELATED FAMILY OF 
CYTOKINES IN TB-IRIS 
6.1       INTRODUCTION 
The Interleukin-10 related family of cytokines comprises of cytokines structurally related to 
IL-10. These include IL-19, IL-20, IL-22, IL-24, IL-26 (AK155), IL-28 and IL-29 in humans 
in addition to some herpesviral and poxviral members (Fickenscher, Hor et al. 2002). 
Cytokines in this group are highly pleiotropic and are linked together mainly through genetic 
similarity and intron-exon gene structure (Commins, Steinke et al. 2008). The IL-10 related 
cytokines were identified in database searches for potential IL-10 homologs, and so far little 
is known about their biological activities of (Fickenscher, Hor et al. 2002) although 
suggestions have been put forward that they may participate in T-cell mediated diseases by a 
distinct regulation of T cell cytokine profiles (Mege, Meghari et al. 2006). One major 
similarity among these cytokines is the sharing of signalling receptors and having conserved 
signalling cascades (Fickenscher, Hor et al. 2002). Figure 32 below shows a summary of the 
relationship between the various signalling receptor subunits of the IL-10 homologs. 
 
 
 
 
 
 
 
 
 
Figure 31 Summary of signalling receptors for IL-10 related homologs           
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Human IL-10 is the most well characterised molecule in this group with multiple biological 
effects including immunoregulatory and anti-inflammatory effects on different cell types 
(Saraiva and O'Garra 2010). The role of IL-10 as a survival, differentiation and proliferation 
factor for B cells and antibody production has also been described. IL-10 functions mainly to 
regulate Th1 cytokines, MHC class II and B7 molecules and the expression of co-stimulator 
molecules on macrophages that are necessary for optimal T-cell activation (Donnelly, 
Dickensheets et al. 1999; Fickenscher, Hor et al. 2002; Commins, Steinke et al. 2008). By 
inhibiting expression of these molecules on antigen presenting cells (APC), IL-10 directly 
suppresses the activation of T-cells and production of T-cell derived cytokines such as IFN-
gamma and IL-2 (Donnelly, Dickensheets et al. 1999). Various immune cells produce IL-10 
among them, activated monocytes, T cells (CD4+ and CD8+), macrophages and dendritic 
cells. The production of  IL-10 is inducible by various stimuli and bacteria while gene 
expression may be delayed relative to other cytokines such as TNF and IL-1β (Donnelly, 
Dickensheets et al. 1999) and thus serves to dampen the inflammatory response by the 
suppression of inflammatory cytokines (Redpath, Ghazal et al. 2001). Growing evidence 
supports a modulating role for IL-10 in human allergic disease (Commins, Steinke et al. 
2008).  
 
Similar to IL-10, the other members of the IL-10 family are secreted as α− helical proteins 
whose amino-acid sequences are up to 30% identical to that of IL-10  with the encoding 
genes being located on two clusters in the human genome (Dumoutier, Van Roost et al. 2000; 
Wolk, Kunz et al. 2002). However, the knowledge of the biology of many of these IL-10 
homologs remains incomplete. IL-19 is primarily produced by monocytes (Commins, Steinke 
et al. 2008), has been implicated in psoriasis and allergic disorders such as asthma (Liao, 
Cheng et al. 2004), and its expression can be induced by LPS, IL-4 and GM-CSF. IL-20 on 
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the other hand, appears to be the more divergent member of the group being produced mainly 
by monocytes and keratinocytes (Wolk, Kunz et al. 2002). Potential roles of IL-20 have been 
found in atherosclerosis, rheumatoid arthritis and angiogenesis with such patients expressing 
higher levels of IL-20 (Commins, Steinke et al. 2008). IL-24 was originally identified as a 
tumour suppressor molecule melanoma differentiation-associated gene 7 (mda-7) that was 
expressed in the melanocytes of healthy volunteers (Jiang, Lin et al. 1995). The majority of 
human cancer derived cell lines, including melanoma cells have been shown to undergo 
apoptosis upon exposure to IL-24 (Chada, Sutton et al. 2004). IL-26 has been shown to be 
generated mainly by CD4+CD45RO+ T cells and Natural Killer (NK) cells (Fickenscher, Hor 
et al. 2002) and is considered to be important in the transformation of human T-cells after 
their infection with Herpes saimiri virus. IL-28 and IL-29 (alternatively named IFN-λ1 and 
IFN-λ3 respectively) have some common features with the type 1 interferons including 
antiviral, anti-proliferative and antitumor activities (Fickenscher, Hor et al. 2002). While 
these genes have significant amino acid homology with type 1 interferons, their intron-exon 
structure more closely resembles that of IL-10, hence their classification into this group.  
 
IL-21, although not a member of the IL-10 family, is a potent regulator of immune cells 
primarily expressed in activated CD4+ T cells (Parrish-Novak, Dillon et al. 2000). IL-21 has 
been tried as a therapy to alleviate allergic responses and was shown to successfully decrease 
T cell produced pro-inflammatory cytokines and mitigates allergic responses in mice studies. 
IL-21 may also be a critical factor in the control of persistent viral infections, including HIV 
infection (Hiromura, Kishida et al. 2007; Iannello, Boulassel et al. 2010) where it has been 
shown to improve the HIV-specific cytotoxic T cell responses  and NK cell functions (White, 
Krishnan et al. 2007; Iannello, Boulassel et al. 2010). 
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IL-22 (IL-10 related T-cell derived inducible factor, IL-TIF) is a pro-inflammatory cytokine 
which plays an important role in innate pathogen defence (Dumoutier, Van Roost et al. 2000; 
Wolk, Kunz et al. 2004). More recently, studies in mice have shown that IL-22 is a Th17 
cytokine (Liang, Tan et al. 2006) findings which however, have not been confirmed in human 
studies (Scriba, Kalsdorf et al. 2008). Expression of IL-22 has been shown to be highest in 
activated memory CD4 T cells, and lowest in activated natural killer cells (Commins, Steinke 
et al. 2008), with little or no expression being observed in other immune cells (Wolk K, Witte 
E, Immunity 2004). The preferential production of IL-22 by T cells suggests that increased 
expression of this molecule may exist in T-cell mediated diseases (Commins, Steinke et al. 
2008; Wolk, Witte et al. 2009). IL-22 acts on non-immune cells and has been linked with 
severe inflammation in chronic T cell-mediated inflammatory diseases such as psoriasis, 
Chron’s disease and rheumatoid arthritis (Wolk, Kunz et al. 2002; Wolk, Kunz et al. 2004; 
Hodge, Srinivasula et al. 2011).  The link between IL-22 and severe inflammation suggests 
that IL-22 may contribute to the human anti-mycobacterial immune response. 
 
The resolution of most infections is generally dependent on a host’s ability to mount a 
protective immunoregulatory response to regulate the magnitude of inflammatory and 
immune responses. IRIS results from excessive pathological immune responses occurring 
during immune reconstitution in patients responding to cART. For this study, I hypothesized 
that IL-10 and its related homologs may have a role in the immune dysregulation that is 
associated with TB-IRIS. 
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6.2 RESULTS 
6.2.1 Baseline characteristics of TB-IRIS patients versus non-IRIS controls 
For this analysis, a subset of 20 paradoxical TB-IRIS patients versus 20 non-IRIS control 
patients was selected. Samples were well matched for gender distribution, biological age and 
baseline CD4 count. There were no significant differences between the two patient groups in 
terms of previous TB disease, TB disease form and median days of cART to IRIS onset (or 
sample collection in the case of non-IRIS controls). However, TB-IRIS patients had a 
significantly shorter duration between TB treatment and cART, (p=0.028). This is consistent 
with previous findings that have shown a shorter duration between TB- treatment and cART 
as one of the risk factors for developing TB-IRIS. Table 14 shows a summary of the baseline 
demographic and clinical characteristics for the patients analysed in this study. 
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Table 14 Baseline characteristics of 20 TB-IRIS versus 20 non-IRIS patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TB-IR IS non-IRIS p-valuc 
" 
20 20 N/A 
Female n, (%) ( I I) 55 12 (60) 0,27 
Median age (years. IQR) 31 .4 35.8 0 .273 
(23,2-45.7) (22.2- 54 ,1 ) 
Baseline C D4 count 56 49.5 0 .59 
(14 .0- 193.0) (5.0- 302) 
Median days orTB-treatment 51.5 78.0 0.028 
Prior to cA RT ( 14 .0 - 207.0) (29.0-
173.0) 
Med ian days o r cA RT to IRI S onset 14 14 0.94 
or sample (5.0-78.0) (14-1 4) 
Previous TB 5 (25) 4 (20) 1.00 
'I'll Disease ronn n (%) 
Pulmo nary TB only 10 (50) 16 (80) 0.096 
Disscmi nated TB 10 (50) 4 (20) 0.096 
Smear and culture positive n. (%) 10 (50) 13 (65) 0.52 
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6.2.2 Analysis of IL-10 gene expression, in vitro and in vivo protein levels 
As previously reported in Chapter 3, IL-10 was highly expressed and was differentially 
higher in TB-IRIS patients at all levels of analysis (summarised in Figure 33). At the mRNA 
level, IL-10 was highly induced in TB-IRIS at 6 hours and even more so at 24 hours and this 
was statistically significant at both time points (p=0.04 and 0.0002 respectively).  Secretion 
of IL-10 protein into corresponding tissue culture supernatants was also observed to be 
significantly higher in TB-IRIS compared to controls (p=0.012). Similarly, when in vivo 
secretion of IL-10 was determined in these patients by analysing serum samples, levels of IL-
10 protein were shown to be much higher (more than a thousand fold) in TB-IRIS as 
compared to non-IRIS controls (p=0.0004). Thus, there were consistently higher levels of IL-
10 in TB-IRIS compared to controls. To further explore the expression profiles the IL-10 
related cytokines, IL-19, IL-21, IL-22, IL-24, IL-26, IL-27, IL28 and IL-29 mRNA transcript 
profiles were analysed. 
 
 
 
Figure 32 IL-10 log fold induction, supernatant and serum protein concentrations 
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6.2.3 Transcript abundance of other IL-10 related genes analysed 
To further explore the expression profiles the IL-10 related homologs; IL-19, IL-22, IL-24, 
IL-26, IL-27, IL28 and IL-29 mRNA transcript profiles were analysed (Figure 34). IL-21, a 
regulatory cytokine was also included in this analysis. Transcript abundance was quantified 
by subtracting the cycle threshold (Ct) of beta-actin, the endogenous control, from the Ct of 
the gene of interest to obtain delta Ct (Table 16 and 17). At 6 hours, IL-22 transcript was 
significantly higher in IRIS than in non-IRIS patients in the simulated cultures. However, IL-
24 transcript was significantly higher in non-IRIS controls than in TB-IRIS patients. Only IL-
26 had significantly higher transcript in both the stimulated and unstimulated PBMC cultures 
of TB-IRIS patients. IL-28 transcript was marginally higher in non-IRIS patients and this 
difference was statistically significant. IL-29 transcript was basely detectable with most of 
the cycle thresholds being assigned the maximum value of 40 at both 6 and 24 hours. 
 
At 24 hours, IL-20, IL-21 and IL-26 transcript levels were significantly higher in the 
stimulated cultures of TB-IRIS patients but not in the unstimulated cultures. However, IL-22 
transcript levels were observed to be higher in non-IRIS in the unstimulated cultures, but 
increased significantly upon MTB stimulation (p=0.015). IL-28 transcripts were observed to 
significantly higher in non-IRIS at in the 24 hour unstimulated cultures but not so in the 
stimulated cultures. When comparing the effect of MTB stimulation on transcript levels in 
general, the transcripts of many of the IL-10 related genes increased significantly in both the 
IRIS and non-IRIS cultures upon MTB stimulation in the at both the 6 and 24 hour time 
points. 
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Table 15 Delta Ct values for IL-10 related cytokines genes after 6 hours of in vitro stimulation 
with heat killed M.tb 
 
 
 
Table 16 Delta Ct values for IL-10 related cytokines genes after 24 hours of in vitro stimulation 
with heat killed M.tb 
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6.2.4 Fold induction analysis of IL-10 related genes 
For many of the IL-10 related genes analysed, there was upregulation (as opposed to 
repression) of these genes in response to MTB stimulation (Figure 34). IL-19 and IL-20 were 
shown to be constitutively expressed as no differences were noted in the fold induction 
between stimulated and unstimulated samples and between IRIS and non-IRIS patients at 
both 6 and 24 hours. For IL-21, there was significant upregulation of the gene in TB-IRIS 
patients at 6 hours but not at the 24 hour time point (p=0.0119 and 0.759 respectively). IL-22 
was the only gene that consistently showed significant upregulation at both 6 and 24 hours in 
TB-IRIS compared to non-IRIS 6 (p=0.004 and 0.0015 respectively). However for IL-24, IL-
26 and IL-28 there were no significant differences observed between IRIS and non-IRIS at 
either time points. IL-28 and IL-29 were barely expressed in these cultures with IL-29 being 
marginally detectable 6 hours, but not detected in the 24 hour cultures (Figure 34). 
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Figure 33 Fold induction analysis of IL-10 related cytokines 
c 
0 
.~ 
~ 
~ 
is 
il 
~ 
;§ 
~ 
.Q 
<if' 
,l" 
c 
.~ 
~ 
• j; 
0 g 
~ 
" .Q ~ 
.Q 
<if' 
,.' 
c 
0 
. 
~ 
~ 
c 
0 g 
~ 
;§ 
~ 
<if' 
,l" 
IL-19 
OF' ~ ~~ l' .,,~ 
,0' .,,~ 
0(1'<:. o<f~ 
• • Patient category 
IL-21 
OF' ~ ~ l' l' !I>~ 
,l" .,,~ 
o<f'" ,,' 
• .0 
Patient category 
IL-24 
0.620 
0.466 
OF' ~ ~~ l' .,,~ 
,0' !I>~ 
,,' o<f'" .0 
• 
Patient category 
IL-28 
0291 
~ l' .,,~ 
,,' 
• 0 
Patient category 
IL-20 
c 
0 
.~ 
~ 
~ 
~ 
i 
u 
Jl 
~ 
.Q 
<if' .~ ~ ~ l' l' 
,0' .,,~ ,.' .,,~ o<f~ rl 
• .0 
Patient category 
IL-22 
c 
.~ 
~ 
• j; 
0 g 
~ 
" .Q ~ 
.Q 
<if' .~ ~ ~ l' l' 
,0' !I>~ 
-$-&' .,,~ , 
i' ,,' 
.0 
Patient category 
IL-26 
c 
Q 
i 
~ 
0 g 
~ 
" .Q ~ 
~ .,.' <if' ... ' l' 
.. -« .,,~ ,.' ~'?'V 
,,' 
c 
0 
1.0 
.• 
~ 0.5 
~ g 
-O.S ¥ 
~ -1.0 
~ -1.5 
.0 o<f"l!. 
• 
Patient category 
IL-29 
0.957 
." !I>~ 
of!'" 
• 
Patient category 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 134 
6.2.5 Analysis of protein secretion into tissue culture supernatant and serum samples 
As a follow-up on the gene expression results, for those genes that showed significant 
differences in the protein mRNA levels, depending on availability of sample, protein levels 
were determined either in the tissue culture supernatants or serum samples or in both IL-19 
protein secretion was determined in the corresponding tissue culture supernatants. IL-19 
protein secretion in tissue supernatants was significantly higher level of IL-19 being detected 
in non-IRIS compared to IRIS patients upon MTB-stimulation (Figure 35).  Follow-up 
analysis of IL-19 in vivo did not show any IL-19 protein in the serum samples with all values 
for the analysed samples falling below the detection limit of the assay for both patient groups.  
 
 
 
Figure 34 IL-19 concentrations in tissue culture supernatants 
 
As a follow up on the IL-21 gene expression results obtained by quantitative RT-PCR, which 
showed significant fold induction of the IL-21 gene in TB-IRIS patients at 6 hour (figure 36), 
IL-21 protein was measured in the serum samples of TB-IRIS and non-IRIS patients. There 
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was no significant difference observed in the serum concentrations of IL-21 between IRIS 
and non-IRIS control patients in this experiment (Figure 36). 
 
 
 
Figure 35 Serum (in vivo) concentrations of IL-21 
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Figure 36 IL-22 concentrations in tissue culture supernatants 
 
IL-22 secretion into tissue culture supernatants was not measured (due to inadequate sample 
availability) but was measured in the corresponding serum samples. Significantly higher 
levels of IL-22 were detected in the serum samples of TB-IRIS patients (p=0.0017) (Figure 
37). Thus, IL-22 much like IL-10 showed consistent expression at different levels of analysis 
in these patients. 
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6.3 Discussion 
In summary, analysis of the IL-10 related cytokines at different levels showed consistent and 
significant upregulation of IL-22 in TB-IRIS patients compared to non-IRIS controls. At gene 
expression level IL-22 fold induction was significantly higher in IRIS (p= 0.004 at 6 hours 
and p= 0.0015 at 24 hours), while IL-22 protein levels in serum were significantly higher in 
IRIS patients (p= 0.0017), much like the results observed for IL-10. IL-19 transcript tended to 
be marginally higher in non-IRIS patients and protein expression of IL-19 into tissue culture 
supernatant was significantly higher in non-IRIS patients (0.036). However, in vivo analysis 
of IL-19 did not show this differential expression with IL-19 protein being absent in the 
serum samples of either patient group. Apart from IL-22 and IL-19, none of the other IL-10 
related genes (IL-20, IL-24, IL-26, IL-28 and IL-29) showed any differential expression 
between the two patient groups at any level of analysis. While IL-21 showed higher fold 
induction in IRIS at 6 hours, there was no significant difference between IRIS and non-IRIS 
control patients at 24 hours. Furthermore, analysis of IL-21 protein in the serum samples of 
these patients did not show any significant difference between the two patient groups 
(p=0.825). 
 
While the regulatory role of IL-10 in vitro and in animal models is well documented, the role 
of this cytokine in clinical situations, particularly in infectious diseases is still the subject of 
intense investigation (Mege, Meghari et al. 2006).  The production of IL-10 is regulated both 
at the transcriptional and translation level (Moore, de Waal Malefyt et al. 2001). However, 
production of IL-10 can also be stimulated by bacteria, viruses and parasites (Awomoyi, 
Marchant et al. 2002). Studies have now shown an association of IL-10 with increased 
susceptibility to infections caused by mycobacteria (Turner, Gonzalez-Juarrero et al. 2002). 
IL-10 has been shown to interfere with the innate and adaptive immune responses, thus 
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creating a favourable environment for the persistence of microbes, intracellular pathogens 
and chronic infections (Mege, Meghari et al. 2006). The viral versions of IL-10 are believed 
to assist in this immune evasion by tricking the immune system. The increased ability of 
macrophages to produce IL10 when stimulated with TLR ligands is also associated with an 
increased tendency to develop primary progressive TB (Saraiva and O'Garra 2010). The 
production of IL-10 has also been reported to be higher in patients who had active TB 
compared to TST responders (Vankayalapati, Wizel et al. 2003). In this study, measuring 
serum cytokine concentrations in M. tuberculosis infected patients, consistently high levels of 
IL-10 were observed in TB-IRIS, suggesting an involvement of IL-10 in the 
immunopathology of TB-IRIS (Vankayalapati, Wizel et al. 2003). TB-IRIS is a highly 
inflammatory condition. Thus it is also likely that the high levels of IL-10 observed in the 
blood of TB-IRIS patients in this study reflect an overspill of IL-10 from the sites of 
inflammation where IL-10 may be involved in regulating and resolving inflammation.   
 
 Recent studies in mice have reported that IL-10 deficient mice showed enhanced control of 
M.tb infection with significantly reduced bacterial loads (Redford, Boonstra et al. 2010), 
suggesting that IL-10 maybe suppressing the immune response to infection. However, the 
results of IL-10 studies in mice and in humans have been inconsistent to date and should be 
interpreted with caution. Other human studies have show that IL-10 may be associated with 
susceptibility to infections caused by fast growing mycobacteria (Muller, Aukrust et al. 
1998). Thus, IL-10 may be contributing to the immunopathology that is evident in TB-IRIS 
patients. However, the mechanism by this happens is not clear and would require further 
investigation. 
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An association of IL-10 with HIV has been previously reported with significantly higher 
levels of circulating IL-10 being demonstrated in HIV-infected patients than in healthy 
controls (Stylianou, Aukrust et al. 1999). The highest levels of IL-10 were observed in 
patients with the most advanced clinical and immunological disease and virus load.   IL-10 
production has also been shown to increase in M. avium stimulated monocytes from HIV-
infected patients, with the highest expression being observed in patients with advanced AIDS 
(Muller, Aukrust et al. 1998). Considering that the all of the patients investigated in this study 
were HIV-infected with the majority having very low CD4 counts (median 56 and 50 in TB-
IRIS and non-IRIS respectively) it may be interesting to see if the high IL-10 levels observed 
in these patients correlated with HIV-1 viral load or clinical symptoms.  However, routine 
viral load was not performed for these patients and could be addressed in future studies.  
 
It is interesting that IL-22, like IL-10 was found to be significantly higher in TB-IRIS at both 
gene expression and serum protein levels. IL-22 has been previously implicated to have a role 
in T-lymphocyte disease, innate pathogen defence and in acute phase responses (Commins, 
Steinke et al. 2008) and has been associated with increased innate immunity in tissues (Wolk, 
Kunz et al. 2004) with expression being higher in outer body barriers such as skin, the 
respiratory and digestive system. The findings in this study suggest that IL-22 may be 
associated with the immunopathology in TB-IRIS. The co-expression of IL-10 and IL-22 as 
seen in this study has been investigated with suggestions that there may be interaction 
between these cytokines. However it has been shown despite having opposite effects (being 
anti-inflammatory and pro-inflammatory respectively) and sharing a signalling receptor 
subunit, IL-10 and IL-22 do not seem to interact as previously thought (Wolk, Witte et al. 
2004). 
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While higher levels of IL-19 were observed in the tissue culture supernatants of non-IRIS 
patients, no IL-19 protein was detected in serum i.e. in vivo. IL-19, like IL-20 has been 
shown to be produced under inflammatory conditions and are thought to play an important 
role in the pathogenesis of some inflammatory diseases (Sabat, Wallace et al. 2007) although 
it remains unclear whether these cytokines regulate the function of immune cells. Recently, it 
has been suggested that IL-19, IL-20 and IL-24 could have potential roles in autoimmune 
diseases (Leng, Pan et al. 2011). However, from this study it remains unclear whether IL-19 
and the other IL-10 homologs (IL-20, Il-24, IL-26, IL-28 and IL-29) have a role in TB-IRIS 
immunopathology.  
 
Although not a member of the IL-10 super family, IL-21 has potential regulatory effects on 
cells of the immune system, including natural killer (NK) cells and cytotoxic T cells (Parrish-
Novak, Dillon et al. 2000; Day, Abrahams et al. 2011). Expression of IL-21 has been shown 
to be higher in activated human CD4 T cells but not in most other tissues with Th17 cells 
producing higher levels of IL-21 than Th2 cells (Korn, Bettelli et al. 2007). IL-21 has also 
been implicated in auto-immune disease models and in the control of persistent viral 
infections (Nurieva, Yang et al. 2007; White, Krishnan et al. 2007). In this study, although 
higher IL-21 fold induction was detected at 6 hours in IRIS patients, this was not confirmed 
in vivo. Thus, whether IL-21 has a significant biological role in TB and in TB-IRIS may 
require further investigation. 
 
The role of the other IL-10 related family cytokines has not been previously studied in TB or 
in TB-IRIS. Thus this work contributes substantial novelty to this subject. Considering the 
heterogeneity within this family of cytokines, it is likely that IL-20, IL-24, IL-26, IL-28 and 
IL-29 may be not have a clear role in this condition as shown by the findings reported here. 
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In summary, IL-10 and IL-22 but not IL-20, IL-24, IL-26, IL-28 and IL-29 appear to have a 
role in contributing to the immunopathology in TB-IRIS. 
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7   CHAPTER 7: GENERAL DISCUSSION AND CONCLUSIONS  
While the clinical presentation of TB-IRIS is highly heterogeneous, diagnosis is mainly 
clinical and mainly relies on exclusion of alternative diagnosis. Thus, the study of the 
immunopathogenesis of TB-IRIS is important in enhancing understanding of the condition 
and could give insight into protective and pathogenic immune reconstitution. Thus, in 
addition to enhancing our understanding of the immunopathogenesis of TB-IRIS, studies of 
this nature could lead to the identification of biomarkers, which in turn may help in earlier 
prediction and diagnosis of the condition. This may also inform improved treatments and 
interventions to modulate TB-IRIS. 
 
To determine whether dysregulated cytokine responses may be playing a role in the 
immunopathology of TB-IRIS, I conducted a case control analysis of paradoxical TB-IRIS 
patients vs. non-IRIS control patients who were on similar treatment but did not develop TB-
IRIS. Stimulation of PBMC with M.tuberculosis increased the transcript abundance and 
concentrations of multiple cytokines in vitro for TB-IRIS vs. non-IRIS control patients. 
Follow-up analysis of those cytokines that were differentially upregulated in vitro in the 
corresponding serum samples i.e. in vivo demonstrated higher concentrations of the pro-
inflammatory cytokines IL-6, TNF and IFN-gamma in TB-IRIS patients. Comparison of 
prednisone vs. placebo treated patients showed a significant decrease of both IL-6 and TNF 
but not IFN-gamma in prednisone treated patients. The elevation of many pro- and anti-
inflammatory cytokine transcripts and protein levels shown in this study strongly suggests 
that cytokine release contributes to the immunopathology and symptoms in TB-IRIS.  
 
While the levels of cytokines observed in this study may not be as high as those reported in 
the TGN1412 trial (Suntharalingam, Perry et al. 2006) or in H5N1 infection (de Jong, 
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Simmons et al. 2006) it is evident from these findings that the exaggerated cytokine 
expression observed in TB-IRIS contributes substantially to immunopathology in this 
condition. TNF has consistently been associated with both protection and pathology in TB 
(Bekker, Maartens et al. 1998; Keane, Gershon et al. 2001). While recent studies have 
documented a beneficial effect of TNF blockade on paradoxically deteriorating TB in HIV-1 
uninfected patients, the potential use of this therapy in TB-IRIS patients presents challenges 
as could potentially lead to the reactivation of latent TB (Keane, Gershon et al. 2001).  
 
The use of prednisone therapy in TB-IRIS cases has been shown to result in more rapid 
symptom resolution in TB-IRIS cases as compared to placebo treated patients (Meintjes, 
Wilkinson et al. 2010).  It is interesting to note that, in keeping with these clinical findings, 
prednisone treatment in TB-IRIS patients significantly downregulated the levels of TNF and 
IL-6. Taken together, these results suggest that prednisone therapy modulates the pro-
inflammatory cytokine response characteristic of TB-IRIS. Thus, short-term adjunct 
prednisone therapy is potentially a useful intervention in TB-IRIS. A phase II study in 
patients with know drug sensitive TB undergoing severe TB-IRIS in whom cortecosteroid 
therapy was either ineffective or contraindicated may be justifiable.  
 
While the findings on the potential modulation of TNF and IL-6 by prednisone in TB-IRIS 
are insightful, caution should be exercised in translating these findings to a clinical trial. It 
may also be prudent to confirm these findings in a larger sample size. Similarly, the results of 
stratification of IRIS patients on the basis of severity showed a trend towards lower cytokine 
levels in patients who had less severe IRIS. However this study was underpowered and so 
significant conclusions on the association of cytokine levels and TB-IRID severity. Further 
work, possibly with larger samples would be recommended in order to validate these 
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preliminary findings. While there has been work published to suggest that IL-7 could be used 
as a biomarker in HIV-TB patients who developed IRIS, (Hodge, Srinivasula et al. 2011), the 
results presented in this thesis did not confirm these findings. Further work on the possible 
association of IL-7 with and its potential use as a biomarker in TB-IRIS would be 
recommended. 
 
The hypothesis that a deficiency of regulation may contribute to TB-IRIS has been previously 
put forward and is of considerable interest. Analysis of the anti-inflammatory cytokine, IL-10 
showed significantly elevated levels of this immunoregulatory cytokine in TB-IRIS compared 
to non-IRIS control patients. IL-10 was consistently higher in TB-IRIS at mRNA, in vitro 
protein and in vivo protein concentrations. Further analysis of the gene expression and in vivo 
protein concentrations for the other IL-10 related cytokines showed IL-22 to be significantly 
more upregulated in TB-IRIS at mRNA level. Follow-up analysis of IL-22 in vivo showed 
that IL-22 protein expression in serum was significantly higher in TB-IRIS, a trend that was 
very similar to that observed for IL-10 hence suggesting a potential role of these two related 
cytokines in the immunopathology of TB-IRIS. The other IL-10 related homologs did not 
appear to have a clear role in TB-IRIS. However, this may be justifiable considering the 
substantial heterogeneity within the goup of IL-10 related cytokines. It would be interesting 
to investigate further whether the involvement of IL-10 and IL-22 in the immunopthology of 
TB-IRIS is via a similar  mechanism.  
 
TB-IRIS is typically characterised by matrix destruction and excessive immune-mediated 
tissue damage according to clinical observations. In this study, I hypothesised that MMPs 
may be playing a central part in this immunopathology (Elkington and Friedland 2006; 
Elkington, D'Armiento et al. 2011). My findings (Chapter 4) showed that M. tuberculosis 
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stimulation of PBMC differentially increased the transcript levels for multiple MMPs in 
paradoxical TB-IRIS patients. The up-regulation of MMP-1, -3, -7 and -10 by M. 
tuberculosis is consistent with previous reports in primary human macrophages, monocytes 
(Harris, Green et al. 2007; Elkington, Green et al. 2009) and PBMC. MMP-7 and MMP-10 
remained differentially induced in TB-IRIS patients at both 6 and 24 hours. MMP-7 
correlated closely with IRIS and was suppressed by prednisone treatment. While high levels 
of MMP-9 were detected, divergent MMP-9 gene expression or secretion between the TB-
IRIS and non-IRIS patients was not demonstrated. These findings suggest that while MMP-9 
may be generally associated with the pathogenesis of tuberculosis as observed in a 
M.tuberculosis model in zebrafish (Volkman, Pozos et al. 2010), it does not appear to be 
specifically associated with the immunopathology that is evident in TB-IRIS.  
 
The biology of MMPs is still incomplete and is currently under intense investigation. While 
the available assays may measure pro-MMP (e.g. the MMP-10 assay), active MMP only (e.g. 
MMP-9 assay) or both the active and pro-enzyme forms (e.g. MMP-1), most of the available 
assays do not reliably measure all forms of the proteins available in a biological sample 
concurrently. This places a limitation on the analysis of MMPs as it means that not all 
biologically available protein can be accurately measured in a given sample. While blood is 
the most readily used biological sample for the study of the immunology of tuberculosis, 
admittedly it is not the best compartment and may not be representative of the immunological 
changes occurring at the site of disease. Ideally, MMPs would preferably be measured in site 
of disease samples or using tissue biopsies, samples that were not readily available for our 
study. The MMPs that filter through to serum may only be a spillover of what is produced at 
the site of disease. Hence the levels of these enzymes available in systemic circulation i.e. in 
the blood compartment (serum) may not always correspond to what is present at the site of 
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disease. To this end, it would be necessary to further investigate these findings in 
representative site of disease samples inorder to confirm whether the observations noted at 
the site of disease confirm our findings on the involvement of MMPs in TB-IRIS 
immunopathology. Studies of MMPs in BAL, sputum or tissue biopsies of TB-IRIS patients 
would be recommended in thi this regard. 
 
Apart from degrading the extracellular matrix, MMPs have been shown to have other roles, 
including immunomodulation, and facilitating the generation of chemotactic gradients, thus 
acting on other non-matrix substrates including cytokines and growth factors (McCawley and 
Matrisian 2001). In this thesis, in vitro analysis of the concentrations of multiple MMPs 
analysed correlated significantly with the concentrations of several cytokines including IL-1 
beta, TNF, IL-6 and GM-CSF in addition to IL-10 mainly in TB-IRIS patients. These 
findings further suggest that the co-expression of MMPs, cytokines and chemokines 
altogether associates strongly with the immunopathology in TB-IRIS. Further work on this, 
particularly in vitro assays or work I animal models may help to elucidate the mechanisms by 
which co-expression of MMPs and cytokines are involved in TB-IRIS immunopathology. 
 
In conclusion, the immunopathogenesis of TB-IRIS appears to be mediated by the interaction 
of a variety of immune mediators including pro-inflammatory cytokines, anti-inflammatory 
cytokines, chemokines and matrix metalloproteinases. The findings presented in this thesis 
also give strong evidence for the involvement of tissue degrading enzymes, MMPs in the 
immunopathology of paradoxical TB-IRIS. Whilst one of the largest studies of TB-IRIS to 
date, the series of studies presented in this thesis show comprehensive analyses which make 
substantial contributions, thus expanding our knowledge on the immunopathology of TB-
IRIS. Here, I have comprehensively characterised the immunopathology of paradoxical TB-
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IRIS. This work makes a significant contribution to knowledge and to existing literature on 
the subject and the study of TB-IRIS immunopathology. Novel findings are presented in this 
thesis showing in-depth immunological profiles associated with paradoxical HIV-TB-IRIS. 
The data presented in this thesis show distinct patterns with regards to the cytokines, matrix 
metalloproteinases, and the correlations showing potential interactions of these immune 
mediator molecules in association with TB-IRIS immunopathology.  
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MAIN OUTPUT FROM THIS WORK 
The work presented in this thesis has been presented at various local and international 
Scientific meetings as detailed below: 
POSTER PRESENTATIONS 
1. “Pro- and anti-inflammatory cytokine mRNA profiling of the HIV-tuberculosis 
immune reconstitution inflammatory syndrome.”  
Rebecca Tadokera, Graeme Meintje, Katalin Wilkinson, Molebogeng Rangaka, Kerryn van 
Veen, Keira Skolimowska, Gary Maartens and Robert J Wilkinson.  5th IAS Conference on 
HIV Pathogenesis, Treatment and Prevention, Cape Town, South Africa, July 2008.  
2. “Matrix Metalloproteinases in HIV-Tuberculosis associated Immune Reconstitution 
Inflammatory Syndrome.”   
Rebecca Tadokera, Graeme Meintjes, Keira Skolimowska, Katalin A. Wilkinson, Paul T. 
Elkington, Kerryn van Veen1, Ronnett Seldon, Gary Maartens and Robert J. Wilkinson. 
Overcoming the Crisis of TB and AIDS (T2-2010) Arusha International Conference Centre, 
Arusha, Tanzania, October 20 - October 25, 2009.  *Received a Keystone Global Health 
Travel scholarship based on the abstract. 
3.  “Matrix Metalloproteinases in HIV-Tuberculosis associated Immune Reconstitution 
Inflammatory Syndrome.”   
Tadokera R,  Meintjes GA, Wilkinson KA , Rangaka MX ,  Skolimowksa KH, K1, Rebe  K , 
Chegou NN, Walzl G, Maartens G, and  Wilkinson RJ. South African Immunological Society 
Conference 9-11 December 2009, Vineyard Hotel, Colinton Road, Newlands, Cape Town. 
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4. “Hypercytokinaemia accompanies HIV-associated TB-IRIS.”   
Tadokera R,  Meintjes GA, Wilkinson KA , Rangaka MX ,  Skolimowksa KH, , Rebe  K , 
Chegou NN, Walzl G, Maartens G, and  Wilkinson RJ. 14th International Congress of 
Immunology,  (ICI 2010). Kobe, Japan, 22-27 August, 2010. *Received a Travel scholarship 
for postgraduate students to attend the conference. 
5. “Contribution of cytotoxic cells to antiretroviral induced pathological immunity in 
HIV associated tuberculosis (TB-IRIS)” 
Tadokera R,  Meintjes GA, Skolimowska KH, Matthews K, Nicol MP, Martens G, Rangaka 
MX , Rangaka MX, Wilkinson RJ. Wilkinson KA.  Keystone Symposia Tuberculosis: 
Immunology, Cell Biology and Novel Vaccine Strategies. Vancouver, British Columbia, 
January 15-January 20, 2011. * Received an NIAD Scholarship to attend this conference  
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ORAL PRESENTATIONS ARISING FROM THIS WORK 
1. “Pro- and anti-inflammatory gene expression and the HIV-TB immune reconstitution 
inflammatory syndrome.”  
Rebecca Tadokera, Graeme Meintjes, Katalin Wilkinson, Molebogeng Rangaka, Kerryn van 
Veen, Keira Skolimowska, Gary Maartens and Robert J Wilkinson. MLW Research 
Conference, Club Makokola, Mangochi, 30th August 2009 - 2nd September 2009. * 
Received a CIDRI scholarship to attend the conference based on the abstract. 
2. “Exaggerated cytokine release and the HIV-tuberculosis immune reconstitution 
inflammatory syndrome.”  
Rebecca Tadokera, IIDMM Immunology Seminar Series, Wolfson Pavillion, Institute of 
Infectious Disease and Molecular Medicine, University of Cape Town, 9 June 2010. 
3. “Exaggerated cytokine release and the HIV-TB associated immune reconstitution 
inflammatory syndrome.” 
Rebecca Tadokera, Graeme Meintjes, Katalin Wilkinson, Molebogeng X Rangaka, Kerryn 
van Veen, Keira Skolimowska, Gary Maartens and Robert J Wilkinson. UCT/GSH Annual 
Medical Research Day, GHS, Cape Town, 30 September 201 
4. “MMP-7 and tissue damage in HIV associated TB-IRIS” 
Rebecca Tadokera, Graeme Meintjes, Katalin A Wilkinson, Keira H Skolimowska, Naomi 
Walker, Jon S Friedland, Gary Maartens, Paul T G Elkington, Robert J Wilkinson. CIDRI 
and Imperial College Wellcome Centre Annual Scientific Meeting. IIDMM, University of 
Cape Town, 12-14 March 2011 
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PUBLICATIONS ARISING FROM THIS WORK 
1. Part of the work presented in Chapter 3 was published in the European Respiratory 
Journal, September 2010 (epub ahead of print) : Hypercytokinemia characterizes 
antiretroviral-induced pathological immunity in HIV-associated tuberculosis (TB-IRIS). 
Rebecca Tadokera, Graeme Meintjes, Keira H Skolimowksa, Katalin A Wilkinson, 
Kerryn Matthews, Ronnett Seldon, Novel Chegou, Gary Maartens, Molebogeng Xheeda 
Rangaka ,Kevin Rebe, Gerhard Walzl, Robert J Wilkinson 
 
2. Part of the work presented in Chapter 4 has been submitted and is under review:  
Matrix metalloproteinase-7 and tissue damage in paradoxical HIV-Tuberculosis associated 
Immune Reconstitution Inflammatory Syndrome. 
Rebecca Tadokera, Graeme A Meintjes, Katalin A Wilkinson, Keira H Skolimowska, 
Naomi Walker, Jon S Friedland, Gary Maartens, Paul T G Elkington,  Robert J Wilkinson 
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9 APPENDICES 
Appendix 1: Summary of Cytokine and MMP genes analysed, assay ID numbers and the 
primer amplicon lengths  
 
 
 
 
Molecule Gene name Assay ID Details Amplicon Length 
lL-1 ~ interleukin I-beta HsOOl74097 ml 94 
IL-2 interleukin 2 HsOOl74114 ml 94 
ILA interleukin 4 HsOOl74122 ml 70 
IL-5 interleukin 5 HsOO I 74200 ml 87 
IL-6 interleukin 6 Hs00985639 ml 66 
IL-7 interleukin 7 HsOOl74202 ml 75 
IL-8 interleukin 8 HsOOl74103 ml 101 
lL-9 interleukin 9 HsOOl74125 ml 92 
IL-IO interleukin 10 HsOOl74086 ml 119 
IL-12p40 interleukin 12p40 HsOlO1I518 ml 72 
IL-13 interleukin 13 HsOOl74379 ml 82 
IL-15 interleukin 15 Hs00542562 ml 67 
lL-17A interleukin 17a HsOOl74383 ml 80 
IL-18 interleukin 18 HsOI038788 ml 115 
IL-19 interleukin 19 Hs00604657 ml 68 
IL-20 interleukin 20 Hs00218888 ml 78 
IL-21 interleukin 21 HsOO222327 ml 84 
IL-22 interleukin 22 HsOO220924 ml 68 
IL-23NIL-23p 19 interleukin 23 alpha subunit Hs00413259 ml 53 
lL-24 interleukin 24 HsO ll14274 ml 67 
IL-26 interleukin 26 Hs00218189 ml 81 
IL-27 interleukin 27 Hs00377399 ml 75 
lFN-y interferon gamma HsOOl74143 ml 79 
CSF2/GMCSF Granulocyte macrophage colony stimulating HsOOl71266 ml 113 
TNF Tumour necrosis factor HsOOl74128 ml 80 
TGF-~I Transfonning growth factor HsOOl71257 ml 63 
lL-27 NIL-27p28 interleukin 27 Hs00377366 ml 75 
IL-28 interleukin 28 Hs00820 125 g 1 53 
MMP-I matrix metaliopeptidase-l Hs00899658 m 1 64 
MMP-2 matrix metaliopeptidase-2 Hs01548727 ml 65 
MMP-3 matrix metallopeptidase-3 Hs00968308 ml 98 
MMP-7 matrix metaliopeptidase-7 HsO I042795 ml 101 
MMP-8 matrix metaliopeptidase-8 HsOI029057m I 67 
MMP-9 matrix metaliopetidase-9 Hs00957555 ml 79 
MMP-IO matrix metaliopeptidase-I 0 Hs00233987 ml 82 
MMP-li matrix metallopeptidase-ll Hs00968295 ml 60 
MMP-12 matrix metallopeptidase-12 HsOOl59178 ml 62 
MMP-13 matrix metaliopeptidase-13 Hs00233992 ml 91 
TIMP-I metaliopeptidase inhibitor I Hs99999 1 39 ml 55 
TIMP-2 metaliopeptidase inhibitor 2 Hs00234278 ml 73 
MIP-l a (CCL3) Macrophage inflammatory protein-l HsOO234142_m1 53 
MIP-l ~ (CCL4) Macrophage inflammatory protein-2 Hs99999148_m1 94 
RANTES Chemokine motif Ligand 5 Hs00174575 m1 63 
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Appendix 2: Preparation of Solutions and Buffers for Gelatinase Zymography 
 
Solution/Buffer Ingredients Recipe/Supplier 
1.2% gelatin solution 1.2g  gelatin  
100 ml Deionised water  
Merck 1.04070 
Mixture was heated in a 65ºC water bath for 
10 minutes and aliquots stored at 4oC.   
11% Running gel (for 2 
gels) 15cm x 15cm x 1mm 
40% acrylamide   
20 mls Running gel buffer 
30 mls Deionised H2O 
8 mls  1.2% gelatin   
160µ l  TEMED     
320 µ l  10% (w/v) APS  
 
Merck 1.00641 
 
 
Merk 1.04070 
Merck 1.10732 
Merck 1.01201 
Stock made up and frozen as 1ml aliquots for 
single time use. TEMED and APS were added 
just before pouring the gel. 
Stacking gel (for 2 gels) - 
5% acrylamide 
 
2.5mls  40%  acrylamide  
5mls  stacking gel buffer  
12.5mls distilled H2O 
40µ l  TEMED 
80µ l  10% (w/v) APS 
Merck 1.00641 
 
 
Merck 1.10732 
Merck 1.01201 
Running buffer  (10x 
stock) 
 
Running buffer (1x 
working solution) 
30.28g  Tris base   
144.12g  glycine 
 
10ml  10% (w/v) SDS 
100ml  stock as above 
Sigma-Aldrich T4661-1KG 
Sigma L4509  
Add to 1L distilled water  
Sigma L6026  
Make up to 1L with distilled water 
Sample loading buffer 
(5x) 
5mls 0.5M Tris HCl (pH 
6.8) 
5ml Glycerol  
0.5g  SDS 
Crystals of Bromophenol 
Sigma T6666 
Sigma G6279 
Sigma L6026  
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blue   
MMP-9 standard buffer Tris-HCl  2.36g 60mM 
250mls distilled water  
CaCl2  0.55g 15mM 
NaCl      1.17g  80mM 
BSA  0.1% 0.25g  
Make  up in 250mls distilled water and  freeze  
as 0.5ml aliquots    
Merck 1.02378 
Sigma Aldrich S5886-1KG 
Sigma A9418-100G 
2.5%  Triton  X-100 
renaturing buffer 
25mls Triton X-100  
1L De-ionised water  
Merck 648466 
Low salt collagenase 
buffer (10x) 
 
 
 
 
 
1x working solution 
 
60.6g Tris base  MW 121g 
117g  NaCl  MW 58 
5.5g CaCl2  MW 111g  
 
 
 
670µl Brij-35  (30% w/v) 
100mls 10x stock,  
900mls deionised water 
Sigma-Aldrich T466-1KG 
Sigma Aldrich S5886-1KG 
Sigma Aldrich S5670 
Make up to 900mls with deionised water 
Adjust pH to 7.6 with conc.  HCL  and top up 
to 1L 
 
Check and adjust pH to pH  if required 
Destain solution 200mls glacial acetic acid 
600mls methanol 
1200ml distilled H20 
Make in 1200ml distilled water. Store at RT 
0.2%  Coomassie blue 
(stock solution) 
 
Coomassie blue 
(working solution) – 
sufficient for 2 gels 
1 tablet  PhastGel-Blue-R 
Coomassie blue tablets 
80mls distilled water 
 
10ml of stock solution 
190mls of destain solution. 
 
Pharmacia, Sweden, GE Healthcare  17-0518-
01 
 Stir for 10 minutes. Add 120mls methanol.  
Filter (Whatman No. 1 filter paper). Stored at 40C 
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Appendix 3: IL-17 standard curve 
 
 
 
 
Appendix 4: IL-7 standard curve 
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Appendix 5: Standard curve of IL-21  
 
 
 
 
 
Appendix 6: Standard curve of IL-23 ready set go ELISA 
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Appendix 7:  Standard curve for TGF-B1 duoset ELISA 
 
 
 
 
Appendix 8: IL-22 Quantikine ELISA standard curve 
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Appendix 9: IL-19 Quantikine ELISA standard curve 
 
 
 
 
 
 
 
 
 
 
 
Appendix 10: MMP-10 Quantikine ELISA standard curve 
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Appendix 11: TIMP-1 ELISA standard curve 
 
 
 
 
Appendix 12: TIMP-2 ELISA standard curve 
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Appendix 13: MMP-9/TIMP-2 ELISA 
 
  
 
 
 
Appendix 14: MMP-2/TIMP-1 ELISA 
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